<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>

    <title>Pocket Medicine, 8e</title>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
  <link rel="stylesheet" type="text/css" href="../stylesheet.css"/>
<link rel="stylesheet" type="text/css" href="../page_styles.css"/>

  


<link href="../calibreHtmlOutBasicCss.css" type="text/css" rel="stylesheet" />

</head>
<body>

<div class="calibreMeta">
  <div class="calibreMetaTitle">
  
  
    
    <h1>
      <a href="../../j09u21sl.html">Pocket Medicine (Pocket Notebook Series)
</a>
    </h1>
    
    
  
  </div>
  <div class="calibreMetaAuthor">
    Marc Sabatine

  </div>
</div>

<div class="calibreMain">

  <div class="calibreEbookContent">
    
      <div class="calibreEbNavTop">
        
          <a href="part0006.html" class="calibreAPrev">previous page
</a>
        

        
          <a href="part0008.html" class="calibreANext">next page
</a>
        
      </div>
    

    
<h2 class="ct"><a id="h1" class="calibre8"></a><a id="page_1-1" class="calibre8"></a><a href="part0003.html#rh5" class="calibre8">ELECTROCARDIOGRAPHY</a></h2>
<p class="h">Approach <span class="r">(a systematic approach is vital)</span></p>
<p class="noindent1">• <b class="calibre7">Rate</b> (? tachy or brady), <b class="calibre7">rhythm</b> (? P waves, regularity, P &amp; QRS relationship)</p>
<p class="noindent1">• <b class="calibre7">Intervals</b> (PR, QRS, QT), <b class="calibre7">axis</b> (? LAD or RAD), <b class="calibre7">chamber abnl</b> (? LAA, RAA, LVH, RVH)</p>
<p class="noindent1">• <b class="calibre7">QRST changes</b> (? Q waves, poor R-wave progression V<sub class="calibre10">1</sub>–V<sub class="calibre10">6</sub>, ST ↑/↓ or T-wave ∆s)</p>
<div class="cap">
<p class="caption"><a id="fig1-1" class="calibre4"></a><b class="calibre7">Figure 1-1</b> QRS axis</p>
<p class="imagef1"><img src="../images/00004.jpeg" alt="" class="calibre5"/></p>
</div>
<p class="h">Left axis deviation <span class="r">(LAD)</span></p>
<p class="noindent1">• <b class="calibre7">Definition:</b> axis beyond –30° (S &gt;R in lead II)</p>
<p class="noindent1">• <b class="calibre7">Etiologies:</b> LVH, LBBB, inferior MI, WPW</p>
<p class="noindent1">• <b class="calibre7">Left anterior fascicular block (LAFB):</b> LAD (–45 to –90°) <i class="calibre6">and</i> qR in aVL <i class="calibre6">and</i> QRS &lt;120 msec <i class="calibre6">and</i> no other cause of LAD (eg, IMI)</p>
<p class="h">Right axis deviation <span class="r">(RAD)</span></p>
<p class="noindent1">• <b class="calibre7">Definition:</b> axis beyond +90° (S &gt;R in lead I)</p>
<p class="noindent1">• <b class="calibre7">Etiologies:</b> RVH, PE, COPD (usually not &gt;+110°), septal defects, lateral MI, WPW</p>
<p class="noindent1">• <b class="calibre7">Left posterior fascicular block (LPFB):</b> RAD (90–180°) <i class="calibre6">and</i> rS in I &amp; aVL <i class="calibre6">and</i> qR in III &amp; aVF <i class="calibre6">and</i> QRS &lt;120 msec <i class="calibre6">and</i> no other cause of RAD</p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre12"/>
<col class="calibre12"/>
<col class="calibre13"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="3"><p class="tbodyc"><b class="calibre7">Bundle Branch Blocks</b> <span class="sm">(<i class="calibre6">Circ</i> 2009;119:e235)</span></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Normal</b></p></td>
<td class="th1"><p class="tbodyc"><img src="../images/00005.jpeg" alt="" class="calibre5"/></p></td>
<td class="th1"><p class="tbody">Initial depol. left to right across septum (r in V<sub class="calibre17">1</sub> &amp; q in V<sub class="calibre17">6</sub>; nb, absent in LBBB) followed by LV &amp; RV free wall, with LV dominating (nb, RV depol. later and visible in RBBB).</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">RBBB</b></p></td>
<td class="th1"><p class="tbodyc"><img src="../images/00006.jpeg" alt="" class="calibre5"/></p></td>
<td class="th1"><p class="tnl"><span class="tft">1.</span> QRS ≥120 msec (110–119 msec = IVCD or “incomplete”)</p>
<p class="tnl"><span class="tft">2.</span> rSR′ in R precordial leads (V<sub class="calibre17">1</sub>, V<sub class="calibre17">2</sub>)</p>
<p class="tnl"><span class="tft">3.</span> Wide S wave in I and V<sub class="calibre17">6</sub></p>
<p class="tnl"><span class="tft">4.</span> ± ST↓ or TWI in R precordial leads</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">LBBB</b></p></td>
<td class="th1"><p class="tbodyc"><img src="../images/00007.jpeg" alt="" class="calibre5"/></p></td>
<td class="th1"><p class="tnl"><span class="tft">1.</span> QRS ≥120 msec (110–119 msec = IVCD or “incomplete”)</p>
<p class="tnl"><span class="tft">2.</span> Broad, slurred, monophasic R in I, aVL, V<sub class="calibre17">5</sub>–V<sub class="calibre17">6</sub> (± RS in V<sub class="calibre17">5</sub>–V<sub class="calibre17">6</sub> if cardiomegaly)</p>
<p class="tnl"><span class="tft">3.</span> Absence of Q in I, V<sub class="calibre17">5</sub>, and V<sub class="calibre17">6</sub> (may have narrow q in aVL)</p>
<p class="tnl"><span class="tft">4.</span> Displacement of ST &amp; Tw opposite major QRS deflection</p>
<p class="tnl"><span class="tft">5.</span> ± PRWP, LAD, Qw’s in inferior leads</p></td>
</tr>
</tbody>
</table>
<p class="tfn">Bifascicular block: RBBB + LAFB/LPFB. “Trifascicular block”: bifascicular block + 1° AVB.</p>
<p class="h">Prolonged QT interval <span class="r1">(</span><span class="r2">NEJM</span><span class="r1"> 2008;358:169; <a href="http://www.torsades.org" class="calibre4">www.torsades.org</a>)</span></p>
<p class="noindent1">• Measure QT using threshold method (start of QRS to end of Tw at isoelectric line) or tangent (QRS to where tangent of Tw downslope intersects baseline) when long tail. Use longest QT (often V<sub class="calibre10">2</sub> or V<sub class="calibre10">3</sub>) and omit U wave <span class="r1">(</span><span class="r2">Circ</span><span class="r1"> 2018;138:2345)</span>.</p>
<p class="noindent1">• QT varies w/ HR → corrected w/ Bazett formula: <img class="mid" src="../images/00008.jpeg" alt=""/> (RR in sec), overcorrects at high HR, undercorrects at low HR (nl QTc &lt;450 msec ♂, &lt;460 msec ♀)</p>
<p class="noindent1">• Fridericia’s formula preferred at very high or low <img class="mid" src="../images/00009.jpeg" alt=""/></p>
<p class="noindent1">• QT prolongation a/w ↑ risk TdP (espec &gt;500 msec); establish baseline QT and monitor if using QT prolonging meds, no estab guidelines for stopping Rx if QT prolongs</p>
<p class="noindent1">• Etiologies:</p>
<p class="noindent2"><b class="calibre7">Antiarrhythmics:</b> class Ia (procainamide, disopyramide), class III (amio, sotalol, dofet)</p>
<p class="noindent2"><b class="calibre7">Psych drugs:</b> antipsychotics (phenothiazines, haloperidol, atypicals), Li, ? SSRI, TCA</p>
<p class="noindent2"><b class="calibre7">Antimicrobials:</b> macrolides, quinolones, azoles, pentamidine, atazanavir</p>
<p class="noindent2"><b class="calibre7">Other:</b> antiemetics (droperidol, 5-HT<sub class="calibre10">3</sub> antagonists), alfuzosin, methadone, ranolazine</p>
<p class="noindent2"><b class="calibre7">Electrolyte disturbances:</b> hypoCa (nb, hyperCa a/w ↓ QT), ± hypoK, ? hypoMg</p>
<p class="noindent2"><b class="calibre7">Autonomic dysfxn:</b> ICH (deep TWI), Takotsubo, stroke, CEA, neck dissection</p>
<p class="noindent2"><b class="calibre7">Congenital</b> (long QT syndrome): K, Na, &amp; Ca channelopathies <span class="r1">(</span><span class="r2">Circ</span><span class="r1"> 2013;127:126)</span></p>
<p class="noindent2"><b class="calibre7">Misc:</b> CAD, CMP, bradycardia, high-grade AVB, hypothyroidism, hypothermia, BBB</p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre12"/>
<col class="calibre18"/>
<col class="calibre18"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="3"><p class="tbodyc"><b class="calibre7">Bundle Branch Blocks</b> <span class="sm">(<i class="calibre6">Circ</i> 2009;119:e235)</span></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbodyc"><b class="calibre7">ECG P-wave criteria</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Left Atrial Abnormality (LAA)</b></p>
<p class="tbodyc"><img src="../images/00010.jpeg" alt="" class="calibre5"/></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Right Atrial Abnormality (RAA)</b></p>
<p class="tbodyc"><img src="../images/00011.jpeg" alt="" class="calibre5"/></p></td>
</tr>
</tbody>
</table>
<p class="h">Left ventricular hypertrophy <span class="r">(LVH)</span> <span class="r1">(</span><span class="r2">Circ</span><span class="r1"> 2009;119:e251)</span></p>
<p class="noindent1">• Etiologies: HTN, AS/AI, HCM, coarctation of aorta</p>
<p class="noindent1">• Criteria (all w/ Se &lt;50%, Sp &gt;85%; accuracy affected by age, sex, race, BMI)</p>
<p class="noindent2"><b class="calibre7">Sokolow-Lyon:</b> S in V<sub class="calibre10">1</sub> + R in V<sub class="calibre10">5</sub> or V<sub class="calibre10">6</sub> ≥35 mm or R in aVL ≥11 mm (↓ Se w/ ↑ BMI)</p>
<p class="noindent2"><b class="calibre7">Cornell:</b> R in aVL + S in V<sub class="calibre10">3</sub> &gt;28 mm in men or &gt;20 mm in women</p>
<p class="noindent2"><a id="page_1-2" class="calibre4"></a><b class="calibre7">Romhilt-Estes point-score system</b> (4 points = probable; 5 points = diagnostic): ↑ volt: limb lead R or S ≥20 mm <i class="calibre6">or</i> S in V<sub class="calibre10">1</sub> or V<sub class="calibre10">2</sub> ≥30 mm <i class="calibre6">or</i> R in V<sub class="calibre10">5</sub> or V<sub class="calibre10">6</sub> ≥30 mm (3 pts)</p>
<p class="noindent2">ST displacement opposite to QRS deflection: w/o dig (3 pts); w/ dig (1 pt)</p>
<p class="noindent2">LAA (3 pts); LAD (2 pts); QRS duration ≥90 msec (1 pt)</p>
<p class="noindent2">Intrinsicoid deflection (QRS onset to peak of R) in V<sub class="calibre10">5</sub> or V<sub class="calibre10">6</sub> ≥50 msec (1 pt)</p>
<p class="noindent2"><b class="calibre7">If LAFB present:</b> S in III + max (R+S) in any lead ≥30 mm in men or ≥28 mm in women</p>
<p class="h">Right ventricular hypertrophy <span class="r">(RVH)</span> <span class="r1">(</span><span class="r2">Circ</span><span class="r1"> 2009;119:e251;</span> <span class="r2">JACC</span><span class="r1"> 2014;63:672)</span></p>
<p class="noindent1">• Etiologies: cor pulmonale, congenital (tetralogy of Fallot, TGA, PS, ASD, VSD), MS, TR</p>
<p class="noindent1">• Criteria [all insensitive, but specific (except in COPD); all w/ poor PPV in general population]</p>
<p class="noindent2">R &gt;S in V<sub class="calibre10">1</sub>, R in V<sub class="calibre10">1</sub> ≥6 mm, S in V<sub class="calibre10">5</sub> ≥10 mm, S in V<sub class="calibre10">6</sub> ≥3 mm, R in aVR ≥4 mm</p>
<p class="noindent2">RAD ≥110° (LVH + RAD <i class="calibre6">or</i> prominent S in V<sub class="calibre10">5</sub> or V<sub class="calibre10">6</sub> → consider <i class="calibre6">biventricular</i> hypertrophy)</p>
<p class="h">Ddx of dominant R wave in V<sub class="calibre10">1</sub> or V<sub class="calibre10">2</sub></p>
<p class="noindent1">• Ventricular abnl: RVH (RAD, RAA, deep S waves in I, V<sub class="calibre10">5</sub>, V<sub class="calibre10">6</sub>); HCM; Duchenne’s</p>
<p class="noindent1">• Posterior MI: anterior R wave = posterior Q wave; often with IMI</p>
<p class="noindent1">• Abnormal depolarization: RBBB (QRS &gt;120 msec, rSR′); WPW (↓ PR, δ wave, ↑ QRS)</p>
<p class="noindent1">• Other: dextroversion; counterclockwise rotation; lead misplacement; nl variant</p>
<p class="h">Poor R wave progression <span class="r">(PRWP)</span> <span class="r1">(</span><span class="r2">Am Heart J</span> <span class="r1">2004;148:80)</span></p>
<p class="noindent1">• Definition: loss of anterior forces w/o frank Q waves (V<sub class="calibre10">1</sub>–V<sub class="calibre10">3</sub>); R wave in V<sub class="calibre10">3</sub> ≤3 mm</p>
<p class="noindent1">• Etiologies: old anteroseptal MI (w/ R wave V<sub class="calibre10">3</sub> ≤1.5 mm, ± persistent ST ↑ or TWI V<sub class="calibre10">2</sub> &amp; V<sub class="calibre10">3</sub>)</p>
<p class="noindent2">LVH (delayed RWP w/ ↑ left precordial voltage); RVH; COPD (may also have RAA, RAD, limb lead QRS amplitude ≤5 mm, S<sub class="calibre10">I</sub>S<sub class="calibre10">II</sub>S<sub class="calibre10">III</sub> w/ R/S ratio &lt;1 in those leads)</p>
<p class="noindent2">LBBB; WPW; clockwise rotation of the heart; lead misplacement; CMP; PTX</p>
<p class="h">Pathologic Q waves</p>
<p class="noindent1">• Definition: ≥30 msec (≥20 msec V<sub class="calibre10">2</sub>–V<sub class="calibre10">3</sub>) or &gt;25% height of R wave in that QRS complex</p>
<p class="noindent1">• Small (septal) q waves in I, aVL, V<sub class="calibre10">5</sub> &amp; V<sub class="calibre10">6</sub> are nl, as can be isolated Qw in III, aVR, V<sub class="calibre10">1</sub></p>
<p class="noindent1">• “Pseudoinfarct” pattern may be seen in LBBB, infiltrative dis., HCM, COPD, PTX, WPW</p>
<p class="h">ST elevation <span class="r">(STE)</span> <span class="r1">(</span><span class="r2">NEJM</span><span class="r1"> 2003;349:2128;</span> <span class="r2">Circ</span><span class="r1"> 2009;119:e241 &amp; e262)</span></p>
<p class="noindent1">• <b class="calibre7">Acute MI:</b> upward convexity STE (ie, a “frown”) ± TWI (or prior MI w/ persistent STE)</p>
<p class="noindent1">• <b class="calibre7">Coronary spasm:</b> Prinzmetal’s angina; transient STE in a coronary distribution</p>
<p class="noindent1">• <b class="calibre7">Pericarditis:</b> diffuse, upward concavity STE (ie, a “smile”); a/w PR ↓; Tw usually upright</p>
<p class="noindent1">• <b class="calibre7">HCM, Takotsubo CMP, ventricular aneurysm,</b> cardiac contusion</p>
<p class="noindent1">• <b class="calibre7">Pulmonary embolism:</b> occ. STE V<sub class="calibre10">1</sub>–V<sub class="calibre10">3</sub>; classically a/w TWI V<sub class="calibre10">1</sub>–V<sub class="calibre10">4</sub>, RAD, RBBB, S<sub class="calibre10">1</sub>Q<sub class="calibre10">3</sub>T<sub class="calibre10">3</sub></p>
<p class="noindent1">• <b class="calibre7">Repolarization abnormalities:</b></p>
<p class="noindent2">LBBB (↑ QRS duration, STE discordant from QRS complex; see “ACS” for dx MI in LBBB)</p>
<p class="noindent2">LVH (↑ QRS amplitude); Brugada syndrome (rSR′, downsloping STE V<sub class="calibre10">1</sub>–V<sub class="calibre10">2</sub>); pacing</p>
<p class="noindent2">Hyperkalemia (↑ QRS duration, tall Ts, no P’s); epsilon waves (late afterdepol.) in ARVC</p>
<p class="noindent1">• <b class="calibre7">aVR:</b> STE &gt;1 mm a/w ↑ mortality in STEMI; STE aVR &gt; V<sub class="calibre10">1</sub> a/w left main disease</p>
<p class="noindent1">• <b class="calibre7">Early repolarization:</b> most often seen in V<sub class="calibre10">2</sub>–V<sub class="calibre10">5</sub> in young adults <span class="r1">(</span><span class="r2">Circ</span><span class="r1"> 2016;133:1520)</span></p>
<p class="noindent2">1–4 mm elev of notch peak or start of slurred downstroke of R wave (ie, J point); ± up concavity of ST &amp; large Tw (∴ ratio of STE/T wave &lt;25%; may disappear w/ exercise)</p>
<p class="noindent2">? early repol in inf leads may be a/w ↑ risk of VF <span class="r1">(</span><span class="r2">NEJM</span><span class="r1"> 2009;361:2529;</span> <span class="r2">Circ</span><span class="r1"> 2011;124:2208)</span></p>
<p class="noindent1">• <b class="calibre7">Post-ROSC:</b> transient STE can be seen w/in 1<sup class="calibre19">st</sup> ~8 mins; not indicative of ACS</p>
<p class="h">ST depression <span class="r">(STD)</span></p>
<p class="noindent1">• <b class="calibre7">Myocardial ischemia</b> (± Tw abnl)</p>
<p class="noindent1">• <b class="calibre7">Acute true posterior MI:</b> posterior STE appearing as anterior STD (± ↑ R wave) in V<sub class="calibre10">1</sub>–V<sub class="calibre10">3</sub> ✓ posterior ECG leads; manage as a STEMI with rapid reperfusion (see “ACS”)</p>
<p class="noindent1">• Digitalis effect: downsloping ST ± Tw abnl; does <i class="calibre6">not</i> correlate w/ dig levels</p>
<p class="noindent1">• Hypokalemia (± U wave)</p>
<p class="noindent1">• Repolarization abnl a/w LBBB or LVH (usually in leads V<sub class="calibre10">5</sub>, V<sub class="calibre10">6</sub>, I, aVL, called “LV strain”)</p>
<p class="h">T wave inversion <span class="r">(TWI; generally ≥</span>1<span class="r"> mm; deep if ≥5 mm)</span> <span class="r1">(</span><span class="r2">Circ</span><span class="r1"> 2009;119:e241)</span></p>
<p class="noindent1">• Ischemia or infarct; <i class="calibre6">Wellens’ sign</i> (deep, symm precordial TWI) → critical prox LAD lesion</p>
<p class="noindent1">• Myopericarditis; CMP (Takotsubo, ARVC, apical HCM); MVP; PE (espec if TWI V<sub class="calibre10">1</sub>–V<sub class="calibre10">4</sub>)</p>
<p class="noindent1">• Repolarization abnl in a/w LVH/RVH (“strain pattern”); BBB; nl variant if QRS predom. ⊖</p>
<p class="noindent1">• Posttachycardia or postpacing (“memory” T waves)</p>
<p class="noindent1">• Electrolyte, digoxin, PaO<sub class="calibre10">2</sub>, PaCO<sub class="calibre10">2</sub>, pH/core temp ∆’s, intracranial bleed (“cerebral Tw”)</p>
<p class="h">Low voltage</p>
<p class="noindent1">• QRS amplitude (R + S) &lt;5 mm in all limb leads &amp; &lt;10 mm in all precordial leads</p>
<p class="noindent1">• Etiol: COPD, pericardial/pleural effusion, myxedema, ↑ BMI, infiltrative CMP, diffuse CAD</p>
<p class="h">Electrolyte abnormalities</p>
<p class="noindent1">• ↑<b class="calibre7"> K:</b> tented Tw, ↓ QT, ↑ PR, AVB, wide QRS, STE; ↓<b class="calibre7"> K:</b> flattened Tw, U waves, ↑ QT</p>
<p class="noindent1">• ↑<b class="calibre7"> Ca:</b> ↓ QT, flattened Tw &amp; Pw, J point elevation; ↓<b class="calibre7"> Ca:</b> ↑ QT; Tw ∆s</p>
<p class="h"><b class="calibre7">ECG in young athletes</b> <span class="r1">(</span><span class="r2">JACC</span><span class="r1"> 2017;69:805)</span></p>
<p class="noindent1">• Normal patterns may include LVH, RVH, early repolarization</p>
<p class="noindent1">• Evaluate if: arrhythmia, HR &lt;30, ↑ QT, ε/δ waves, LBBB, Brugada pattern, QRS &gt;140 ms, PR &gt;400 ms, Mobitz II, 3˚ AVB, ST depression, TWI</p>
<h2 class="ct"><a id="h2" class="calibre8"></a><a id="page_1-3" class="calibre8"></a><a href="part0003.html#rh6" class="calibre8">CHEST PAIN</a></h2>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre20"/>
<col class="calibre21"/>
</colgroup>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th"><p class="tbody"><b class="calibre7">Disorder</b></p></td>
<td class="th"><p class="tbody"><b class="calibre7">Typical Characteristics &amp; Diagnostic Studies</b></p></td>
</tr>
<tr class="calibre15">
<td colspan="2" class="thh"><p class="tbodyc"><b class="calibre7"><i class="calibre6">Cardiovascular Causes</i></b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Angina/ACS</b></p>
<p class="tbody">(&lt;10% of</p>
<p class="tbody">chest pain in ED)</p></td>
<td class="th1"><p class="tbody">Substernal “pressure” (⊕ LR 1.3) → neck, jaw, arm (⊕ LR 1.3–1.5)</p>
<p class="tbody">Sharp, pleuritic, positional, or reprod. w/ palp all w/ ⊕ LR ≤0.35</p>
<p class="tbody">Diaphoresis (⊕ LR 1.4), dyspnea (⊕ LR 1.2), a/w exertion (⊕ LR 1.5–1.8)</p>
<p class="tbody">≈ prior MI (⊕ LR 2.2); ↓ w/ NTG/rest (but not reliable; <span class="sm"><i class="calibre6">Annals EM</i> 2005;45:581</span>)</p>
<p class="tbody">± ECG ∆s: STE, STD, TWI, hyperacute Tw, Qw. ± ↑ Troponin.</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Pericarditis &amp; myo-pericarditis</b></p></td>
<td class="th1"><p class="tbody">Sharp pain → trapezius, ↑ w/ respiration, ↓ w/ sitting forward. ± Pericardial friction rub. ECG ∆s (diffuse STE &amp; PR ↓, opposite in aVR) ± pericardial effusion. If myocarditis, same as above + ↑ Tn and ± s/s HF and ↓ EF.</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Aortic dissection</b></p></td>
<td class="th1"><p class="tbody">Sudden severe tearing pain (absence ⊖ LR 0.3). ± Asymm (&gt;20 mmHg) BP or pulse (⊕ LR 5.7), focal neuro deficit (⊕ LR &gt;6), AI, widened mediast. on CXR (absence ⊖ LR 0.3); false lumen on imaging.</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">PE</b></p></td>
<td class="th1"><p class="tbody">Sudden onset pleuritic pain. ↑ RR &amp; HR, ↓ S<sub class="calibre17">a</sub>O<sub class="calibre17">2</sub>, ECG ∆s (sinus tach, RAD, RBBB, S<sub class="calibre17">I</sub>Q<sub class="calibre17">III</sub>T<sub class="calibre17">III</sub>, TWI V<sub class="calibre17">1</sub>–V<sub class="calibre17">4</sub>, occ STE V<sub class="calibre17">1</sub>–V<sub class="calibre17">3</sub>), + CTA or V/Q, ± ↑ Tn.</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Pulm HTN</b></p></td>
<td class="th1"><p class="tbody">Exertional pressure, DOE. ↓ S<sub class="calibre17">a</sub>O<sub class="calibre17">2</sub>, loud P<sub class="calibre17">2</sub>, RV heave, right S<sub class="calibre17">3</sub> and/or S<sub class="calibre17">4</sub>.</p></td>
</tr>
<tr class="calibre15">
<td colspan="2" class="thh"><p class="tbodyc"><b class="calibre7"><i class="calibre6">Pulmonary Causes</i></b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Pneumonia</b></p></td>
<td class="th1"><p class="tbody">Pleuritic; dyspnea, fever, cough, sputum. ↑ RR, crackles. CXR infiltrate.</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Pleuritis</b></p></td>
<td class="th1"><p class="tbody">Sharp, pleuritic pain. ± Pleuritic friction rub.</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">PTX</b></p></td>
<td class="th1"><p class="tbody">Sudden onset, sharp pleuritic pain. Hyperresonance, ↓ BS. PTX on CXR.</p></td>
</tr>
<tr class="calibre15">
<td colspan="2" class="thh"><p class="tbodyc"><b class="calibre7"><i class="calibre6">GI Causes</i></b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Esoph reflux</b></p></td>
<td class="th1"><p class="tbody">Substernal burning, acid taste in mouth, ↑ by meals. See “GERD.”</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Esoph spasm</b></p></td>
<td class="th1"><p class="tbody">Intense substernal pain. ↑ by swallowing, ↓ by NTG/CCB. Manometry.</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Mallory-Weiss</b></p></td>
<td class="th1"><p class="tbody">Esoph tear precipitated by vomiting. ± Hematemesis. Dx w/ EGD.</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Boerhaave</b></p></td>
<td class="th1"><p class="tbody">Esoph rupture. Severe pain, ↑ w/ swallow. Mediastinal air palpable &amp; on CT.</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">PUD</b></p></td>
<td class="th1"><p class="tbody">Epigastric pain, relieved by antacids. ± GIB. EGD, ± <i class="calibre6">H. pylori</i> test.</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Biliary dis.</b></p></td>
<td class="th1"><p class="tbody">RUQ pain, N/V. ↑ by fatty foods. RUQ U/S, CT, MRCP; ↑ LFTs.</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Pancreatitis</b></p></td>
<td class="th1"><p class="tbody">Epigastric/back discomfort. ↑ amylase &amp; lipase; abdominal CT.</p></td>
</tr>
<tr class="calibre15">
<td colspan="2" class="thh"><p class="tbodyc"><b class="calibre7"><i class="calibre6">Musculoskeletal and Miscellaneous Causes</i></b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Costochond</b></p></td>
<td class="th1"><p class="tbody">Localized sharp pain. ↑ w/ movement. Reproduced by palpation.</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Zoster</b></p></td>
<td class="th1"><p class="tbody">Intense unilateral pain. Pain may precede dermatomal rash.</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Anxiety</b></p></td>
<td class="th1"><p class="tbody">“Tightness,” dyspnea, palpitations, other somatic symptoms</p></td>
</tr>
</tbody>
</table>
<p class="tfn">(<i class="calibre6">Braunwald’s Heart Disease</i>, 12<sup class="calibre22">th</sup> ed, 2022; <i class="calibre6">JAMA</i> 2015;314:1955)</p>
<p class="h">Initial diagnostic studies</p>
<p class="noindent1">• <b class="calibre7">Focused history:</b> quality, severity, location, radiation; provoking/palliating factors; intensity at onset; duration, freq, &amp; pattern; setting; assoc sx; cardiac hx &amp; risk factors</p>
<p class="noindent1">• <b class="calibre7">Targeted exam:</b> VS (incl. BP in both arms); gallops, murmurs, rubs; signs of vascular dis. (carotid/femoral bruits, ↓ pulses) or CHF; lung &amp; abd. exam; chest wall for reproducibility</p>
<p class="noindent1">• •	<b class="calibre7"><sub class="calibre10">1</sub>2-lead ECG:</b> obtain w/in 10 min; comp to priors &amp; obtain serial ECGs; consider <i class="calibre6">posterior leads</i> (V<sub class="calibre10">7</sub>–V<sub class="calibre10">9</sub>) if hx c/w ACS but stnd ECG unrevealing or ST ↓ V<sub class="calibre10">1</sub>–V<sub class="calibre10">3</sub> &amp; pain refractory</p>
<p class="noindent1">• <b class="calibre7">Troponin:</b> &gt;<i class="calibre6">99th %ile w/ rise and/or fall in approp. setting is dx of AMI</i> <span class="r1">(</span><span class="r2">Circ</span><span class="r1"> 2018;138:e618)</span></p>
<p class="noindent2">High-sens Tn (hsTn) detectable 1 h after injury, peaks ~24 h, can be elevated for &gt;1 wk</p>
<p class="noindent2">✓ at presentation &amp; 1–3 h later; repeat if clinical or ECG ∆s; assess absolute level &amp; Δ</p>
<p class="noindent2">Ddx: <i class="calibre6">MI</i> (type 1 [plaque rupture] or 2 [supply-demand mismatch not due to Δ in CAD), <i class="calibre6">non-ischemic cardiac</i> (eg, myocarditis, ADHF, Takotsubo, defibrillation, contusion), <i class="calibre6">systemic illness</i> (eg, PE, PHT, stroke, SAH, critical illness)</p>
<p class="noindent1">• <b class="calibre7">CXR;</b> other imaging (echo, PE CTA, etc.) as indicated based on H&amp;P and initial testing</p>
<p class="h">Initial approach <span class="r1">(</span><span class="r2">Circ</span><span class="r1"> 2021;144:e368)</span></p>
<p class="noindent1">• •	R/o life-threatening causes (ACS, PE, AoD, myopericarditis, etc.)</p>
<p class="noindent1">• If possible ACS, risk stratify w/ clinician decision pathway (clinical factors + ECG + Tn)</p>
<p class="noindent1">• <b class="calibre7">Low prob ACS</b> (eg, H&amp;P unconcerning, ⊖ ECG &amp; Tn): d/c to home; risk factor mgmt</p>
<p class="noindent1">• <b class="calibre7">Intermed prob ACS</b> (neither low nor high clinical risk, ± borderline Tn): ✓ TTE and</p>
<p class="noindent2">If no known CAD → CCTA or stress (former ↓ LOS c/w fxnal testing; <span class="r2">NEJM</span><span class="r1"> 2012;366:1393</span>)</p>
<p class="noindent2">If recent mildly ⊕ stress or known non-obstructive CAD → CCTA</p>
<p class="noindent2">If obstructive but not high-risk CAD → stress test</p>
<p class="noindent2">If recent mod-severely ⊕ stress or high-risk CAD (LM, prox LAD, MVD) → invasive angio</p>
<p class="noindent1">• <b class="calibre7">High prob ACS</b> (eg, ECG Δs, ⊕ Tn, new ↓ LVEF): invasive coronary angiography</p>
<p class="noindent1">• Pts w/ acute CP: CCTA vs. stress testing → ↓ time to dx &amp; LOS (less so in era of hsTn), but ↑ probability of cath/PCI <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2012;366:1393 &amp; 367:299;</span> <span class="r2">JACC</span> <span class="r1">2013;61:880)</span></p>
<h2 class="ct"><a id="h3" class="calibre8"></a><a id="page_1-4" class="calibre8"></a><a href="part0003.html#rh7" class="calibre8">NONINVASIVE EVALUATION OF CAD</a></h2>
<p class="h">Stress testing <span class="r1">(</span><span class="r2">J Nucl Cardiol</span><span class="r1"> 2016;23:606;</span> <span class="r2">EHJ</span><span class="r1"> 2020;41:407)</span></p>
<p class="noindent1">• <b class="calibre7">Indications:</b> evaluate possible CAD sx or ∆ in clinical status in Pt w/ known CAD, risk stratify after chest pain, evaluate exercise tolerance, localize ischemia (imaging required)</p>
<p class="noindent1">• <b class="calibre7">Contraindications</b> <span class="r1">(</span><span class="r2">Circ</span> <span class="r1">2002;106:1883; &amp; 2012;126:2465)</span></p>
<p class="noindent2"><b class="calibre7">Absolute:</b> AMI w/in 48 h, high-risk UA, acute PE, severe sx AS, uncontrolled HF, uncontrolled arrhythmias, severe HTN (SBP &gt;200), myopericarditis, acute AoD</p>
<p class="noindent2"><b class="calibre7">Relative</b> (discuss with stress lab): left main CAD, mod symptomatic valvular stenosis, HCM w/ LVOT obstruction, high-degree AVB, severe electrolyte abnl</p>
<p class="h">Exercise tolerance test <span class="r">(w/ ECG alone)</span></p>
<p class="noindent1">• Generally preferred if Pt can meaningfully exercise; ECG ∆s w/ Se ~65%, Sp ~80%</p>
<p class="noindent1">• Typically via treadmill w/ Bruce protocol (modified Bruce or submax if decond. or recent MI)</p>
<p class="noindent1">• Hold anti-isch. meds (eg, nitrates, βB) if dx’ing CAD but give to assess adequacy of meds</p>
<p class="h">Pharmacologic stress test <span class="r">(nb, requires imaging because ECG not interpretable)</span></p>
<p class="noindent1">• Use if unable to exercise, low exercise tolerance, or recent MI. Se &amp; Sp ≈ exercise.</p>
<p class="noindent1">• Preferred if LBBB, WPW or V-paced, because higher prob of false ⊕ imaging with exercise</p>
<p class="noindent1">• <i class="calibre6">Coronary vasodilator:</i> diffuse vasodilation → relative perfusion defect in vessels w/ fixed epicardial disease. Reveals CAD, but <i class="calibre6">not</i> if Pt <i class="calibre6">ischemic w/ exercise.</i> Regadenoson (↓ side effects), dipyridamole, adenosine. Side effects: flushing, ↓ HR, AVB, SOB, bronchospasm.</p>
<p class="noindent1">• <i class="calibre6">Chronotropes/inotropes</i> (dobuta): more physiologic, but longer test; may precip arrhythmia</p>
<p class="h">Imaging for stress test</p>
<p class="noindent1">• Use if uninterpretable ECG (V-paced, LBBB, resting ST ↓ &gt;1 mm, digoxin, LVH, WPW), after indeterminate ECG test, or if pharmacologic test</p>
<p class="noindent1">• Use when need to localize ischemia (often used if prior coronary revasc)</p>
<p class="noindent1">• Radionuclide myocardial perfusion imaging w/ images obtained at rest &amp; w/ stress</p>
<p class="noindent2"><b class="calibre7">SPECT</b> (eg, <sup class="calibre19">99m</sup>Tc-sestamibi): Se ~85%, Sp ~80%</p>
<p class="noindent2"><b class="calibre7">PET</b> (rubidium-82): Se ~90%, Sp ~85%; requires pharmacologic stress, not exercise</p>
<p class="noindent2">ECG-gated imaging allows assessment of regional LV fxn (sign of ischemia/infarction)</p>
<p class="noindent1">• <b class="calibre7">Echo</b> (exercise or dobuta): Se ~80%, Sp ~85%; no radiation; operator dependent</p>
<p class="h">Test results</p>
<p class="noindent1">• <b class="calibre7">HR</b> (must achieve ≥85% of max pred HR [220-age] for <i class="calibre6">exer.</i> test to be dx), <b class="calibre7">BP</b> response, peak <b class="calibre7">double product</b> (HR × BP; nl &gt;20k), HR recovery (HR<sub class="calibre10">peak</sub> – HR<sub class="calibre10">1 min later</sub>; nl &gt;12)</p>
<p class="noindent1">• <b class="calibre7">Max exercise capacity</b> achieved (METS or min); <b class="calibre7">occurrence of symptoms</b></p>
<p class="noindent1">• <b class="calibre7">ECG</b> ∆<b class="calibre7">s:</b> <i class="calibre6">downsloping</i> or <i class="calibre6">horizontal</i> ST ↓ (≥1 mm) 60–80 ms after QRS predictive of CAD (but does <i class="calibre6">not</i> localize ischemic territory); however, STE highly predictive &amp; localizes</p>
<p class="noindent1">• Duke treadmill score = exercise min – (5 × max ST dev) – (4 × angina index) [0 none, 1 nonlimiting, 2 limiting]; score ≥5 → &lt;1% 1-y mort; –10 to + 4 → 2–3%; ≤–11 → ≥5%</p>
<p class="noindent1">• <b class="calibre7">Imaging:</b> radionuclide defects or echocardiographic regional wall motion abnormalities</p>
<p class="noindent2">reversible defect = ischemia; fixed defect = infarct; transient isch dilation → ? severe 3VD</p>
<p class="noindent2">false ⊕: breast → ant defect; diaphragm → inf defect. False ⊖: balanced (3VD) ischemia.</p>
<p class="h">High-risk test results <span class="r">(PPV ~50% for LM or 3VD,</span> ∴<span class="r"> consider coronary angio)</span></p>
<p class="noindent1">• ECG: ST ↓ ≥2 mm <i class="calibre6">or</i> ≥1 mm in stage 1 <i class="calibre6">or</i> in ≥5 leads <i class="calibre6">or</i> ≥5 min in recovery; ST ↑; VT</p>
<p class="noindent1">• Physiologic: ↓ or fail to ↑ BP, &lt;4 METS, angina during exercise, Duke score ≤–11; ↓ EF</p>
<p class="noindent1">• Radionuclide: ≥1 lg or ≥2 mod. reversible defects, transient LV cavity dilation, ↑ lung uptake</p>
<p class="h">Myocardial viability <span class="r1">(</span><span class="r2">Circ CV Imaging</span><span class="r1"> 2020;13:e53)</span></p>
<p class="noindent1">• Goal: identify hibernating myocardium that could regain fxn after revascularization</p>
<p class="noindent1">• Options: <b class="calibre7">MRI</b> (Se ~95%, Sp ~50%), <b class="calibre7">PET</b> (Se ~90%, Sp ~65%), <b class="calibre7">dobutamine stress</b></p>
<p class="noindent2"><b class="calibre7">echo</b> (Se ~80%, Sp ~80%); <b class="calibre7">SPECT/rest-redistribution</b> (Se ~85%, Sp ~65%)</p>
<p class="noindent1">• Pts w/ ischemic CMP (EF &lt;35%), viability predicts ↑ EF w/ CABG but not survival or benefit of CABG vs. medical Rx <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2011;364:1617 &amp; 2019;381:739)</span></p>
<p class="h">Coronary CT angiography <span class="r1">(</span><span class="r2">JCCT</span> <span class="r1">2021;15:192)</span></p>
<p class="noindent1">• <i class="calibre6">Gated</i> CT of heart timed during peak contrast enhancement in coronary arteries</p>
<p class="noindent1">• NTG given to dilate coronary arteries. β-blockers commonly used to lower HR.</p>
<p class="noindent1">• CT-FFR: uses computational fluid dynamics to estimate fxnal significance of focal lesions</p>
<p class="noindent1">• CAD-RADS score in stable CP improves risk stratif. of CV events <span class="r1">(</span><span class="r2">JACC Img</span> <span class="r1">2020;13:1534)</span></p>
<p class="noindent1">• In stable outPt w/ CP: CCTA added to stnd of care → ↑ early but not overall angiography/revasc; ↑ use of preventive med Rx, and ↓ coronary death/MI by 5 y <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2018;379:924)</span></p>
<p class="h">Coronary artery calcium (CAC) score</p>
<p class="noindent1">• Quantifies extent of calcium; thus, <i class="calibre6">estimates</i> plaque burden (but <i class="calibre6">not</i> % coronary stenosis)</p>
<p class="noindent1">• CAC sensitive (91%) but not specific (49%) for presence of CAD; high NPV to r/o CAD</p>
<p class="noindent1">• In intermediate-risk or selected borderline-risk adults (ie, 10-year ASCVD risk of 5–20%), if decision about statin remains uncertain, reasonable to use CAC score to help guide</p>
<h2 class="ct"><a id="h4" class="calibre8"></a><a id="page_1-5" class="calibre8"></a><a href="part0003.html#rh8" class="calibre8">CORONARY ANGIOGRAPHY &amp; PCI</a></h2>
<p class="h">Precath checklist</p>
<p class="noindent1">• Peripheral arterial exam (radial, femoral, DP, PT pulses; bruits); palmar arch eval (eg, w/ pulse oximetry &amp; plethysmography) not routinely done. ✓ can lie flat × hrs, NPO &gt;6 h.</p>
<p class="noindent1">• ✓ CBC, PT-INR (ideally ≤2), Cr; hold ACEI/ARB if renal dysfxn. Blood bank sample.</p>
<p class="noindent1">• ↓ risk of contrast-induced kidney injury: hold ACEI/ARB/ARNI, NSAIDs, diuretics. PreRx w/ isotonic IVF: data mixed, but may be helpful if high risk <span class="r1">(</span><span class="r2">Lancet</span> <span class="r1">2017;389:1312)</span>.</p>
<p class="noindent1">• If iodinated contrast allergy, preRx w/ steroids &amp; antihistamines</p>
<p class="h">Vascular access</p>
<p class="noindent1">• Radial access preferred for coronary angiography: ↓ major bleeding &amp; vascular complications, and possibly mortality benefit <span class="r1">(</span><span class="r2">Circ CI</span> <span class="r1">2018;11:e000035)</span></p>
<p class="noindent1">• Femoral artery commonly used; high puncture ↑ risk of retroperitoneal bleed; low puncture ↑ risk of arterial complic. (eg, AV fistula, superficial femoral artery cannulation)</p>
<p class="h">Periprocedural pharmacotherapy for PCI</p>
<p class="noindent1">• <b class="calibre7">ASA</b> 325 mg × 1. <b class="calibre7">P2Y<sub class="calibre10">12</sub> inhibitor</b>: ticagrelor or prasugrel preferred over clopidogrel in ACS. Outside of STEMI, preRx load not recommended when anatomy unknown. Cangrelor (IV P2Y<sub class="calibre10">12</sub> inhib) ↓ peri-PCI events vs. clopi w/o PreRx <span class="r1">(</span><span class="r2">NEJM</span><span class="r1"> 2013;368:1303)</span>.</p>
<p class="noindent1">• GP IIb/IIIa inhibitor: sometimes added if periprocedural thrombotic complication</p>
<p class="noindent1">• <b class="calibre7">Anticoagulant:</b> UFH or bivalirudin (if HIT) typically given during case and stopped at end</p>
<p class="h">PCI and peri-PCI interventions</p>
<p class="noindent1">• <i class="calibre6">Physiology:</i> fractional flow reserve (FFR): ratio of max flow (induced by adenosine) distal vs. prox to stenosis to ID hemodyn. signif. lesions (≤0.80). Instantaneous wave-free ratio (iFR) similar, doesn’t require vasodilator; iFR threshold ≤0.89 <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2017;376:1813 &amp; 1824)</span>.</p>
<p class="noindent1">• <i class="calibre6">Advanced imaging:</i> intravascular U/S (IVUS) or optical coherence tomography (OCT)</p>
<p class="noindent1">• Drug-eluting stents (DES): ↓ cardiac death, MI, repeat revasc, &amp; stent thrombosis vs. BMS <span class="r1">(</span><span class="r2">Lancet</span> <span class="r1">2019;393:2503)</span>. Balloon angioplasty alone reserved for lesions too narrow to stent.</p>
<p class="h">Peri-PCI complications</p>
<p class="noindent1">• No or slow reflow: Rx with local delivery of vasodilators</p>
<p class="noindent1">• Coronary artery dissection: treat with stent</p>
<p class="noindent1">• Coronary perforation: immediate balloon tamponade, ✓ for effusion, seal w/ covered stent</p>
<p class="h">Vascular access post-PCI complications</p>
<p class="noindent1">• Postprocedure ✓ vascular access site, distal pulses, ECG, CBC, Cr</p>
<p class="noindent1">• <b class="calibre7">Bleeding</b>: reverse/stop anticoag (d/w interventionalist); IV fluids/PRBC/plts as required</p>
<p class="noindent2"><i class="calibre6">hematoma/overt bleeding:</i> <b class="calibre7">manual compression</b></p>
<p class="noindent2"><i class="calibre6">retroperitoneal bleed</i>: may p/w ↓ Hct ± flank or back pain. CT abd/pelvis (I<sup class="calibre19">–</sup>) or angio if unstable. If does not auto-tamponade, intravascular balloon and/or covered stent.</p>
<p class="noindent1">• <b class="calibre7">Vascular damage</b> (~1% of dx angio, ~5% of PCI; <span class="r2">Circ</span><span class="r1"> 2007;115:2666</span>)</p>
<p class="noindent2"><i class="calibre6">pseudoaneurysm:</i> triad of pain, expansile mass, systolic bruit; diagnose w/ U/S;</p>
<p class="noindent3">Rx (if pain or &gt;2 cm): U/S-directed thrombin injection, surgical repair if former fails</p>
<p class="noindent2"><i class="calibre6">AV fistula:</i> continuous bruit; Dx: U/S; Rx: surgical repair if large or sx</p>
<p class="noindent2"><i class="calibre6">limb ischemia</i> (emboli, dissection, clot): cool, mottled extremity, ↓ distal pulses; Dx: loss of pulses, ↓ pulse volume recording, angio; Rx: percutaneous or surgical repair</p>
<p class="noindent2"><i class="calibre6">radial artery occlusion</i>: if sx, consider 4 weeks LMWH</p>
<p class="h">Other complications <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2017;377:1513)</span></p>
<p class="noindent1">• <b class="calibre7">Contrast-induced AKI:</b> w/in 48 h, peak 3–5 d; pre-hydration reasonable (see “CIAKI”)</p>
<p class="noindent1">• <b class="calibre7">Stroke</b>: ~0.1–0.4% of cases. Usually ischemic from atheroembolic event during cath. Rx depends on sx/location/timing but includes thrombectomy, tPA, DAPT if ischemic.</p>
<p class="noindent1">• <b class="calibre7">Cholesterol emboli syndrome</b>: typically in Pts w/ large burden Ao atheroma; mesenteric ischemia (abd pain, LGIB, pancreatitis); intact distal pulses but livedo and toe necrosis</p>
<p class="h">Stent post-PCI complications</p>
<p class="noindent1">• <b class="calibre7">Stent thrombosis:</b> acute clot formation in stent usually in 1<sup class="calibre19">st</sup> mo but can occur anytime. Typically p/w AMI. Often due to premature d/c antiplt Rx or mech prob. (stent underexpansion or unrecognized dissection, typically presents early).</p>
<p class="noindent1">• <b class="calibre7">In-stent restenosis:</b> develops in previously stented segment mos after PCI. Typically p/w gradual ↑ angina. Due to elastic recoil and neointimal hyperplasia; ↓ w/ DES.</p>
<p class="h">Duration of dual antiplatelet therapy <span class="r1">(</span><span class="r2">JACC</span> <span class="r1">2016;68:1082 &amp;</span> <span class="r2">EHJ</span><span class="r1"> 2018;39:213)</span></p>
<p class="noindent1">• DAPT duration determined by patient presentation (ACS vs. SIHD), long-term ischemic risk (patient and procedural risk factors), and bleeding risk</p>
<p class="noindent1">• Antiplt Rx: DAPT (ASA 81 + P2Y<sub class="calibre10">12</sub> inhib) in SIHD for 4 wk (BMS) or ≥6 mo (DES); in <i class="calibre6">ACS</i> (qv) for 12 mo and possibly beyond <span class="r1">(</span><span class="r2">JAMA Cards</span> <span class="r1">2016;1:627)</span>. Data emerging for DAPT 1–3 mo, followed by P2Y<sub class="calibre10">12</sub> inhib monotherapy <span class="r1">(</span><span class="r2">Circ</span> <span class="r1">2020;142:538)</span>.</p>
<p class="noindent1">• If need long-term oral anticoag, consider clopi+DOAC and consider stopping ASA (? after ~1 wk) as ↓ bleed, but trend small ↑ ischemic risk <span class="r1">(</span><span class="r2">JAMA</span><span class="r1"> Cardiol. 2020;5:582)</span></p>
<h2 class="ct"><a id="h5" class="calibre8"></a><a id="page_1-6" class="calibre8"></a><a href="part0003.html#rh9" class="calibre8">STABLE ISCHEMIC HEART DISEASE</a></h2>
<p class="h">Definition</p>
<p class="noindent1">• SIHD refers to asx and stably sx Pts as well as low-risk new-onset chest pain felt to be due to IHD, and excludes Pts w/ rapidly progressive sx or rest sx (ie, ACS)</p>
<p class="h">Noninvasive testing <span class="r1">(</span><span class="r2">Circ</span> <span class="r1">2012;126:e354 &amp; 2021;144;e368)</span></p>
<p class="noindent1">• Noninvasive dx testing most valuable when pretest probability is <i class="calibre6">intermediate</i> (variably defined as anywhere from 30–70% to 10–90%)</p>
<p class="noindent1">• Several pretest probability scores that take into account age, sex, nature of sx, risk factors</p>
<p class="noindent1">• Exercise ECG testing or CAC reasonable in some low-risk Pts</p>
<p class="noindent1">• In intermediate/high-risk Pts, stress test w/ imaging or CCTA (see “Noninv Eval of CAD”)</p>
<p class="noindent1">• If known nonobstructive CAD &amp; stable chest pain: stress testing or CCTA ± FFR</p>
<p class="noindent1">• If obstructive CAD &amp; stable chest pain: stress testing or invasive angio if high-risk CAD</p>
<p class="h">Coronary angiography for SIHD <span class="r1">(</span><span class="r2">Circ</span> <span class="r1">2014;130:1749)</span></p>
<p class="noindent1">• High-risk noninvasive testing results suggestive of left main or multivessel CAD</p>
<p class="noindent1">• Angina that is refractory to optimal medical therapy</p>
<p class="noindent1">• Uncertain dx after noninvasive testing, occupational need (eg, pilot)</p>
<p class="noindent1">• Unexplained heart failure or ↓ EF</p>
<p class="h">Major risk factor modification <span class="r1">(</span><span class="r2">Circ</span> <span class="r1">2012;126:e354)</span></p>
<p class="noindent1">• Lipids: <b class="calibre7">statin</b> (typically high-intensity) ± ezetimibe &amp; PCSK9i (see “Dyslipidemia”)</p>
<p class="noindent1">• <b class="calibre7">BP</b> &lt;<b class="calibre7"><sub class="calibre10">1</sub>30/80</b> (see “Hypertension”); in SIHD may opt for ACEI and βB (if angina)</p>
<p class="noindent1">• <b class="calibre7">Diabetes</b> management (qv): Hb<sub class="calibre10">A1c</sub> ≤7% and consider GLP1RA or SGLT2i</p>
<p class="noindent1">• <b class="calibre7">Smoking cessation</b>; influenza vaccine</p>
<p class="noindent1">• Diet (↑ vegetables, fruits, whole grains; ↓ saturated fat, <i class="calibre6">trans</i> fatty acids, sweets, red meat, Na); target BMI 18.5–24.9 kg/m<sup class="calibre19">2</sup>; 30–60 min mod-to-vigorous physical activity ≥5×/wk</p>
<p class="h">Optimal medical therapy (OMT) <span class="r1">(</span><span class="r2">Circ</span> <span class="r1">2012;126:e354)</span></p>
<p class="noindent1">• <b class="calibre7">ASA</b> 75–162 mg/d; can substitute clopi if ASA-intolerant. ~12 mos after PCI, clopi monoRx ↓ risk of ischemic and bleeding events by ~30% c/w ASA monoRx <span class="r1">(</span><span class="r2">Lancet</span> <span class="r1">2021;397:2487)</span>.</p>
<p class="noindent1">• <b class="calibre7">βB</b> for 3 years post-MI or if ↓ EF; can consider in all Pts w/ SIHD</p>
<p class="noindent1">• <b class="calibre7">ACEI</b> (or ARB if intolerant of ACEI) if HTN, DM, CKD, or ↓ EF <span class="r1">(</span><span class="r2">Lancet</span> <span class="r1">2006;368:581)</span></p>
<p class="noindent1">• Dual antiplatelet therapy (ASA + P2Y<sub class="calibre10">12</sub> inhibitor): ↓ CV events by ~10% in Pts with known IHD w/o MI but w/ DM, but ↑ bleeding <span class="r1">(THEMIS,</span> <span class="r2">NEJM</span><span class="r1"> 2019; 381:1309)</span></p>
<p class="noindent1">• Rivaroxaban 2.5 mg bid + ASA 100 mg/d: 24% ↓ CV events and 18% ↓ death vs. ASA alone, but ↑ major bleeding in stable ASCVD <span class="r1">(COMPASS,</span> <span class="r2">NEJM</span><span class="r1"> 2017;377:1319)</span></p>
<p class="noindent1">• Colchicine (0.5 mg/d): ↓ CV events by 31%, but ? ↑ non-CV death <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2020;383:1838)</span></p>
<p class="h">Medical therapies for symptomatic relief <span class="r1">(</span><span class="r2">Circ</span> <span class="r1">2014;130:1749)</span></p>
<p class="noindent1">• <b class="calibre7">Beta-blockers</b> <i class="calibre6">1<sup class="calibre19">st</sup>-line therapy</i>; CCB (except short-acting dihydropyridines)</p>
<p class="noindent1">• <b class="calibre7">Long-acting nitrates</b></p>
<p class="noindent1">• Ranolazine (↓ late inward Na+ current to ↓ myocardial demand): 2<sup class="calibre19">nd</sup>-line anti-anginal</p>
<p class="h">Revascularization <span class="r1">(</span><span class="r2">JAMA</span> <span class="r1">2021;325:1765;</span> <span class="r2">Circ</span> <span class="r1">2022;145:e18)</span></p>
<p class="noindent1">• OMT should be initial focus if stable &amp; w/o evidence of critical anatomy &amp; w/ normal EF</p>
<p class="noindent1">• Goal of revasc should be to ↓ risk of CV morbidity &amp; mortality or to relieve refractory sx</p>
<p class="noindent1">• <i class="calibre6">Older studies:</i> survival benefit w/ revascularization (CABG) vs. medical Rx (pre-statin era) if: left main disease (≥50% stenosis); 3VD (≥70% stenoses) especially if ↓ EF, 2VD w/ critical proximal LAD, DM, ? 1–2 VD w/ large area of viable, ischemic myocardium</p>
<p class="noindent1">• <i class="calibre6">More recent studies:</i> revascularization (largely if not exclusively PCI) vs. OMT did not Δ risk of death, ↑ peri-PCI MI, and ± ↓ spontaneous MI <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2007;356:1503 &amp; 2020;382:1395)</span></p>
<p class="noindent1">• In the most recent trial <span class="r1">(ISCHEMIA,</span> <span class="r2">NEJM</span><span class="r1"> 2020;382:1395)</span>, which enrolled Pts w/ moderate-severe ischemia by noninvasive testing w/o LM disease and w/ preserved LVEF, revasc (~¾ PCI, ~¼ CABG) ↑ 5-yr rate of peri-procedural MI by ~2% and ↓ 5-yr rate of spontaneous MI by 3%. Nonsignificant ~1% lower rate of CV death by 5 yrs that appeared to start to emerge after 2 yrs. Magnitude of benefit tended to be greater in those with multivessel disease, proximal LAD disease, or diabetes.</p>
<p class="noindent1">• In Pts w/ CAD, HF, &amp; LVEF &lt;35%, CABG compared w/ medical Rx ↓ mortality by 16% and ↓ CV mortality by 21% after a median of 10 yrs <span class="r1">(STICHES,</span> <span class="r2">NEJM</span> <span class="r1">2016;374:1511)</span></p>
<p class="noindent1">• Thus, recommendations <span class="r1">(</span><span class="r2">Circ</span> <span class="r1">2012;126:e354 &amp;</span> <span class="r2">EHJ</span> <span class="r1">2019;40:87)</span> for revascularization include:</p>
<p class="noindent2"><i class="calibre6">Indicated in:</i> ≥50% left main stenosis, 3VD (≥70% stenoses), 2VD w/ proximal LAD, unacceptable angina despite OMT</p>
<p class="noindent2"><i class="calibre6">Reasonable if:</i> 2VD + extensive myocardial ischemia, MVD or proximal LAD disease + ↓ EF, proximal LAD disease + extensive ischemia, MVD + diabetes (if can get CABG)</p>
<p class="noindent1">• Trials of PCI vs. CABG in Pts w/ MVD or LM disease have shown CABG ↓ risk of spontaneous MI, repeat revascularization, ± death. These benefits appear greater in those with more complex coronary anatomy or with diabetes <span class="r1">(</span><span class="r2">Lancet</span><span class="r1"> 2018;391:939 &amp; 2021;398:2247)</span>.</p>
<h2 class="ct"><a id="h6" class="calibre8"></a><a id="page_1-7" class="calibre8"></a><a href="part0003.html#rh10" class="calibre8">ACUTE CORONARY SYNDROMES</a></h2>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre23"/>
<col class="calibre23"/>
<col class="calibre23"/>
<col class="calibre23"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="4"><p class="tbodyc"><b class="calibre7">Spectrum of Acute Coronary Syndromes</b></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Dx</b></p></td>
<td class="th1"><p class="tbodyc"><b class="calibre7">UA</b></p></td>
<td class="th1"><p class="tbodyc"><b class="calibre7">NSTEMI</b></p></td>
<td class="th1"><p class="tbodyc"><b class="calibre7">STEMI</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Coronary thrombosis</b></p></td>
<td colspan="2" class="th1"><p class="tbodyc">Subtotal occlusion</p></td>
<td class="th1"><p class="tbodyc">Total occlusion</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">History</b></p></td>
<td colspan="2" class="th1"><p class="tbodyc">Angina that is new-onset, crescendo or at rest; usually &lt;30 min</p></td>
<td class="th1"><p class="tbodyc">Angina at rest</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">ECG</b></p></td>
<td colspan="2" class="th1"><p class="tbodyc">± ST depression and/or TWI</p>
<p class="tbodyc"><img src="../images/00012.jpeg" alt="" class="calibre5"/></p></td>
<td class="th1"><p class="tbodyc">ST elevations</p>
<p class="tbodyc"><img src="../images/00013.jpeg" alt="" class="calibre5"/></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Troponin/CK-MB</b></p></td>
<td class="th1"><p class="tbodyc">⊖</p></td>
<td class="th1"><p class="tbodyc">⊕</p></td>
<td class="th1"><p class="tbodyc">⊕ ⊕</p></td>
</tr>
</tbody>
</table>
<p class="h">Ddx<span class="r"> (causes of myocardial ischemia/infarction other than atherosclerotic plaque rupture)</span></p>
<p class="noindent1">• <b class="calibre7">Ischemia w/o plaque rupture</b> (“type 2” MI): ↑ demand (eg, ↑ HR), ↓ supply (eg, HoTN). More likely in older, ♀, non-CAD comorbidities (CKD, etc.) <span class="r1">(</span><span class="r2">JACC</span><span class="r1"> 2021;77:848)</span>. Distinguishing from ACS is clinical dx; angiography is gold standard.</p>
<p class="noindent1">• <b class="calibre7">Nonatherosclerotic coronary artery disease</b> <span class="r1">(</span><span class="r2">JACC</span> <span class="r1">2018;72:2231)</span></p>
<p class="noindent2">Spasm: Prinzmetal’s variant, cocaine-induced (6% of chest pain + cocaine use r/i for MI)</p>
<p class="noindent2">Dissection: spontaneous (vasculitis, CTD, pregnancy), aortic dissection with retrograde extension (usually involving RCA → IMI) or mechanical (PCI, surgery, trauma)</p>
<p class="noindent2">Embolism <span class="r1">(</span><span class="r2">Circ</span> <span class="r1">2015;132:241):</span> AF, thrombus/myxoma, endocard., prosth valve thrombosis</p>
<p class="noindent2">Vasculitis: Kawasaki syndrome, Takayasu arteritis, PAN, Churg-Strauss, SLE, RA</p>
<p class="noindent2">Congenital: anomalous origin from aorta or PA, myocardial bridge (intramural segment)</p>
<p class="noindent1">• <b class="calibre7">Direct myocardial injury:</b> myocarditis; Takotsubo/stress CMP; toxic CMP; cardiac contusion</p>
<p class="h">Clinical manifestations <span class="r1">(</span><span class="r2">JAMA</span> <span class="r1">2015;314:1955)</span></p>
<p class="noindent1">• <b class="calibre7">Cardiac chest pain (“angina”):</b> retrosternal pressure/pain/tightness ± radiation to neck, jaw, arms. Precipitated by exertion (physical or emotional), ↓ w/ rest or NTG. In ACS: new-onset, crescendo or at rest.</p>
<p class="noindent1">• <b class="calibre7">Associated symptoms:</b> dyspnea, diaphoresis, N/V, palpitations or light-headedness</p>
<p class="noindent1">• Nonclassic sx (incl N/V &amp; epig pain) ? more common in ♀, elderly, diabetes, inf. ischemia</p>
<p class="h">Physical exam <span class="r">(may be seen, but often are not)</span></p>
<p class="noindent1">• Signs of ischemia: S<sub class="calibre10">4</sub>, new MR murmur 2° pap. muscle dysfxn, paradoxical S<sub class="calibre10">2</sub>, diaphoresis</p>
<p class="noindent1">• Signs of HF (eg, if large MI or ischemic MR): ↑ JVP, crackles, ⊕ S<sub class="calibre10">3</sub>, HoTN, cool extremities</p>
<p class="noindent1">• Signs of other vascular disease: asymmetric BP, carotid or femoral bruits, ↓ distal pulses</p>
<p class="h">Diagnostic studies <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2017;376:2053)</span></p>
<p class="noindent1">• <b class="calibre7">ECG:</b> ST ↓/↑, TWI, new LBBB, hyperacute Tw; Qw/PRWP may suggest prior MI &amp; ∴ CAD</p>
<p class="noindent2">✓ ECG w/in 10 min of presentation, with any ∆ in sx &amp; at 6–12 h; compare w/ baseline</p>
<p class="noindent1">• STEMI dx challenging w/ old LBBB or ventricular pacing:</p>
<p class="noindent2">Sgarbossa: ≥1 mm STE <i class="calibre6">concordant</i> w/ QRS (Se 73%, Sp 92%), STD ≥1 mm V<sub class="calibre10">1</sub>–V<sub class="calibre10">3</sub> (Se 25%, Sp 96%), STE ≥5 mm <i class="calibre6">discordant</i> w/ QRS (Se 31%, Sp 92%)</p>
<p class="noindent2">Barcelona: ST deviation ≥1 mm <i class="calibre6">concordant</i> w/ QRS in any lead, or ST deviation ≥1 mm <i class="calibre6">discordant</i> w/ QRS in leads with max voltage (largest R or S) ≤6 mm (Se 93%, Sp 94%)</p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre20"/>
<col class="calibre18"/>
<col class="calibre20"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="3"><p class="tbodyc"><b class="calibre7">Localization of MI</b></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbodyc"><b class="calibre7">Anatomic Area</b></p></td>
<td class="th1"><p class="tbodyc"><b class="calibre7">ECG Leads w/ STE</b></p></td>
<td class="th1"><p class="tbodyc"><b class="calibre7">Coronary Artery</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc">Septal</p></td>
<td class="th1"><p class="tbodyc">V<sub class="calibre17">1</sub>–V<sub class="calibre17">2</sub> ± aVR</p></td>
<td class="th1"><p class="tbodyc">Proximal LAD</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc">Anterior</p></td>
<td class="th1"><p class="tbodyc">V<sub class="calibre17">3</sub>–V<sub class="calibre17">4</sub></p></td>
<td class="th1"><p class="tbodyc">LAD</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc">Apical</p></td>
<td class="th1"><p class="tbodyc">V<sub class="calibre17">5</sub>–V<sub class="calibre17">6</sub></p></td>
<td class="th1"><p class="tbodyc">Distal LAD, LCx, or RCA</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc">Lateral</p></td>
<td class="th1"><p class="tbodyc">I, aVL</p></td>
<td class="th1"><p class="tbodyc">LCx</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc">Inferior</p></td>
<td class="th1"><p class="tbodyc">II, III, aVF ± aVR</p></td>
<td class="th1"><p class="tbodyc">RCA (~85%), LCx (~15%)</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc">RV</p></td>
<td class="th1"><p class="tbodyc">V<sub class="calibre17">1</sub>–V<sub class="calibre17">2</sub> &amp; V<sub class="calibre17">4</sub>R (most Se)</p></td>
<td class="th1"><p class="tbodyc">Proximal RCA</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc">Posterior</p></td>
<td class="th1"><p class="tbodyc">ST <i class="calibre6">depression</i> V<sub class="calibre17">1</sub>–V<sub class="calibre17">3</sub> (= STE V<sub class="calibre17">7</sub>–V<sub class="calibre17">9</sub> posterior leads, ✓ if clinical suspicion)</p></td>
<td class="th1"><p class="tbodyc">RCA or LCx</p></td>
</tr>
</tbody>
</table>
<p class="tfn">If ECG non-dx &amp; suspicion high, ✓ leads V<sub class="calibre24">7</sub>–V<sub class="calibre24">9</sub> (⊕ if ≥0.5 mm STE) to assess distal LCx/RCA territory. ✓ R-sided precordial leads in IMI to detect RV involvement (STE in V<sub class="calibre24">4</sub>R most Se). STE in III &gt;STE in II and lack of STE in I or aVL suggest RCA rather than LCx culprit in IMI. STE in aVR suggests LM, prox LAD, or diffuse ischemia.</p>
<p class="noindent1">• <b class="calibre7">Cardiac biomarkers:</b> ✓ Tn (pref. over CK-MB) at presentation &amp; 3–6 h if stnd assay or 1 h later if high-sens assay; repeat if clinical or ECG ∆s. <b class="calibre7">Universal definition of MI:</b> &gt;99th %ile w/ rise and/or fall in appropriate clinical setting (eg, sx, ECG ∆s, WMA on TTE, thrombus on coronary angiography).</p>
<p class="noindent1">• If low prob, <b class="calibre7">stress test</b> <span class="r">or</span><b class="calibre7"> CT angio</b> to r/o CAD; new wall motion abnl on TTE suggests ACS</p>
<p class="noindent1">• <b class="calibre7">Coronary angio</b> gold standard for epicardial CAD</p>
<p class="h"><a id="page_1-8" class="calibre4"></a>Prinzmetal’s (variant) angina</p>
<p class="noindent1">• Coronary spasm → transient STE usually w/o MI (<i class="calibre6">but</i> MI, AVB, VT can occur)</p>
<p class="noindent1">• Pts usually young, smokers, ± other vasospastic disorders (eg, migraines, Raynaud’s)</p>
<p class="noindent1">• Angiography: nonobstructive CAD (spasm can be provoked during cath but rarely done)</p>
<p class="noindent1">• Treatment: high-dose CCB &amp; standing nitrates (+SL prn), ? α-blockers/statins; d/c smoking; avoid high-dose ASA (can inhibit prostacyclin and worsen spasm), nonselect βB, triptans</p>
<p class="noindent1">• Cocaine-induced vasospasm: CCB, nitrates, ASA; ? avoid βB, but labetalol appears safe</p>
<p class="h">MI in absence of obstructive CAD <span class="r">(MINOCA)</span></p>
<p class="noindent1">• Definition: MI but w/o coronary stenosis ≥50% in any major epicardial vessel</p>
<p class="noindent1">• More common in younger Pts, women, Black/Pacific race or Hispanic</p>
<p class="noindent1">• Advanced coronary imaging (eg, OCT) &amp; cardiac MRI to exclude missed coronary obstruction, other causes of myocyte injury (eg, myocarditis), other causes of ↑ Tn (eg, PE)</p>
<p class="noindent1">• ~75% ischemic (ie, plaque disruption identified) and 25% alternative dx (eg, myocarditis)</p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre25"/>
<col class="calibre23"/>
<col class="calibre20"/>
<col class="calibre20"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="4"><p class="tbodyc"><b class="calibre7">Likelihood of ACS</b> <span class="sm"><i class="calibre6">(Circ 2007;116:e148; Circ 1994;90[1]:613-22)</i></span></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Feature</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">High</b> (any of below)</p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Intermediate</b> (no high features, any of below)</p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Low</b> (no high/inter. features, may have below)</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">History</b></p></td>
<td class="th1"><p class="tbody">Chest or L arm pain like prior angina, h/o CAD (incl MI)</p></td>
<td class="th1"><p class="tbody">Chest or arm pain, age &gt;70 y, male, diabetes</p></td>
<td class="th1"><p class="tbody">Atypical sx (eg, pleuritic, sharp or positional pain)</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Exam</b></p></td>
<td class="th1"><p class="tbody">HoTN, diaphoresis, HF, transient MR</p></td>
<td class="th1"><p class="tbody">PAD or cerebrovascular disease</p></td>
<td class="th1"><p class="tbody">Pain reproduced on palp.</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">ECG</b></p></td>
<td class="th1"><p class="tbody">New STD (≥1 mm) TWI in mult leads</p></td>
<td class="th1"><p class="tbody">Old Qw, STD (0.5-0.9 mm), TWI (&gt;1 mm)</p></td>
<td class="th1"><p class="tbody">TWF/TWI (&lt;1 mm) in leads w/ dominant R wave</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Biomarkers</b></p></td>
<td class="th1"><p class="tbody">⊕ Tn or CK-MB</p></td>
<td class="th1"><p class="tbody">Normal</p></td>
<td class="th1"><p class="tbody">Normal</p></td>
</tr>
</tbody>
</table>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre20"/>
<col class="calibre21"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="2"><p class="tbodyc"><b class="calibre7">Acute Anti-Ischemic and Analgesic Treatment</b></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbodyh"><b class="calibre7">Nitrates</b> (SL or IV) 0.3–0.4 mg SL q5min × 3, then consider IV if still sx</p></td>
<td class="th1"><p class="tbodyh">Use for relief of sx, Rx for HTN or HF. No clear ↓ in mortality.</p>
<p class="tbodyh"><i class="calibre6">Caution</i> if preload-sensitive (eg, HoTN, AS, sx RV infarct); contraindicated if recent PDE5 inhibitor use.</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">β-blockers</b></p>
<p class="tbodyh">eg, metop 25–50 mg PO q6h titrate slowly to HR 50–60 IV only if HTN and no HF</p></td>
<td class="th1"><p class="tbodyh">↓ ischemia &amp; progression of UA to MI <span class="sm">(<i class="calibre6">JAMA</i> 1988;260:2259)</span></p>
<p class="tbodyh">STEMI: ↓ arrhythmic death &amp; reMI, but high doses can ↑ cardiogenic shock early (espec if signs of HF) <span class="sm">(<i class="calibre6">Lancet</i> 2005;366:1622)</span></p>
<p class="tbodyh"><i class="calibre6">Contraindic.</i> PR &gt;0.24 sec, HR &lt;60, 2°/3° AVB, severe bronchospasm, s/s HF or low output, risk factors for shock (eg, &gt;70 y, HR &gt;110, SBP &lt;120, late presentation STEMI)</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyh"><b class="calibre7">CCB</b> (nondihydropyridines)</p></td>
<td class="th1"><p class="tbodyh">If cannot tolerate βB b/c bronchospasm</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Morphine</b></p></td>
<td class="th1"><p class="tbodyh">Relieves pain/anxiety; venodilation ↓ preload. Do not mask refractory sx. May delay antiplt effects of P2Y<sub class="calibre17">12</sub> inhib.</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Oxygen</b></p></td>
<td class="th1"><p class="tbodyh">Use prn to keep S<sub class="calibre17">a</sub>O<sub class="calibre17">2</sub> &gt;90% <span class="sm">(<i class="calibre6">NEJM</i> 2017;377:1240)</span></p></td>
</tr>
</tbody>
</table>
<p class="h">Other early adjunctive therapy</p>
<p class="noindent1">• <b class="calibre7">High-intensity statin therapy</b> (eg, atorva 80 mg qd; PROVE-IT TIMI 22, <span class="r2">NEJM</span><span class="r1"> 2004;350:1495</span>); ↓ ischemic events w/ benefit emerging w/in wks <span class="r1">(</span><span class="r2">JAMA</span> <span class="r1">2001;285:1711 &amp;</span> <span class="r2">JACC</span><span class="r1"> 2005;46:1405)</span>; ↓ peri-PCI MI <span class="r1">(</span><span class="r2">JACC</span> <span class="r1">2010;56:1099)</span>; ? ↓ contrast-induced nephropathy <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2019;380:2156)</span></p>
<p class="noindent1">• <b class="calibre7">Ezetimibe:</b> ↓ CV events when added to statin (IMPROVE-IT, <span class="r2">NEJM</span><span class="r1"> 2015;372:2387</span>)</p>
<p class="noindent1">• <b class="calibre7">ACEI/ARB:</b> start once hemodynamics and renal function stable (hold if anticipate CABG)</p>
<p class="noindent2">Strong indication for ACEI/ARB if heart failure, EF &lt;40%, HTN, DM, CKD; ~10% ↓ mortality, greatest benefit in ant. STEMI or prior MI <span class="r1">(</span><span class="r2">Lancet</span> <span class="r1">1994;343:1115 &amp; 1995;345:669)</span></p>
<p class="noindent1">• IABP: can be used for refractory angina when PCI not available</p>
<p class="h1cr">NSTE-ACS <span class="r3">(<i class="calibre6">Circ</i> 2014;130:e344; <i class="calibre6">EHJ</i> 2021;42:1289)</span></p>
<p class="center"><i class="calibre6">Key issues are antithrombotic regimen and decision regarding angiography</i></p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre26"/>
<col class="calibre26"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="2"><p class="tbodyc"><b class="calibre7">Antiplatelet Therapy</b></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Aspirin</b></p>
<p class="tbody">162–325 mg × 1, then 81 mg qd</p>
<p class="tbody">(non–enteric-coated, chewable)</p></td>
<td class="th1"><p class="tbody">50–70% ↓ D/MI <span class="sm">(<i class="calibre6">NEJM</i> 1988;319:1105)</span></p>
<p class="tbody">Low dose (~81 mg) pref long term <span class="sm">(<i class="calibre6">NEJM</i> 2010;363:930)</span></p>
<p class="tbody">If allergy, use clopi and/or desensitize to ASA</p></td>
</tr>
<tr class="calibre15">
<td class="th1" colspan="2"><p class="tbody"><b class="calibre7">P2Y</b><sub class="calibre17">1<b class="calibre7">2</b></sub> <b class="calibre7">(ADP receptor) inhibitor</b> (choose one of the following in addition to ASA).</p>
<p class="tbodyh">Timing (on presentation or at angiography) remains controversial.</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><a id="page_1-9" class="calibre4"></a><p class="tnl"><span class="tft">•</span> <b class="calibre7">Ticagrelor</b> (preferred over clopi)</p>
<p class="tbodyh1">180 mg × 1 → 90 mg bid</p>
<p class="tbodyh1">Reversible, but wait 3–5 d prior to surg. Antidote being developed <span class="sm">(<i class="calibre6">NEJM</i> 2019;380:1825)</span>.</p></td>
<td class="th1"><p class="tbodyh">More rapid and potent plt inhib c/w clopi</p>
<p class="tbodyh">16% ↓ CVD/MI/stroke &amp; 21% ↓ CV death c/w clopi; ↑ non-CABG bleeding <span class="sm">(<i class="calibre6">NEJM</i> 2009;361;1045)</span></p>
<p class="tbodyh">Given upstream or at time of PCI</p>
<p class="tbodyh">Dyspnea (but S<sub class="calibre17">a</sub>O<sub class="calibre17">2</sub> &amp; PFTs nl) &amp; ventricular pauses</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tnl"><span class="tft">•</span> <b class="calibre7">Prasugrel</b> (preferred over clopi)</p>
<p class="tbodyh1">60 mg × 1 at PCI → 10 mg qd (consider 5 mg/d if &lt;60 kg)</p>
<p class="tbodyh1">Wait 7 d prior to surgery</p>
<p class="tbodyh1">Contraindicated if h/o TIA/CVA; caution if &gt;75 y</p></td>
<td class="th1"><p class="tbodyh">More rapid and potent plt inhib c/w clopi</p>
<p class="tbodyh">19% ↓ CVD/MI/stroke in ACS w/ planned PCI vs. clopi, but ↑ bleeding <span class="sm">(<i class="calibre6">NEJM</i> 2007;359:2001)</span>, incl fatal bleeds</p>
<p class="tbodyh">In NSTE-ACS, should be given at time of PCI and not upstream due to ↑ bleeding <span class="sm">(<i class="calibre6">NEJM</i> 2013;369:999)</span></p>
<p class="tbodyh">? ↓ MACE vs ticagrelor <span class="sm">(<i class="calibre6">NEJM</i> 2019;381:1524)</span></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tnl"><span class="tft">•</span> <b class="calibre7">Clopidogrel</b></p>
<p class="tbodyh1">300–600 mg × 1 → 75 mg qd</p>
<p class="tbodyh1">~6 h to steady state</p>
<p class="tbodyh1">Wait 5 d prior to surgery</p></td>
<td class="th1"><p class="tbodyh">ASA+clopi → 20% ↓ CVD/MI/stroke vs. ASA alone. ~30% pop has ↓ fxn CYP2C19 → ↑ CV events if PCI on clopi <span class="sm">(<i class="calibre6">NEJM</i> 2009;360:354)</span>.</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tnl"><span class="tft">•</span> <b class="calibre7">Cangrelor</b><sup class="calibre27"><a id="fn8-s1" class="calibre8"></a><a href="part0007.html#rfn8-s1" class="calibre8">*</a></sup></p>
<p class="tbodyh1">Only IV P2Y<sub class="calibre17">12</sub> inhibitor</p>
<p class="tbodyh1">Rapid onset/offset; t½ 3–5 min</p></td>
<td class="th1"><p class="tbodyh">22% ↓ CV events (mostly peri-PCI MI and stent thrombosis) vs. clopi 300 mg at time of PCI; no significant ↑ bleeding <span class="sm">(<i class="calibre6">NEJM</i> 2013;368:1303)</span></p>
<p class="tbodyh">Consider for rapidly reversible P2Y<sub class="calibre17">12</sub> inhib peri-PCI or as bridge to surgery in high-risk Pts who need to stop P2Y<sub class="calibre17">12</sub></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">GP IIb/IIIa inhibitors (GPI)</b></p>
<p class="tbodyh">abciximab; eptifibatide; tirofiban</p>
<p class="tbodyh">Infusions given ≤24 h peri &amp; post PCI; shorter (~2 h) as effective w/ ↓ bleeding <span class="sm">(<i class="calibre6">JACC</i> 2009;53:837)</span></p></td>
<td class="th1"><p class="tbodyh">No clear benefit for routinely starting prior to PCI and ↑ bleeding <span class="sm">(<i class="calibre6">NEJM</i> 2009;360:2176)</span></p>
<p class="tbodyh">Consider if refractory ischemia despite optimal Rx while awaiting angio or in high-risk Pts (eg, large clot burden) at time of PCI, espec if using clopi and no preRx.</p></td>
</tr>
</tbody>
</table>
<p class="tfn"><sup class="calibre22"><a id="rfn8-s1" class="calibre8"></a><a href="part0007.html#fn8-s1" class="calibre8">*</a></sup>Transition from cangrelor to oral P2Y<sub class="calibre24">12</sub> inhib.: ticagrelor loading dose during infusion or immediately after d/c of infusion; prasugrel or clopidogrel loading dose only immediately <i class="calibre6">after</i> d/c of infusion.</p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre26"/>
<col class="calibre26"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="2"><p class="tbodyc"><b class="calibre7">Anticoagulant Therapy (choose one)</b></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">UFH:</b> 60 U/kg IVB (max 4000 U) then 12 U/kg/h (max 1000 U/h initially) × 48 h or until end of PCI</p></td>
<td class="th1"><p class="tbody">24% ↓ D/MI <span class="sm">(<i class="calibre6">JAMA</i> 1996;276:811)</span></p>
<p class="tbody">Titrate to aPTT 1.5–2× control (~50–70 sec)</p>
<p class="tbody">Hold until INR &lt;2 if already on warfarin</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Enoxaparin</b> (low-molec-wt heparin) 1 mg/kg SC bid (± 30 mg IVB) (qd if CrCl &lt;30) × 2–8 d or until PCI</p></td>
<td class="th1"><p class="tbody">~10% ↓ D/MI vs. UFH <span class="sm">(<i class="calibre6">JAMA</i> 2004;292:45,89)</span>. Can perform PCI on enox <span class="sm">(<i class="calibre6">Circ</i> 2001;103:658)</span>, but ↑ -bleeding if switch b/w enox and UFH.</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Bivalirudin</b> (direct thrombin inhibitor) 0.75 mg/kg IVB at PCI → 1.75 mg/kg/h</p></td>
<td class="th1"><p class="tbody">No diff in bleeding, MI, or death c/w UFH <span class="sm">(<i class="calibre6">NEJM</i> 2017;377:1132)</span>. Use instead of UFH if HIT.</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Fondaparinux</b> (Xa inh) 2.5 mg SC qd</p></td>
<td class="th1"><p class="tbody">Rarely used; must supplement w/ UFH if PCI.</p></td>
</tr>
</tbody>
</table>
<p class="h">Coronary angiography <span class="r1">(</span><span class="r2">Circ</span> <span class="r1">2014;130:e344)</span></p>
<p class="noindent1">• <b class="calibre7">Immediate/urgent coronary angiography</b> (w/in 2 h) if refractory/recurrent angina or hemodynamic or electrical instability</p>
<p class="noindent1">• <b class="calibre7">Routine angiography</b> (aka “invasive strategy”) = coronary angiography for all</p>
<p class="noindent2"><i class="calibre6"><span class="underline">Early</span> (w/in 24 h) if:</i> ⊕ Tn, ST ∆, GRACE risk score &gt;140 <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2009;360:2165;</span> <span class="r2">Circ</span><span class="r1"> 2018;138:2741)</span></p>
<p class="noindent2"><i class="calibre6"><span class="underline">Delayed</span> (ie, w/in 72 h) acceptable if w/o above features but w/:</i> diabetes, EF &lt;40%, GFR &lt;60, post-MI angina, TRS ≥3, GRACE score 109–140, PCI w/in 6 mo, prior CABG</p>
<p class="noindent2">32% ↓ rehosp for ACS, nonsignif 16% ↓ MI, no ∆ in mort. c/w select angio <span class="r1">(</span><span class="r2">JAMA</span><span class="r1"> 2008;300:71)</span></p>
<p class="noindent2">↑ peri-PCI MI counterbalanced by ↓↓ in spont. MI. Mortality benefit seen in some studies, likely only if cons. strategy w/ low rate of angio.</p>
<p class="noindent1">• <b class="calibre7">Selective angiography</b> (“conservative strategy”): med Rx w/ pre-d/c stress test; angio only if recurrent ischemia or strongly ⊕ ETT. <i class="calibre6">Indicated for:</i> low TIMI Risk Score, Pt or physician pref in absence of high-risk features, or low-risk women <span class="r1">(</span><span class="r2">JAMA</span> <span class="r1">2008;300:71)</span>.</p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre26"/>
<col class="calibre28"/>
<col class="calibre28"/>
<col class="calibre20"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="4"><p class="tbodyc"><b class="calibre7">TIMI Risk Score (TRS) for UA/NSTEMI</b> <span class="sm">(<i class="calibre6">JAMA</i> 2000;284:835)</span></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbodyc"><b class="calibre7">Calculation of Risk Score</b></p></td>
<td class="th1"><p class="tbodyh"> </p></td>
<td colspan="2" class="th1"><p class="tbodyc"><b class="calibre7">Application of Risk Score</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc"><b class="calibre7">Characteristic</b></p></td>
<td class="th1"><p class="tbodyc"><b class="calibre7">Point</b></p></td>
<td class="th1"><p class="tbodyc"><b class="calibre7">Score</b></p></td>
<td class="th1"><p class="tbodyc"><b class="calibre7">D/MI/UR by</b> 1<b class="calibre7">4 d</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyh"><i class="calibre6">Historical</i></p></td>
<td class="th1"><p class="tbodyh"> </p></td>
<td class="th1"><p class="tbodyc">0–1</p></td>
<td class="th1"><p class="tbodyc">5%</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyh1">Age ≥65 y</p></td>
<td class="th1"><p class="tbodyc">1</p></td>
<td class="th1"><p class="tbodyc">2</p></td>
<td class="th1"><p class="tbodyc">8%</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyh1">≥3 Risk factors for CAD</p></td>
<td class="th1"><p class="tbodyc">1</p></td>
<td class="th1"><p class="tbodyc">3</p></td>
<td class="th1"><p class="tbodyc">13%</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyh1">Known CAD (stenosis ≥50%)</p></td>
<td class="th1"><p class="tbodyc">1</p></td>
<td class="th1"><p class="tbodyc">4</p></td>
<td class="th1"><p class="tbodyc">20%</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyh1">ASA use in past 7 d</p></td>
<td class="th1"><p class="tbodyc">1</p></td>
<td class="th1"><p class="tbodyc">5</p></td>
<td class="th1"><p class="tbodyc">26%</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyh"><i class="calibre6">Presentation</i></p></td>
<td class="th1"><p class="tbodyh"> </p></td>
<td class="th1"><p class="tbodyc">6–7</p></td>
<td class="th1"><p class="tbodyc">41%</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyh1">Severe angina (≥2 episodes w/in 24 h)</p></td>
<td class="th1"><p class="tbodyc">1</p></td>
<td class="tb" colspan="2" rowspan="4"><p class="tbodyc">Higher risk Pts (TRS ≥3) derive ↑ benefit from LMWH, GP IIb/IIIa inhibitors and early angiography <span class="sm">(<i class="calibre6">JACC</i> 2003;41:89S)</span></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyh1">ST deviation ≥0.5 mm</p></td>
<td class="th1"><p class="tbodyc">1</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyh1">⊕ cardiac marker (troponin, CK-MB)</p></td>
<td class="th1"><p class="tbodyc">1</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyh"><b class="calibre7">RISK SCORE</b> = <b class="calibre7">Total points</b></p></td>
<td class="th1"><p class="tbodyc"><b class="calibre7">(0–7)</b></p></td>
</tr>
</tbody>
</table>
<p class="h1cr">STEMI <span class="r3">(<i class="calibre6">Circ</i> 2013;127:529; <i class="calibre6">EHJ</i> 2018;39:119)</span></p>
<div class="cap">
<p class="caption"><a id="page_1-10" class="calibre4"></a><a id="fig1-2" class="calibre4"></a><b class="calibre7">Figure 1-2</b> Approach to UA/NSTEMI</p>
<p class="imagef1"><img src="../images/00014.jpeg" alt="" class="calibre5"/></p>
</div>
<p class="h">Requisite STE <span class="r">(at J point)</span></p>
<p class="noindent1">• ≥2 contiguous leads w/ ≥1 mm (except for V<sub class="calibre10">2</sub>–V<sub class="calibre10">3</sub>: ≥2 mm in ♂ and ≥1.5 mm in ♀), <i class="calibre6">or</i></p>
<p class="noindent1">• New or presumed new LBBB w/ compelling H&amp;P, <i class="calibre6">or</i></p>
<p class="noindent1">• True posterior MI: ST depression V<sub class="calibre10">1</sub>–V<sub class="calibre10">3</sub> ± tall Rw w/ STE on posterior leads (V<sub class="calibre10">7</sub>–V<sub class="calibre10">9</sub>)</p>
<p class="h">Reperfusion <span class="r">(“time is muscle”)</span></p>
<p class="noindent1">• In PCI-capable hospital, goal should be <b class="calibre7">primary PCI w/in 90 min</b> of 1<sup class="calibre19">st</sup> medical contact</p>
<p class="noindent1">• In non–PCI-capable hospital, consider <i class="calibre6">transfer</i> to PCI-capable hospital (see below), o/w <b class="calibre7">fibrinolytic therapy</b> w/in 30 min of hospital presentation</p>
<p class="noindent1">• Do not let decision regarding <i class="calibre6">method</i> of reperfusion delay <i class="calibre6">time</i> to reperfusion</p>
<p class="h">Primary PCI <span class="r1">(</span><span class="r2">JACC</span><span class="r1"> 2013;61:e78 &amp; 2016;67:1235)</span></p>
<p class="noindent1">• Definition: immediate PCI upon arrival to hospital or transfer for immediate PCI</p>
<p class="noindent1">• <b class="calibre7">Indic: STE</b> + sx onset w/in &lt;12 h; ongoing ischemia 12–24 h after sx onset; shock</p>
<p class="noindent1">• Superior to lysis: 27% ↓ death, 65% ↓ reMI, 54% ↓ stroke, 95% ↓ ICH <span class="r1">(</span><span class="r2">Lancet</span> <span class="r1">2003;361:13)</span></p>
<p class="noindent1">• <i class="calibre6">Transfer</i> to center for 1° PCI superior to lysis <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2003;349:733)</span>, see below</p>
<p class="noindent1">• PCI of non-culprit lesions (stenoses ≥70% or FFR ≤0.80 if 50–69%) early after event (during initial PCI, prior to or early after d/c) ↓ recurrent MACE, primarily recurrent MI vs. culprit alone <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2019;381:1411-21)</span>; may harm if cardiogenic shock <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2018;379:1699)</span></p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre29"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th"><p class="tbodyc"><b class="calibre7">Fibrinolysis vs. Hospital Transfer for Primary PCI: Assess Time and Risk</b></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tnl"><span class="tft">1.</span> <b class="calibre7">Time required for transport to skilled PCI lab:</b> door-to-balloon &lt;120 min &amp; [door-to-balloon]–[door-to-needle] &lt;1 h favors transfer for PCI</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tnl"><span class="tft">2.</span> <b class="calibre7">Risk from STEMI:</b> high-risk Pts (eg, shock) fare better with mechanical reperfusion</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tnl"><span class="tft">3.</span> <b class="calibre7">Time to presentation:</b> efficacy of lytics ↓ w/ ↑ time from sx onset, espec &gt;3 h</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tnl"><span class="tft">4.</span> <b class="calibre7">Risk of fibrinolysis:</b> if high risk of ICH or bleeding, PCI safer option</p></td>
</tr>
</tbody>
</table>
<p class="tfn">Adapted from ACC/AHA 2013 STEMI Guidelines (<i class="calibre6">Circ</i> 2013;127:529)</p>
<p class="h">Fibrinolysis</p>
<p class="noindent1">• Indic: STE/LBBB + sx &lt;12 h (&amp; &gt;120 min before PCI can be done); benefit if sx &gt;12 h less clear; reasonable if persist. sx &amp; STE, hemodynamic instability or large territory at risk</p>
<p class="noindent1">• Mortality ↓ ~20% in anterior MI or LBBB and ~10% in IMI c/w Ø reperfusion Rx</p>
<p class="noindent1">• Prehospital lysis (ie, ambulance): further 17% ↓ in mortality <span class="r1">(</span><span class="r2">JAMA</span> <span class="r1">2000;283:2686)</span></p>
<p class="noindent1">• ~1% risk of ICH; high risk incl elderly (~2% if &gt;75 y), ♀, low wt. ? PCI more attractive</p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre26"/>
<col class="calibre26"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="2"><p class="tbodyc"><b class="calibre7">Contraindications to Fibrinolysis</b></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Absolute Contraindications</b></p></td>
<td class="th1"><p class="tbodyh"><b class="calibre7">Relative Contraindications</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tnl"><span class="tft">•</span> Any prior ICH</p>
<p class="tnl"><span class="tft">•</span> Intracranial neoplasm, aneurysm, AVM</p>
<p class="tnl"><span class="tft">•</span> Ischemic stroke or closed head trauma w/in 3 mo; head/spinal surg. w/in 2 mo</p>
<p class="tnl"><span class="tft">•</span> Active internal bleeding or known bleeding diathesis</p>
<p class="tnl"><span class="tft">•</span> Suspected aortic dissection</p>
<p class="tnl"><span class="tft">•</span> Severe uncontrollable HTN</p>
<p class="tnl"><span class="tft">•</span> For SK, SK Rx w/in 6 mo</p></td>
<td class="th1"><p class="tnl"><span class="tft">•</span> H/o severe HTN, SBP &gt;180 or DBP &gt;110 on presentation (? absolute if low-risk MI)</p>
<p class="tnl"><span class="tft">•</span> Ischemic stroke &gt;3 mo prior</p>
<p class="tnl"><span class="tft">•</span> CPR &gt;10 min; trauma/major surg. w/in 3 wk</p>
<p class="tnl"><span class="tft">•</span> Internal bleed w/in 2–4 wk; active PUD</p>
<p class="tnl"><span class="tft">•</span> Noncompressible vascular punctures</p>
<p class="tnl"><span class="tft">•</span> Pregnancy</p>
<p class="tnl"><span class="tft">•</span> Current use of anticoagulants</p>
<p class="tnl"><span class="tft">•</span> For SK, prior SK exposure</p></td>
</tr>
</tbody>
</table>
<p class="h"><a id="page_1-11" class="calibre4"></a>Nonprimary PCI</p>
<p class="noindent1">• Rescue PCI if shock, unstable, failed reperfusion, or persistent sx <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2005;353:2758)</span></p>
<p class="noindent1">• Routine angio ± PCI w/in 24 h of successful lysis: ↓ D/MI/revasc <span class="r1">(</span><span class="r2">Lancet</span> <span class="r1">2004;364:1045)</span> and w/in 6 h ↓ reMI, recurrent ischemia, &amp; HF compared to w/in 2 wk <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2009;360:2705)</span>;</p>
<p class="noindent2">∴<i class="calibre6"> if lysed at non-PCI-capable hosp., consider transfer to PCI-capable hosp.. ASAP espec if high-risk (eg, ant. MI, IMI w/</i> ↓<i class="calibre6"> EF or RV infarct, extensive STE/LBBB, HF,</i> ↓<i class="calibre6"> BP or</i> ↑<i class="calibre6"> HR)</i></p>
<p class="noindent1">• <i class="calibre6">Late</i> PCI (median day 8) of occluded infarct-related artery: no benefit <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2006;355:2395)</span></p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre26"/>
<col class="calibre26"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="2"><p class="tbodyc"><b class="calibre7">Antiplatelet Therapy</b></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Aspirin</b> 162–325 mg × 1</p>
<p class="tbodyh">(crushed/chewed) then 81 mg qd</p></td>
<td class="th1"><p class="tbodyh">23% ↓ in death <span class="sm">(<i class="calibre6">Lancet</i> 1988;ii:349)</span></p>
<p class="tbodyh">Should not be stopped if CABG required</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">P2Y</b><sub class="calibre17">1<b class="calibre7">2</b></sub> <b class="calibre7">inhibitor</b></p>
<p class="tbodyh">Give ASAP (do not wait for angio) b/c onset inhib delayed in STEMI Pts</p>
<p class="tbodyh">Ticagrelor or prasugrel (if PCI) as detailed above</p>
<p class="tbodyh">Clopidogrel: 600 mg pre-PCI; 300 mg if lysis (no LD if &gt;75 y) → 75 mg qd</p></td>
<td class="th1"><p class="tbodyh"><i class="calibre6">PCI:</i> prasugrel and ticagrelor ↓ CV events c/w clopi <span class="sm">(<i class="calibre6">Lancet</i> 2009;373:723 &amp; <i class="calibre6">Circ</i> 2010;122:2131)</span></p>
<p class="tbodyh">Prehospital ticagrelor may be safe &amp; ? ↓ rate of stent thrombosis <span class="sm">(<i class="calibre6">NEJM</i> 2014;371:1016)</span></p>
<p class="tbodyh"><i class="calibre6">Lysis:</i> clopidogrel 41% ↑ in patency, 7% ↓ mort, no Δ major bleed or ICH <span class="sm">(<i class="calibre6">NEJM</i> 2005;352:1179; <i class="calibre6">Lancet</i> 2005;366:1607)</span>; no data for pras or ticag w/ lytic</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">GP IIb/IIIa inhibitors</b></p>
<p class="tbody">abciximab, eptifibatide, tirofiban</p></td>
<td class="th1"><p class="tbody"><i class="calibre6">Lysis:</i> no indication <span class="sm">(<i class="calibre6">Lancet</i> 2001;357:1905)</span></p>
<p class="tbody"><i class="calibre6">Peri-PCI:</i> 60% ↓ D/MI/UR <span class="sm">(<i class="calibre6">NEJM</i> 2001;344:1895)</span></p></td>
</tr>
</tbody>
</table>
<p class="tfn">(<i class="calibre6">Circ</i> 2013;127:529; <i class="calibre6">NEJM</i> 2021;384:452; <i class="calibre6">JAMA</i> 2021;325:1545)</p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre26"/>
<col class="calibre26"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="2"><p class="tbodyc"><b class="calibre7">Anticoagulant Therapy (choose one)</b></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">UFH</b></p>
<p class="tbodyh">60 U/kg IVB (max 4000 U)</p>
<p class="tbodyh">12 U/kg/h (max 1000 U/h initially)</p></td>
<td class="th1"><p class="tbodyh">No demonstrated mortality benefit</p>
<p class="tbodyh">↑ patency with fibrin-specific lytics</p>
<p class="tbodyh">Titrate to aPTT 1.5–2× control (~50–70 sec)</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Enoxaparin</b></p>
<p class="tbodyh"><i class="calibre6">Lysis:</i> 30 mg IVB → 1 mg/kg SC bid (adjust for age &gt;75 &amp; CrCl)</p>
<p class="tbodyh"><i class="calibre6">PCI:</i> 0.5 mg/kg IVB</p></td>
<td class="th1"><p class="tbodyh"><i class="calibre6">Lysis:</i> 17% ↓ D/MI w/ ENOX × 7 d vs. UFH × 2 d <span class="sm">(<i class="calibre6">NEJM</i> 2006;354:1477)</span></p>
<p class="tbodyh"><i class="calibre6">PCI:</i> ↓ D/MI/revasc and ≈ bleeding vs. UFH <span class="sm">(<i class="calibre6">Lancet</i> 2011;378:693)</span></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Bivalirudin</b></p>
<p class="tbodyh">0.75 mg/kg IVB → 1.75 mg/kg/hr IV</p></td>
<td class="th1"><p class="tbodyh"><i class="calibre6">PCI:</i> similar bleeding, ± ↑ MI, ↑ stent thromb, ↓ mortality in some but not all trials <span class="sm">(<i class="calibre6">Lancet</i> 2014;384:599; <i class="calibre6">JAMA</i> 2015;313:1336; <i class="calibre6">NEJM</i> 2015;373:997)</span></p></td>
</tr>
</tbody>
</table>
<p class="tfn">Fondaparinux can be used (if CrCl &gt;30 mL/min) in setting of lysis, where superior to UFH w/ less bleeding (<i class="calibre6">JAMA</i> 2006;295:1519). Adapted from ACC/AHA 2013 STEMI Guidelines (<i class="calibre6">Circ</i> 2013;127:529; <i class="calibre6">Lancet</i> 2013;382:633).</p>
<p class="h">LV failure <span class="r">(occurs in ~25%)</span></p>
<p class="noindent1">• Diurese to achieve PCWP ~14 → ↓ pulmonary edema, ↓ myocardial O<sub class="calibre10">2</sub> demand</p>
<p class="noindent1">• ↓ Afterload → ↑ stroke volume &amp; CO, ↓ myocardial O<sub class="calibre10">2</sub> demand. Can use IV NTG or nitroprusside (although risk of coronary steal) → short-acting ACEI.</p>
<p class="noindent1">• Inotropes if HF despite diuresis &amp; ↓ afterload; use dopamine, dobutamine, or milrinone</p>
<p class="noindent1">• <b class="calibre7">Cardiogenic shock</b> (~7%) = MAP &lt;60 mmHg, CI &lt;2.2 L/min/m<sup class="calibre19">2</sup>, PCWP &gt;18 mmHg.</p>
<p class="noindent2">If not done already, coronary revasc <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">1999;341:625)</span></p>
<p class="noindent2">Support w/ inotropes or mechanical circulatory support to keep CI &gt;2</p>
<p class="noindent3"><b class="calibre7">Intraaortic balloon pump (IABP)</b> counterpulsation offers ~0.5 L/min CO and ↑ coronary perfusion, but no survival benefit if early revasc <span class="r1">(</span><span class="r2">NEJM</span><span class="r1"> 2012;367:1287)</span></p>
<p class="noindent3"><b class="calibre7">Axial flow pumps (eg, Impella)</b> offer up to 3–5 L/min CO, but no data that improves clinical outcomes <span class="r1">(</span><span class="r2">JACC</span><span class="r1"> 2017;69:278)</span></p>
<p class="h">IMI complications <span class="r1">(</span><span class="r2">Circ</span> <span class="r1">1990;81:401;</span> <span class="r2">NEJM</span> <span class="r1">1994;330:1211;</span> <span class="r2">JACC</span><span class="r1"> 2003;41:1273)</span></p>
<p class="noindent1">• <b class="calibre7">Heart block:</b> ~20%, occurs in part because RCA typically supplies AV node</p>
<p class="noindent2">40% on present., 20% w/in 24 h, rest by 72 h; high-grade AVB can develop abruptly</p>
<p class="noindent2">Rx: atropine, epi, aminophylline (100 mg/min × 2.5 min), temp pacing wire</p>
<p class="noindent1">• <b class="calibre7">RV infarct:</b> proximal RCA occlusion → ↓ flow to RV marginals</p>
<p class="noindent2">Angiographically present in 30–50% of cases, but only ~½ clinically significant</p>
<p class="noindent2">HoTN; ↑ JVP, ⊕ Kussmaul’s; ≥1 mm STE in V<sub class="calibre10">4</sub>R; RA/PCWP ≥0.8; RV dysfxn on TTE</p>
<p class="noindent2">Rx: optimize preload (RA goal 10–14 mmHg; <span class="r2">BHJ</span> <span class="r1">1990;63:98</span>); ↑ contractility (dobutamine); maintain AV synchrony (pacing as necessary); reperfusion <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">1998;338:933)</span>; mechanical support (IABP or RVAD); pulmonary vasodilators (eg, inhaled NO)</p>
<p class="h">Mechanical complications <span class="r">(incid. &lt;</span>1<span class="r">% for each; typically occur a few days post-MI)</span></p>
<p class="noindent1">• <b class="calibre7">Free wall rupture:</b> ↑ risk w/ lysis, large MI, ↑ age, ♀, HTN; p/w PEA or hypoTN, pericardial sx, tamponade; Rx: volume resusc., ? pericardiocentesis, inotropes, <b class="calibre7">surgery</b></p>
<p class="noindent1">• <b class="calibre7">VSD:</b> large MI in elderly; AMI → apical VSD, IMI → basal septum; 90% w/ harsh murmur ± thrill <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2002;347:1426)</span>; Rx: diuretics, vasodil., inotropes, IABP, <b class="calibre7">surgery</b>, perc. closure</p>
<p class="noindent1">• <b class="calibre7">Papillary muscle rupture:</b> more common after IMI (PM pap m. supplied by PDA alone) than AMI (AL supplied by OMs &amp; diags); 50% w/ new murmur; ↑ <i class="calibre6">v</i> wave in PCWP tracing; asymmetric pulmonary edema on CXR. Rx: diuretics, vasodilators, IABP, <b class="calibre7">surgery</b>.</p>
<p class="h"><a id="page_1-12" class="calibre4"></a>Arrhythmias post-MI <span class="r">(treat all per ACLS protocols if unstable or symptomatic)</span></p>
<p class="noindent1">• AF (10–16% incidence): βB or amio, ± digoxin (particularly if HF), heparin</p>
<p class="noindent1">• <b class="calibre7">VT/VF:</b> lido or amio × 6–24 h, then reassess; ↑ βB as tol., replete K &amp; Mg, r/o ischemia; VT &lt;48 h post-MI does <i class="calibre6">not</i> worsen prognosis; &gt;48 h, consider ICD (see below)</p>
<p class="noindent1">• Accelerated idioventricular rhythm (AIVR): slow ventricular rhythm (&lt;120 bpm), often after reperfusion; typically asx, gradual onset/offset, and does not require treatment</p>
<p class="noindent1">• Backup transcutaneous <i class="calibre6">or</i> transvenous pacing if: 2° AVB type II; BBB + AVB</p>
<p class="noindent1">• <b class="calibre7">Transvenous pacing</b> if: 3° AVB; new BBB + 2° AVB type II; alternating LBBB/RBBB</p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre30"/>
<col class="calibre30"/>
<col class="calibre30"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="3"><p class="tbodyc"><b class="calibre7">Other Post-MI Complications</b></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Complication</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Clinical Features</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Treatment</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">LV thrombus</b></p></td>
<td class="th1"><p class="tbody">~30% incid. (espec lg antero-apical MI)</p></td>
<td class="th1"><p class="tbody">AC×3-6 mo (? warfarin pref)</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Ventricular aneurysm</b></p></td>
<td class="th1"><p class="tbody">Noncontractile outpouching of LV; 8–15% incid. (espec ant); persist STE</p></td>
<td class="th1"><p class="tbody">Surgery or perc repair if HF, thromboemboli, arrhythmia</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Ventricular pseudoaneurysm</b></p></td>
<td class="th1"><p class="tbody">Rupture (narrow neck) → sealed by thrombus and pericardium (esp in inf).</p></td>
<td class="th1"><p class="tbody">Urgent surgery (or percutaneous repair)</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Pericarditis</b></p></td>
<td class="th1"><p class="tbody">10–20% incid.; 1–4 d post-MI ⊕ pericardial rub; ECG Δs rare</p></td>
<td class="th1"><p class="tbody">High-dose ASA, colchicine, narcotics; minimize anticoag</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Dressler’s syndrome</b></p></td>
<td class="th1"><p class="tbody">&lt;4% incid.; 2–10 wk post-MI fever, pericarditis, pleuritis</p></td>
<td class="th1"><p class="tbody">High-dose aspirin, NSAIDs</p></td>
</tr>
</tbody>
</table>
<p class="h1cr">C<small class="calibre31">HECKLIST AND</small> L<small class="calibre31">ONG</small>-T<small class="calibre31">ERM</small> P<small class="calibre31">OST</small>-ACS M<small class="calibre31">ANAGEMENT</small></p>
<p class="h">Risk stratification</p>
<p class="noindent1">• Stress test if anatomy undefined; consider stress if signif residual CAD post-PCI of culprit</p>
<p class="noindent1">• Assess LVEF prior to d/c; EF ↑ ~6% in STEMI over 6 mo <span class="r1">(</span><span class="r2">JACC</span> <span class="r1">2007;50:149)</span></p>
<p class="h">Antiplatelet therapy</p>
<p class="noindent1">• <b class="calibre7">Aspirin:</b> 81 mg daily (no clear benefit to higher doses)</p>
<p class="noindent1">• <b class="calibre7">P2Y<sub class="calibre10">12</sub> inhibitor:</b> ticagrelor or prasugrel preferred over clopi. In landmark analyses, benefit over clopidogrel both early &amp; late. De-escalation (ticag → clopi or pras 10 → 5 mg) after 1 mo ↓ bleeding w/o clear ↑ MACE, but wide CIs <span class="r1">(</span><span class="r2">Lancet</span> <span class="r1">2020;396:1079 &amp; 2021;398:1305)</span>.</p>
<p class="noindent1">• Duration controversial. Traditionally ASA lifelong and P2Y<sub class="calibre10">12</sub> inhib for 12 mos. <i class="calibre6">Prolonged P2Y12 inhib</i> &gt;12 mos → ↓ MACE but ↑ bleeding <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2014;371:2155 &amp; 2015;372:1791)</span>. Consider if high ischemic and low bleeding risk. Shorter duration (eg, 3–6 mo) if converse or if require major surgery. <i class="calibre6">D/c ASA</i> after 1–3 mos and continuing P2Y<sub class="calibre10">12</sub> inhib monoRx (preferably ticagrelor) ↓ bleeding with no ↑ MACE <span class="r1">(</span><span class="r2">Circ</span> <span class="r1">2020;142:538)</span>.</p>
<p class="h">Anticoagulation</p>
<p class="noindent1">• If need therapeutic a/c (eg, AF) in addition to anti-plt Rx, consider full-dose apixa + P2Y<sub class="calibre10">12</sub> (typically clopi) and d/c ASA at time of hospital d/c <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2019;380:1509)</span></p>
<p class="noindent1">• In Pts w/o indic. for anticoag, once DAPT completed, rivaroxaban 2.5 bid + ASA ↓ MACE &amp; CV death and ↑ bleeding vs. ASA monoRx <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2017;377:1319)</span></p>
<p class="h">Other CV drugs</p>
<p class="noindent1">• <b class="calibre7">β-blocker:</b> 23% ↓ mortality after MI (benefit beyond 3 yrs less clear)</p>
<p class="noindent1">• <b class="calibre7">ACEI/ARB:</b> lifelong if HF, ↓ EF, HTN, DM; 4–6 wk or at least until hosp. d/c in all STEMI. Trend toward ARNI better than ACEI in post-MI Pts w/ ↓ EF <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2021;385:1845)</span>.</p>
<p class="noindent2">? long-term benefit of ACEI/ARB in CAD w/o HF <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2000;342:145)</span></p>
<p class="noindent1">• <b class="calibre7">Aldosterone antag:</b> 15% ↓ mort. if EF &lt;40% &amp; either s/s of HF or DM <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2003;348:1309)</span></p>
<p class="noindent1">• Nitrates: standing if symptomatic; SL NTG prn for all</p>
<p class="noindent1">• Ranolazine: ↓ recurrent ischemia, no impact on CVD/MI <span class="r1">(</span><span class="r2">JAMA</span> <span class="r1">2007;297:1775)</span></p>
<p class="noindent1">• Low dose colchicine ↓ CV events post MI but ? ↑ PNA <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2019; 381:2497)</span></p>
<p class="h">Risk factors and lifestyle modifications <span class="r1">(</span><span class="r2">Circ</span> <span class="r1">2019;139:e1082 &amp;</span> <span class="r2">EHJ</span> <span class="r1">2020;41:111)</span></p>
<p class="noindent1">• <b class="calibre7">LDL-C</b>: goal &lt;70 mg/dL (U.S) or &lt;55 (Europe) or even &lt;40 if recurrent events</p>
<p class="noindent2"><i class="calibre6">Statin</i>: high-intensity (eg, atorva 80 mg, <span class="r1">PROVE-IT TIMI 22,</span> <span class="r2">NEJM</span><span class="r1"> 2004;350:1495</span>)</p>
<p class="noindent2"><i class="calibre6">Ezetimibe</i>: ↓ CV events when added to statin <span class="r1">(IMPROVE-IT,</span> <span class="r2">NEJM</span><span class="r1"> 2015;372:1500)</span></p>
<p class="noindent2"><i class="calibre6">PCSK9 inhibitor</i>: ↓ CV events when added to statin <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2017;376:1713; 2018;379:2097)</span></p>
<p class="noindent1">• <b class="calibre7">BP</b> &lt;140/90 and &lt;130/80; <b class="calibre7">quit smoking</b></p>
<p class="noindent1">• If diabetic, GLP1-RA ↓ MACE &amp; SGLT2i ↓ hospitalization for HF <span class="r1">(</span><span class="r2">Lancet D&amp;E</span> <span class="r1">2019;7:776 &amp;</span> <span class="r2">Lancet</span> <span class="r1">2019;393:31)</span>; further tailor Hb<sub class="calibre10">A1c</sub> goal based on Pt (avoid TZDs and saxa if HF)</p>
<p class="noindent1">• Exercise (30–60′ 5–7×/wk) 1–2 wk after revasc; cardiac rehab; BMI goal 18.5–24.9 kg/m<sup class="calibre19">2</sup></p>
<p class="noindent1">• Influenza &amp; <i class="calibre6">S. pneumo</i> vaccines <span class="r1">(</span><span class="r2">Circ</span> <span class="r1">2021;144:14764</span> <span class="r2">NEJM</span> <span class="r1">2018;378:345)</span>; ✓ for depression</p>
<p class="h">ICD <span class="r1">(</span><span class="r2">Circ</span> <span class="r1">2018;138:e272)</span></p>
<p class="noindent1">• Sust. VT/VF &gt;2 d post-MI w/o revers. isch; ? ↓ death w/ <i class="calibre6">wearable</i> defib <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2018;379:1205)</span></p>
<p class="noindent1">• 1° prevention of SCD if post-MI EF ≤30–40% (NYHA II–III) or ≤30–35% (NYHA I); wait 40 d after MI <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2004;351:2481 &amp; 2009;361:1427)</span></p>
<h2 class="ct"><a id="h7" class="calibre8"></a><a id="page_1-13" class="calibre8"></a><a href="part0003.html#rh11" class="calibre8">PA CATHETER AND TAILORED THERAPY</a></h2>
<p class="h">Rationale</p>
<p class="noindent1">• Cardiac output (CO) = SV × HR; optimize SV (and thereby CO) by manipulating preload/ LVEDV (w/ IVF, diuretics), contractility (w/ inotropes), &amp; afterload (w/ vasodilators)</p>
<p class="noindent1">• Balloon at catheter tip inflated → floats into “wedge” position. Column of blood extends from tip of catheter, through pulm venous circulation to a point just prox to LA. Under conditions of no flow, PCWP ≈ LA pressure ≈ LVEDP, which is proportional to LVEDV.</p>
<p class="noindent1">• Situations in which these basic assumptions fail:</p>
<p class="noindent2">(1) Catheter tip not in West lung zone 3 (and ? PCWP = alveolar pressure ≠ LA pressure); clues include lack of <i class="calibre6">a</i> &amp; <i class="calibre6">v</i> waves and if PA diastolic pressure &lt; PCWP</p>
<p class="noindent2">(2) PCWP &gt;LA pressure (eg, mediastinal fibrosis, pulmonary VOD, PV stenosis)</p>
<p class="noindent2">(3) Mean LA pressure &gt;LVEDP (eg, MR, MS)</p>
<p class="noindent2">(4) ∆ LVEDP-LVEDV relationship (ie, abnl compliance, ∴ “nl” LVEDP may not be optimal)</p>
<p class="h">Indications <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2013;369:e35;</span> <span class="r2">Circ</span> <span class="r1">2017;136:e268)</span></p>
<p class="noindent1">• <b class="calibre7">Diagnosis and evaluation</b></p>
<p class="noindent2">Ddx of shock (cardiogenic vs. distributive; espec if trial of IVF failed or is high risk) and of pulmonary edema (cardiogenic vs. not; espec if trial of diuretic failed or is high risk)</p>
<p class="noindent2">Evaluation of CO, intracardiac shunt, pulm HTN, MR, tamponade, cardiorenal syndrome</p>
<p class="noindent2">Evaluation of unexplained dyspnea (PAC during provocation w/ exercise, vasodilator)</p>
<p class="noindent1">• <b class="calibre7">Therapeutics</b> <span class="r1">(</span><span class="r2">Circ</span> <span class="r1">2017;136:e232)</span></p>
<p class="noindent2">Tailored therapy to optimize PCWP, SV, S<sub class="calibre10">MV</sub>O<sub class="calibre10">2</sub>, RAP, PVR in heart failure or shock</p>
<p class="noindent2">Guide to vasodilator therapy (eg, inhaled NO, nifedipine) in PHT, RV infarction</p>
<p class="noindent2">Guide periop mgmt in some high-risk Pts, candidacy for mech circ support &amp; transplant</p>
<p class="noindent1">• <b class="calibre7">Contraindications</b></p>
<p class="noindent2"><b class="calibre7">Absolute:</b> right-sided endocarditis, thrombus/mass or mechanical valve; proximal PE</p>
<p class="noindent2"><b class="calibre7">Relative:</b> coagulopathy (reverse), recent PPM or ICD (place under fluoroscopy), LBBB (~5% risk of RBBB → CHB, place under fluoro), bioprosthetic R-sided valve</p>
<p class="h">Efficacy concerns <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2006;354:2213;</span> <span class="r2">JAMA</span> <span class="r1">2005;294:1664)</span></p>
<p class="noindent1">• No benefit to routine PAC use in high-risk surgery <span class="r1">(</span><span class="r2">JACC</span> <span class="r1">2014;62:e77)</span>, sepsis, ARDS</p>
<p class="noindent1">• No benefit in decompensated HF <span class="r1">(</span><span class="r2">JAMA</span> <span class="r1">2005;294:1625)</span>; untested in cardiogenic shock</p>
<p class="noindent1">• But: ~½ of <i class="calibre6">clinical</i> CO &amp; PCWP estimates incorrect; CVP &amp; PCWP not well correl.; ∴ use PAC to (a) answer hemodynamic ? and then remove, or (b) manage cardiogenic shock</p>
<p class="h">Placement <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2013;369:e35)</span></p>
<p class="noindent1">• Insertion site: <b class="calibre7">R IJ</b> or <b class="calibre7">L subclavian veins</b> preferred for “anatomic” flotation into PA</p>
<p class="noindent1">• <b class="calibre7">Inflate</b> balloon (max 1.5 cc, mindful of resistance) when <b class="calibre7">advancing</b> and to <b class="calibre7">measure PCWP</b></p>
<p class="noindent1">• <b class="calibre7">Deflate</b> the balloon when <b class="calibre7">withdrawing</b> and at all other times</p>
<p class="noindent1">• CXR should be obtained after placement to assess for catheter position and PTX</p>
<p class="noindent1">• If catheter cannot be floated (i.e., severe TR, RV dilatation), consider fluoroscopic guidance</p>
<p class="h">Complications</p>
<p class="noindent1">• <b class="calibre7">Central venous access:</b> pneumo/hemothorax (~1%), arterial puncture (if inadvertent cannulation w/ dilation → surgical/endovasc eval), air embolism, thoracic duct injury</p>
<p class="noindent1">• <b class="calibre7">Advancement:</b> atrial or ventricular arrhythmias (3% VT; 20% NSVT and &gt;50% PVC), RBBB (5%), catheter knotting, cardiac perforation/tamponade, PA rupture</p>
<p class="noindent1">• <b class="calibre7">Maintenance:</b> infection (espec if catheter &gt;3 d old), thrombus, pulm infarction (≤1%), valve/chordae damage, PA rupture/pseudoaneurysm (espec w/ PHT), balloon rupture</p>
<p class="h">Intracardiac pressures</p>
<p class="noindent1">• Transmural pressure (≈ preload) = measured intracardiac pressure – intrathoracic pressure</p>
<p class="noindent1">• Intrathoracic pressure (usually slightly ⊖) is transmitted to vessels and heart</p>
<p class="noindent1">• <b class="calibre7">Always measure intracardiac pressure at end-expiration</b>, when intrathoracic pressure closest to 0 (“high point” in spont. breathing Pts; “low point” in Pts on ⊕ pressure vent.)</p>
<p class="noindent1">• If ↑ intrathoracic pressure (eg, PEEP), measured PCWP <i class="calibre6">overestimates</i> true transmural pressures. Can approx by subtracting ~½ PEEP (× ¾ to convert cm H<sub class="calibre10">2</sub>O to mmHg).</p>
<p class="noindent1">• PCWP: LV preload best estimated at <i class="calibre6">a</i> wave; risk of pulm edema driven by avg PCWP</p>
<p class="h">Cardiac output</p>
<p class="noindent1">• <b class="calibre7">Thermodilution:</b> saline injected in RA or intermittent heating of prox thermal filament in some PA lines (“continuous CO”). ∆ in temp over time measured at thermistor (in PA) used to calc CO. Inaccurate if ↓ CO, severe TR, or shunt.</p>
<p class="noindent1">• <b class="calibre7">Fick method:</b> O<sub class="calibre10">2</sub> consumption (L/min) = CO (L/min) × ∆ arteriovenous O<sub class="calibre10">2</sub> content ∴<b class="calibre7"> CO</b> = <b class="calibre7"><img class="mid" src="../images/00015.jpeg" alt=""/>O<sub class="calibre10">2</sub>/C(a-v)O<sub class="calibre10">2</sub></b></p>
<p class="noindent2"><img class="mid" src="../images/00016.jpeg" alt=""/>O<sub class="calibre10">2</sub> ideally measured (esp. if ↑ metab demands), but freq estimated (125 mL/min/m<sup class="calibre19">2</sup>)</p>
<p class="noindent2">C(a-v)O<sub class="calibre10">2</sub> = [10 × 1.36 mL O<sub class="calibre10">2</sub>/g of Hb × Hb g/dL × (S<sub class="calibre10">a</sub>O<sub class="calibre10">2</sub> – S<sub class="calibre10">MV</sub>O<sub class="calibre10">2</sub>)]. <i class="calibre6">S</i><sub class="calibre10">MV</sub><i class="calibre6">O</i><sub class="calibre10">2</sub> <i class="calibre6">is key var that</i> ∆<i class="calibre6">s.</i></p>
<p class="noindent2">If S<sub class="calibre10">MV</sub>O<sub class="calibre10">2</sub> &gt;80%, consider if the PAC is “wedged” (ie, pulm vein sat), L→R shunt, impaired O<sub class="calibre10">2</sub> utilization (severe sepsis, cyanide, carbon monoxide), ↑↑ CO or FiO<sub class="calibre10">2</sub>.</p>
<p class="imaget"><a id="page_1-14" class="calibre4"></a><img src="../images/00017.jpeg" alt="" class="calibre5"/></p>
<p class="tfn">PCWP waveform abnormalities: large <i class="calibre6">a</i> wave → ? mitral stenosis; large <i class="calibre6">v</i> wave → ? mitral regurgitation; blunted <i class="calibre6">y</i> descent → ? tamponade; steep <i class="calibre6">x</i> &amp; <i class="calibre6">y</i> descents → ? constriction.</p>
<p class="imaget"><img src="../images/00018.jpeg" alt="" class="calibre5"/></p>
<p class="tfn">Surrogates: RA ≈ JVP (1 mmHg = 1.36 cm H<sub class="calibre24">2</sub>O); pulmonary edema on CXR implies ↑ PCWP; UOP ∝ CO (barring AKI); delayed capillary refill (ie, &gt;2–3 sec) implies ↑ SVR</p>
<p class="h">Tailored therapy in cardiogenic shock <span class="r1">(</span><span class="r2">Circ</span> <span class="r1">2009;119:e391)</span></p>
<p class="noindent1">• <b class="calibre7">Goals:</b> optimize both MAP and CO while ↓ risk of pulmonary edema</p>
<p class="noindent2">MAP = CO × SVR; CO = HR × SV (which depends on preload, afterload, and contractility)</p>
<p class="noindent2">pulmonary edema when PCWP &gt;20–25 (↑ levels may be tolerated in chronic HF/MS)</p>
<p class="noindent2">hepatic and renal congestion (↓ GFR) occur when CVP/RAP &gt;15 mmHg</p>
<p class="noindent1">• <b class="calibre7">Optimize preload</b> = LVEDV ≈ LVEDP ≈ LAP ≈ PCWP <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">1973;289:1263)</span></p>
<p class="noindent2">goal <b class="calibre7">PCWP ~<sub class="calibre10">1</sub>4–<sub class="calibre10">1</sub>8 in acute MI,</b> <b class="calibre7"><sub class="calibre10">1</sub>4 in acute decompensated HF</b></p>
<p class="noindent2">optimize in individual Pt by measuring SV w/ different PCWP to create Starling curve</p>
<p class="noindent2">↑ by giving crystalloid (albumin w/o clinical benefit over NS; PRBC if significant anemia)</p>
<p class="noindent2">↓ by diuresis (qv), ultrafiltration or dialysis if refractory to diuretics or ESRD</p>
<p class="noindent1">• <b class="calibre7">Optimize afterload</b> ≈ wall stress during LV ejection = [(~SBP × radius) / (2 × wall thick.)] and ∴ ∝ MAP and ∝ SVR = (MAP – CVP / CO); goals: <b class="calibre7">MAP</b> &gt;<b class="calibre7">60</b>, <b class="calibre7">SVR 800–<sub class="calibre10">1</sub>200</b></p>
<p class="noindent2">MAP &gt;60 (&amp; ∴ SVR ↑): vasodilators (eg, nitroprusside, NTG, ACEI, hydral.) or wean pressors</p>
<p class="noindent2">MAP &lt;60 (&amp; ∴ SVR low/nl, ie, inappropriate vasoplegia): start with inopressor (eg, norepinephrine [α &gt; β], dopamine [β → α w/ ↑ doses], epi [β &gt; α at low doses]); better outcomes w/ norepi than dopa even in cardiogenic shock <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2010;362:779)</span></p>
<p class="noindent1">• <b class="calibre7">Optimize contractility</b> ∝ CO for given preload &amp; afterload; <b class="calibre7">goal CI = (CO / BSA)</b> &gt;<b class="calibre7">2.2</b>  if too low despite optimal preload &amp; vasodilators (as MAP permits):</p>
<p class="noindent2">⊕ <i class="calibre6">inotropes:</i> eg, dobutamine (mod inotrope &amp; mild vasodilator) or milrinone (strong inotrope &amp; vasodilator, incl pulm), both proarrhythmic, or epi (strong inotrope &amp; pressor)</p>
<p class="noindent2"><i class="calibre6">mech circulatory support (L/min):</i> IABP (0.5), Impella (3.7–5.5), TandemHeart (5), VAD (L-sided, R-sided or both; temp or perm; 10) or ECMO (6) <span class="r1">(</span><span class="r2">JACC</span><span class="r1"> 2021;77:1243)</span></p>
<h2 class="ct"><a id="h8" class="calibre8"></a><a id="page_1-15" class="calibre8"></a><a href="part0003.html#rh12" class="calibre8">HEART FAILURE</a></h2>
<p class="h">Definitions <span class="r1">(</span><span class="r2">Braunwald’s Heart Disease</span><span class="r1">, 12th ed., 2022)</span></p>
<p class="noindent1">• Failure of heart to pump blood forward at rate sufficient to meet metabolic demands of peripheral tissues, or ability to do so only at abnormally high cardiac filling pressures</p>
<p class="noindent1">• Low output (↓ cardiac output) vs. high output (↑ stroke volume ± ↑ cardiac output)</p>
<p class="noindent1">• Left-sided (pulmonary edema) vs. right-sided (↑ JVP, hepatomegaly, peripheral edema)</p>
<p class="noindent1">• Backward (↑ filling pressures, congestion) vs. forward (impaired systemic perfusion)</p>
<p class="noindent1">• Systolic (inability to expel sufficient blood) vs. diastolic (failure to relax and fill normally)</p>
<p class="noindent1">• Reduced (HFrEF, EF &lt;40%), mildly reduced (HFmrEF, EF 40–49%), &amp; preserved (HFpEF, EF &gt;50%); combination of systolic and diastolic dysfxn may occur regardless of EF</p>
<div class="cap">
<p class="caption"><a id="fig1-3" class="calibre4"></a><b class="calibre7">Figure 1-3</b> Approach to left-sided heart failure</p>
<p class="imagef1"><img src="../images/00019.jpeg" alt="" class="calibre5"/></p>
</div>
<p class="h">History</p>
<p class="noindent1">• Low output: fatigue, weakness, exercise intolerance, ∆ MS, anorexia</p>
<p class="noindent1r">• Congestive: left-sided → dyspnea, orthopnea, paroxysmal nocturnal dyspnea<br class="calibre1"/>right-sided → peripheral edema, RUQ discomfort, bloating, satiety</p>
<p class="h">Functional classification <span class="r">(New York Heart Association class)</span></p>
<p class="noindent1">• Class I: no sx w/ ordinary activity; class II: sx w/ ordinary activity; class III: sx w/ minimal activity; class IV: sx at rest</p>
<p class="h">Physical exam <span class="r">(“2-minute” hemodynamic profile;</span> <span class="r2">JAMA</span> <span class="r1">1996;275:630 &amp; 2002;287:628</span><span class="r">)</span></p>
<p class="noindent1">• <b class="calibre7">Congestion (“dry” vs. “wet”):</b> ↑ JVP (~80% of the time JVP &gt;10 → PCWP &gt;22)</p>
<p class="noindent2">⊕ hepatojugular reflux: ≥3 cm ↑ in JVP for ≥10–15 sec w/ abdominal pressure Se/Sp 73/87% for RA &gt;8 and Se/Sp 55/83% for PCWP &gt;15 <span class="r1">(</span><span class="r2">AJC</span> <span class="r1">1990;66:1002)</span></p>
<p class="noindent2">Abnl Valsalva response: square wave (↑ SBP w/ strain), no overshoot (no ↑ BP after strain)</p>
<p class="noindent2">S<sub class="calibre10">3</sub> (in Pts w/ HF → ~40% ↑ risk of HF hosp. or pump failure death; <span class="r2">NEJM</span><span class="r1"> 2001;345:574</span>)</p>
<p class="noindent2">Rales, dullness at base 2° pleural effus. (<i class="calibre6">often absent</i> in chronic HF due to lymphatic compensation) ± hepatomegaly, ascites and jaundice, peripheral edema</p>
<p class="noindent1">• <b class="calibre7">Perfusion (“warm” vs. “cold”)</b></p>
<p class="noindent2">narrow pulse pressure (&lt;25% of SBP) → CI &lt;2.2 (91% Se, 83% Sp; <span class="r2">JAMA</span> <span class="r1">1989;261:884</span>);</p>
<p class="noindent2">soft S<sub class="calibre10">1</sub> (↓ dP/dt), pulsus alternans, cool &amp; pale extremities, ↓ UOP, muscle atrophy</p>
<p class="noindent1">• ± Other: Cheyne-Stokes resp., abnl PMI (diffuse, sustained or lifting depending on cause of HF), S<sub class="calibre10">4</sub> (diast. dysfxn), murmur (valvular dis., ↑ MV annulus, displaced papillary muscles)</p>
<p class="h">Evaluation for the presence of heart failure</p>
<p class="noindent1">• CXR (see Radiology insert): pulm edema, pleural effusions ± cardiomegaly, cephalization, Kerley B-lines; lung U/S better than CXR (PPV &amp; NPV 92% vs. 77%; <span class="r2">Chest</span><span class="r1"> 2015;148:202</span>)</p>
<p class="noindent1">• BNP/NT-proBNP can help exclude HF; levels ↑ w/ age, renal dysfxn, AF; ↓ w/ obesity Se ≥95%, Sp: ~50%, PPV ~65%, NPV ≥ 94% for HF in Pts p/w SOB <span class="r1">(</span><span class="r2">BMJ</span> <span class="r1">2015;350:h910)</span></p>
<p class="noindent1">• Evidence of ↓ organ perfusion: ↑ Cr, ↓ Na, abnl LFTs</p>
<p class="noindent1">• Echo (see inserts): ↓ EF &amp; ↑ chamber size → systolic dysfxn; hypertrophy, abnl MV inflow, abnl tissue Doppler → ? diastolic dysfxn; abnl valves or pericardium; ↑ estimated RVSP</p>
<p class="noindent1">• PA catheterization: ↑ PCWP, ↓ CO, and ↑ SVR (in low-output failure)</p>
<p class="h"><a id="page_1-16" class="calibre4"></a>Evaluation for the potential causes of heart failure</p>
<p class="noindent1">• <b class="calibre7">ECG:</b> evidence for CAD, LVH, LAE, heart block or low voltage (? infiltrative CMP/DCM)</p>
<p class="noindent1">• <b class="calibre7">TTE:</b> LV &amp; RV size &amp; fxn, valve abnl (cause or consequence?), infiltrative or pericardial dis.</p>
<p class="noindent1">• <b class="calibre7">Cardiac MRI:</b> distinguishes ischemic vs. nonischemic and can help determine etiol. of latter</p>
<p class="noindent1">• <b class="calibre7">Coronary angio</b> (or noninvasive imaging, eg, CT angio); if no CAD, w/u for NICM</p>
<p class="h">Precipitants of acute heart failure</p>
<p class="noindent1">• <b class="calibre7">Dietary indiscretion or medical nonadherence</b> (~40% of cases)</p>
<p class="noindent1">• <b class="calibre7">Myocardial ischemia or infarction</b> (~10–15% of cases); myocarditis</p>
<p class="noindent1">• <b class="calibre7">Renal failure</b> (acute, progression of CKD, or insufficient dialysis) → ↑ preload</p>
<p class="noindent1">• <b class="calibre7">Hypertensive crisis (incl. from RAS), worsening AS</b> → ↑ left-sided afterload</p>
<p class="noindent1">• <b class="calibre7">Drugs</b> (βB, CCB, NSAIDs, TZDs), <b class="calibre7">chemo</b> (anthracyclines, trastuzumab), or <b class="calibre7">toxins</b> (EtOH)</p>
<p class="noindent1">• <b class="calibre7">Arrhythmias; acute valvular dysfxn</b> (eg, endocarditis), espec mitral or aortic regurgitation</p>
<p class="noindent1">• COPD/PE → ↑ right-sided afterload; extreme stress; anemia; systemic infxn; thyroid dis.</p>
<p class="imaget"><img src="../images/00020.jpeg" alt="" class="calibre5"/></p>
<p class="h">Rx of acute decompens. HF <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2017;377:1964)</span></p>
<p class="noindent1">• Assess congestion &amp; adequacy of perfusion</p>
<p class="noindent1">• For <b class="calibre7">congestion: “LMNOP”</b></p>
<p class="noindent2"><b class="calibre7">L</b>asix IV; 1–2.5× usual total daily PO dose Ø clear diff between gtt vs. q12h IV</p>
<p class="noindent2"><b class="calibre7">M</b>orphine (↓ sx, venodilator, ↓ afterload)</p>
<p class="noindent2"><b class="calibre7">N</b>itrates (venodilator)</p>
<p class="noindent2"><b class="calibre7">O</b>xygen ± noninvasive ventilation</p>
<p class="noindent2"><b class="calibre7">P</b>osition (sitting up &amp; legs dangling over side of bed → ↓ preload)</p>
<p class="noindent1">• For <b class="calibre7">low perfusion</b>, see below</p>
<p class="noindent1">• Adjustment of home oral meds: prefer to continue, except:</p>
<p class="noindent2">ACEI/ARB/ARNI: hold or ↓ dose if HoTN; ∆ to hydralazine &amp; nitrates w/ AKI</p>
<p class="noindent2">βB: hold if evidence of hypoperfusion or HoTN</p>
<p class="h">Treatment of acute advanced heart failure <span class="r1">(</span><span class="r2">Circ</span> <span class="r1">2013;128:e240)</span></p>
<p class="noindent1">• Consider PAC if not resp to Rx, unsure re: vol status, HoTN, hypoperfusion, need inotropes</p>
<p class="noindent1">• Tailored Rx w/ PAC (qv); goals of MAP &gt;60, CI &gt;2.2 (MVO<sub class="calibre10">2</sub> &gt;60%), SVR &lt;800, PCWP &lt;18</p>
<p class="noindent1">• <b class="calibre7">IV vasodilators:</b> NTG, nitroprusside (risk of coronary steal if CAD)</p>
<p class="noindent1">• <b class="calibre7">Inotropes</b> (properties in addition to ↑ inotropy listed below)</p>
<p class="noindent2">dobutamine: vasodilation at doses ≤5 µg/kg/min; mild ↓ PVR; desensitization over time</p>
<p class="noindent2">dopamine: splanchnic vasodil. → ↑ GFR &amp; natriuresis; vasoconstrictor at ≥5 µg/kg/min</p>
<p class="noindent2">milrinone: prominent systemic &amp; pulmonary vasodilation; ↓ dose by 50% in renal failure</p>
<p class="noindent1">• <b class="calibre7">Mechanical circulatory support</b> (also see “Tailored Therapy;” <span class="r2">JACC</span><span class="r1"> 2015;65:e7 &amp; 2542</span>)</p>
<p class="noindent2"><i class="calibre6">Temporary:</i> bridge to recovery, transplant, or durable MCS; periprocedural support</p>
<p class="noindent3">Intra-aortic balloon pump (IABP): inflates in diastole &amp; deflates in systole to ↓ impedance to LV ejection, ↓ myocardial O<sub class="calibre10">2</sub> demand &amp; ↑ coronary perfusion; +0.5 L/min CO</p>
<p class="noindent3">Axial flow pumps (eg, Impella): Archimedes screw principle in LV; +3.7–5.5 L/min</p>
<p class="noindent3">Extracorporeal centrifugal pumps: TandemHeart (+5 L/min, percutaneous) &amp; CentriMag (10 L/min, surgical)</p>
<p class="noindent3">Extracorporeal membrane oxygenation (ECMO): 6 L/min <span class="r1">(</span><span class="r2">JACC HF</span> <span class="r1">2018;6:503)</span></p>
<p class="noindent2"><i class="calibre6">Durable:</i> surgically placed LVAD ± RVAD as bridge to sufficient recovery (in 5–50% of niCMP; <span class="r2">JACC</span><span class="r1"> 2017;69:1924</span>), to transplant or as destination Rx (&gt;50% ↓ 1-y mort. vs. med Rx; <span class="r2">NEJM</span> <span class="r1">2001;345:1435 &amp; 2009;361:2241</span>). Current preferred option is fully magnetically levitated centrifugal flow pump (HeartMate 3), ↓ stroke or re-op vs. axial flow models <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2019;380:1618)</span>.</p>
<p class="noindent1">• Cardiac transplantation: ~2200/yr in U.S. &lt;10% mort. in 1<sup class="calibre19">st</sup> y, median survival ~13 y</p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre28"/>
<col class="calibre20"/>
<col class="calibre13"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="3"><p class="tbodyc"><b class="calibre7">Recommended Chronic Therapy by HF Stage</b> <span class="sm">(<i class="calibre6">JACC</i> 2021;77:772)</span></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td colspan="2" class="th1"><p class="tbody"><b class="calibre7">Stage</b> (not NYHA Class)</p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Therapy</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">A</b></p></td>
<td class="th1"><p class="tbody">At risk for HF (eg, HTN); but asx &amp; w/o struct. dis.</p></td>
<td class="th1"><p class="tbody">Rx HTN, lipids, DM; stop smoking, EtOH; ↑ exercise</p>
<p class="tbody">ACEI/ARB if HTN/DM/CAD/PAD</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">B</b></p></td>
<td class="th1"><p class="tbody">⊕ Struct. heart dis.</p>
<p class="tbody">(eg, CMP, LVH), but asx</p></td>
<td class="th1"><p class="tbody">As per stage A + ACEI/ARB + βB if MI/CAD or ↓ EF. ? ICD.</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">C</b></p></td>
<td class="th1"><p class="tbody">⊕ Struct. heart dis.</p>
<p class="tbody">⊕ Any h/o Sx of HF</p></td>
<td class="th1"><p class="tbody">As per stage A + diuretics, ↓ Na.</p>
<p class="tbody">If ↓ EF: ARNI, ACEI or ARB; βB; aldo antag; SGLT2i; ICD; ? CRT; ± nitrate/hydral; ± dig.</p>
<p class="tbody">If preserved EF: ? ARNI; ? aldo antag; SGLT2i</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">D</b></p></td>
<td class="th1"><p class="tbody">Refractory HF requiring specialized interventions</p></td>
<td class="th1"><p class="tbody">All measures for stages A–C. Consider IV inotropes, VAD, transplant, end-of-life care (4-y mortality &gt;50%)</p></td>
</tr>
</tbody>
</table>
<p class="noindent1">• Utility of BNP-guided Rx (inPt and outPt) remains debated <span class="r1">(</span><span class="r2">Eur Heart J</span> <span class="r1">2014;35:16)</span></p>
<p class="noindent1">• Implantable PA pressure sensor in sx Pts: ~19–37% ↓ risk of hosp <span class="r1">(</span><span class="r2">Lancet</span> <span class="r1">2016;387:453 &amp; 2021;398:991)</span></p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre12"/>
<col class="calibre32"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="2"><a id="page_1-17" class="calibre4"></a><p class="tbodyc"><b class="calibre7">Treatment of Chronic HF with Reduced EF</b> <span class="sm">(<i class="calibre6">Circ</i> 2017;136:e137; <i class="calibre6">JACC</i> 2021;77:772)</span></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbody">Diuretics</p></td>
<td class="th1"><p class="tbodyh">Loop ± thiazides diuretics (sx relief; no mortality benefit)</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">RASi</b></p>
<p class="tbody">Choose one of <b class="calibre7">ARNI</b> (ARB + neprilysin inhib),</p>
<p class="tbody"><b class="calibre7">ACEI</b> or <b class="calibre7">ARB</b></p>
<p class="tbody">36-hr washout when transitioning ACEI to ARNI</p></td>
<td class="th1"><p class="tbodyh"><i class="calibre6">ARNI preferred RASi in NYHA II–IV</i>. Neutral endopeptidase (NEP, aka neprilysin) degrades natriuretic peptides, bradykinin &amp; angiotensins. Valsartan + sacubitril (NEPi) ↓ CV mort &amp; HF hosp c/w ACEi; ↑ HoTN, AKI <span class="sm">(<i class="calibre6">NEJM</i> 2014;371:993 &amp; 2019;380:539)</span>. Contraindicated if h/o angioedema.</p>
<p class="tbodyh"><i class="calibre6">ACEI:</i> if unable to tolerate or afford ARNI. ↓ mortality vs. placebo. High-dose more effic. than low. Watch for ↑ Cr, ↑ K (ameliorate by low-K diet, diuretics, K binders), cough, angioedema.</p>
<p class="tbodyh">ARB: consider if cannot tolerate ACEI (eg, b/c cough) as noninferior</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">β-blocker</b></p>
<p class="tbody">(data for carvedilol, metoprolol, bisoprolol)</p></td>
<td class="th1"><p class="tbody"><i class="calibre6">Add in concert w/ RASi</i></p>
<p class="tbodyh">35% ↓ mort. &amp; 40% ↓ rehosp. in NYHA II–IV <span class="sm">(<i class="calibre6">JAMA</i> 2002;287:883)</span></p>
<p class="tbodyh">EF will transiently ↓, then ↑. Contraindicated in ADHF.</p>
<p class="tbodyh">Carvedilol superior to low-dose metop in 1 trial <span class="sm">(<i class="calibre6">Lancet</i> 2003;362:7)</span>, but meta-analysis suggests no diff between βB <span class="sm">(<i class="calibre6">BMJ</i> 2013;346:f55)</span>.</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Aldosterone antagonists</b></p></td>
<td class="th1"><p class="tbodyh"><i class="calibre6">Add after RASi and</i> b<i class="calibre6">B if adeq. renal fxn and w/o hyperkalemia</i></p>
<p class="tbodyh">25–30% ↓ mort. in NYHA II–IV &amp; EF ≤35% <span class="sm">(<i class="calibre6">NEJM</i> 2011;364:11)</span></p>
<p class="tbodyh">15% ↓ mort. in HF post-MI, EF ≤40% <span class="sm">(<i class="calibre6">EPHESUS, NEJM</i> 2003;348:1309)</span></p>
<p class="tbodyh">Watch for ↑ K. Do not use if GFR &lt;30 or K ≥5</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">SGLT2i</b></p></td>
<td class="th1"><p class="tbodyh">~25% ↓ death or HF hospitalization in NYHA II–IV <span class="sm">(<i class="calibre6">DAPA-HF, NEJM</i> 2019; 381:1995, <i class="calibre6">EMPEROR-Reduced; NEJM</i> 2020;383:1413)</span>.</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Hydralazine + nitrates</p></td>
<td class="th1"><p class="tbodyh"><i class="calibre6">Consider if cannot tolerate ACEI/ARB or in black Pts w/ class III/IV</i></p>
<p class="tbodyh">25% ↓ mort. <span class="sm">(<i class="calibre6">NEJM</i> 1986;314:1547)</span>; infer. to ACEI <span class="sm">(<i class="calibre6">NEJM</i> 1991;325:303)</span></p>
<p class="tbodyh">40% ↓ mort. in blacks on standard Rx (A-HEFT, <span class="sm"><i class="calibre6">NEJM</i> 2004;351:2049</span>)</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Ivabradine (I<i class="calibre6"><sub class="calibre17">f</sub></i> blocker w/o ⊖ ino)</p></td>
<td class="th1"><p class="tbodyh"><i class="calibre6">Reasonable if EF</i> ≤<i class="calibre6">35%, NYHA II or III, HR</i> ≥<i class="calibre6">70, NSR on max</i> b<i class="calibre6">B.</i></p>
<p class="tbodyh">18% ↓ CV mort or HF hosp <span class="sm">(<i class="calibre6">Lancet</i> 2010;376:875)</span></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Digoxin</p></td>
<td class="th1"><p class="tbodyh">23% ↓ HF hosp., no ∆ mort <span class="sm">(<i class="calibre6">NEJM</i> 1997;336:525)</span>; ? ↑ mort w/ ↑ levels <span class="sm">(<i class="calibre6">NEJM</i> 2002;347:1403)</span>; optimal 0.5–0.8 ng/mL <span class="sm">(<i class="calibre6">JAMA</i> 2003;289:871)</span></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Vericiguat</p></td>
<td class="th1"><p class="tbodyh">10% ↓ CV mort or HF hosp in NYHA II–IV <span class="sm">(<i class="calibre6">NEJM</i> 2020;382:1883)</span></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Cardiac resynch therapy (CRT, qv)</b></p></td>
<td class="th1"><p class="tbodyh"><i class="calibre6">Consider if EF</i> ≤<i class="calibre6">35%, LBBB (QRS</i> ≥1<i class="calibre6">30 ms) and symptomatic HF</i></p>
<p class="tbodyh">36% ↓ mort. &amp; ↑ EF in NYHA III–IV (CARE-HF, <span class="sm"><i class="calibre6">NEJM</i> 2005;352:1539</span>)</p>
<p class="tbodyh">41% ↓ mort. if EF ≤30%, LBBB and NYHA I/II <span class="sm">(<i class="calibre6">NEJM</i> 2014;370:1694)</span></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">ICD</b> (see “Cardiac Rhythm Mgmt Devices”)</p></td>
<td class="th1"><p class="tbodyh"><i class="calibre6">For</i> 1<i class="calibre6">° prevention if EF</i> ≤<i class="calibre6">30–35% or 2° prevention; not if NYHA IV</i></p>
<p class="tbodyh">↓ mort. in ischemic CMP but perhaps only SCD in modern era in niCMP <span class="sm">(<i class="calibre6">NEJM</i> 2005;352:225 &amp; 2016;375:1221)</span></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Iron supplementation</p></td>
<td class="th1"><p class="tbodyh"><i class="calibre6">? IV (not PO) if NYHA II/III, EF</i> ≤<i class="calibre6">40%, Fe-defic</i> (ferritin &lt;100 or 100– 300 &amp; TSAT &lt;20%). ~20% ↓ HF hosp. <span class="sm">(<i class="calibre6">Lancet</i> 2020;396:1895)</span>.</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Anticoagulation</p></td>
<td class="th1"><p class="tbodyh"><i class="calibre6">If AF, VTE, LV thrombus</i>, ± <i class="calibre6">if large akinetic LV segments.</i></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Heart rhythm</p></td>
<td class="th1"><p class="tbodyh">If AF &amp; NYHA II–IV w/ EF &lt;35%, catheter ablation ↓ D/HF hosp vs. med Rx (rate or rhythm; <span class="sm"><i class="calibre6">NEJM</i> 2018;378:417</span>)</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">BP</p></td>
<td class="th1"><p class="tbodyh">Goal &lt;130/80 <span class="sm">(<i class="calibre6">JACC</i> 2018;71:127)</span></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Diet, exercise</p></td>
<td class="th1"><p class="tbodyh">? Na &lt;2 g/d, fluid restriction, exercise training in ambulatory Pts</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Meds to avoid</p></td>
<td class="th1"><p class="tbodyh">NSAIDs, nondihydropyridine CCB, TZDs</p></td>
</tr>
</tbody>
</table>
<p class="tfn">(<i class="calibre6">Circ</i> 2013;128:e240 &amp; 2016;134:e282; <i class="calibre6">EHJ</i> 2016;37:2129)</p>
<p class="h">Heart failure with preserved EF <span class="r">(HFpEF; “Diastolic HF”)</span> <span class="r1">(</span><span class="r2">JACC</span> <span class="r1">2022;epub)</span></p>
<p class="noindent1">• Epidemiology: ~½ of Pts w/ HF have normal (EF ≥50%); risk factors for HFpEF incl ↑ age, ♀, DM, AF. Mort ≈ to those w/ HFrEF.</p>
<p class="noindent1">• Etiologies (impaired relaxation and/or ↑ passive stiffness): ischemia, prior MI, LVH, HCMP, infiltrative CMP, RCMP, aging, hypothyroidism</p>
<p class="noindent1">• Precipitants of pulmonary edema: <i class="calibre6">volume overload</i> (poor compliance of LV → sensitive to small ↑ in volume); <i class="calibre6">ischemia</i> (↓ relaxation); <i class="calibre6">tachycardia</i> (↓ filling time in diastole), <i class="calibre6">AF</i> (loss of atrial boost to LV filling); <i class="calibre6">HTN</i> (↑ afterload → ↓ stroke volume)</p>
<p class="noindent1">• Dx w/ clinical s/s of HF w/ preserved systolic fxn. Dx supported by evidence of diast dysfxn:</p>
<p class="noindent2">(1) echo: impaired relaxation using tissue Doppler (eg, e′ &lt;9 cm/s), high filling pressures ± impaired relaxation (eg, E/e′ ≥15), large left atrium</p>
<p class="noindent2">(2) exercise-induced ↑ PCWP ± inadequate ↑ stroke volume or CO</p>
<p class="noindent1">• Treatment: <b class="calibre7">diuresis</b>, Rx HTN, tachycardia, and ischemia</p>
<p class="noindent2"><b class="calibre7">SGLT2i</b> ↓ CV death or HF hosp <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2021;385:1451; DELIVER)</span></p>
<p class="noindent2">Nonsignficiant trends toward benefit for ARB vs. placebo. <b class="calibre7">ARNI</b> ↓ CV death or hosp for HF in HFpEF Pts w/ LVEF &lt;60% <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2019; 381:1609)</span></p>
<p class="noindent2"><b class="calibre7">Spironolactone</b> likely ↓ HF hospitalization <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2014;370:1383;</span> <span class="r2">Circ</span> <span class="r1">2015;131:34)</span></p>
<h2 class="ct"><a id="h9" class="calibre8"></a><a id="page_1-18" class="calibre8"></a><a href="part0003.html#rh13" class="calibre8">CARDIOMYOPATHIES</a></h2>
<p class="center"><i class="calibre6">Diseases with mechanical and/or electrical dysfunction of the myocardium</i></p>
<p class="h1cr">D<small class="calibre31">ILATED</small> C<small class="calibre31">ARDIOMYOPATHY</small> (DCM)</p>
<p class="h">Definition and epidemiology <span class="r1">(</span><span class="r2">JACC</span> <span class="r1">2016;67:2996;</span> <span class="r2">Lancet</span><span class="r1"> 2017;390:400)</span></p>
<p class="noindent1">• <b class="calibre7">LV or biventricular dilatation and global</b> ↓ contractility ± ↓ wall thickness in the absence of ischemia/infarct, valvular disease or HTN. Pts w/ prior MI complicated by LV dilation and ↓ EF are often termed “ischemic CMP.”</p>
<p class="h">Etiologies <span class="r1">(</span><span class="r2">JACC</span> <span class="r1">2021;77:2551</span><span class="r">; can also be prior myocarditis, vide infra)</span></p>
<p class="noindent1">• <b class="calibre7">Familial/genetic</b> (&gt;35%): Pt &amp; ≥2 closely related family members w/ unexplained DCM; ~30 genes identified to date, encoding structural &amp; nuclear proteins (eg, titin)</p>
<p class="noindent1">• <b class="calibre7">Idiopathic</b> (&lt;20%): ? undx infectious, EtOH, or genetic cause; ¼ w/ e/o DCM in relative</p>
<p class="noindent1">• <b class="calibre7">Toxic:</b> alcohol (~20%) typ. 7–8 drinks/d × &gt;5 y, but variable; cocaine; XRT (usu RCMP);</p>
<p class="noindent2">anthracyclines (risk ↑ &gt;550 mg/m<sup class="calibre19">2</sup>, may manifest late), CYC, trastuzumab, TKIs.</p>
<p class="noindent1">• <b class="calibre7">Infiltrative</b> (5%): typically RCMP (qv), but can be DCMP with thickened walls; amyloidosis, sarcoidosis, hemochromatosis, tumor</p>
<p class="noindent1">• <b class="calibre7">Peripartum</b> (onset last mo → 5 mo postpartum; <span class="r2">JACC</span> <span class="r1">2020;75:207</span>): ~1:2000; ↑ risk w/ multip, ↑ age, Afr Am; stnd HF Rx (if preg, no ACEI or spironolact.); ~30% recur w/ next preg</p>
<p class="noindent1">• <b class="calibre7">Stress-induced</b> (Takotsubo = apical ballooning): typically postmenopausal ♀; mimics MI (chest pain, ± STE &amp; ↑ Tn; deep TWI &amp; ↑ QT); mid/apex dyskinesis; ? Rx w/ βB, ACEI; usu. improves over wks <span class="r1">(</span><span class="r2">JAMA</span> <span class="r1">2011;306:277)</span>. In-hosp morb/mort similar to ACS <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2015;373:929)</span>.</p>
<p class="noindent1">• <b class="calibre7">Tachycardia</b> <span class="r1">(</span><span class="r2">JACC</span> <span class="r1">2019;73:2328)</span>: likelihood ∝ rate/duration; often resolves w/ rate cntl</p>
<p class="noindent1">• <b class="calibre7">Arrhythmogenic right ventricular cardiomyopathy</b> (ACM/ARVC): fibrofatty replacement of RV → dilation (dx w/ MRI); ECG: ± RBBB, TWI V<sub class="calibre10">1</sub>–V<sub class="calibre10">3</sub>, ε wave; VT risk <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2017;376:61)</span></p>
<p class="noindent1">• <b class="calibre7">LV noncompaction</b> <span class="r1">(</span><span class="r2">Lancet</span> <span class="r1">2015;386:813)</span>: prominent trabeculae, arrhythmias, cardioemboli</p>
<p class="noindent1">• <b class="calibre7">Metab/other:</b> hypothyroid, acromegaly, pheo, OSA, Vit B<sub class="calibre10">1</sub>, selenium or carnitine defic.</p>
<p class="h">Clinical manifestations</p>
<p class="noindent1">• <b class="calibre7">Heart failure:</b> both congestive &amp; poor forward flow sx; signs of L- &amp; R-sided HF</p>
<p class="noindent2"><b class="calibre7">diffuse</b>, <b class="calibre7">laterally displaced PMI</b>, <b class="calibre7">S3</b>, ± MR or TR (annular dilat., displaced pap. muscle)</p>
<p class="noindent1">• Embolic events (~10%), supraventricular/ventricular arrhythmias, &amp; palpitations</p>
<p class="h">Diagnostic studies and workup <span class="r1">(</span><span class="r2">JACC</span> <span class="r1">2016;67:2996)</span></p>
<p class="noindent1">• ECG: may see PRWP, Q waves, or BBB; low-voltage; AF (20%); may be normal</p>
<p class="noindent1">• Echocardiogram: LV dilatation, ↓ EF, <i class="calibre6">regional or global</i> LV HK ± RV HK, ± mural thrombi</p>
<p class="noindent1">• Cardiac MRI: high Se for myocarditis or infiltration; extent of scar correlated w/ mortality</p>
<p class="noindent1">• Labs: TFTs, Fe panel, HIV, SPEP, ANA; viral sero <i class="calibre6">not</i> recommended; others per suspicion</p>
<p class="noindent1">• Family hx (20–35% w/ familial dis.), genetic counseling ± genetic testing <span class="r1">(</span><span class="r2">JAMA</span> <span class="r1">2009;302:2471)</span></p>
<p class="noindent1">• Coronary CT angiography (or invasive) to r/o CAD if risk factors, h/o angina, Qw MI</p>
<p class="noindent1">• Endomyocardial biopsy: consider if fulminant myocarditis or suspect infiltrative disease</p>
<p class="h">Treatment <span class="r">(see “Heart Failure” for standard HF Rx)</span></p>
<p class="noindent1">• Possibility of reversibility of CMP may temper implantation of devices</p>
<p class="noindent1">• Prognosis differs by etiology <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2000;342:1077)</span>: postpartum (best), ischemic/GCM (worst)</p>
<p class="h1cr">M<small class="calibre31">YOCARDITIS</small></p>
<p class="h">Etiologies</p>
<p class="noindent1">• <b class="calibre7">Infectious</b> <span class="r1">(</span><span class="r2">Lancet</span> <span class="r1">2012;379:738;</span> <span class="r2">JACC</span> <span class="r1">2012;59:779)</span></p>
<p class="noindent2">Viruses (parvoB19, Coxsackie, adeno, HIV, SARS-CoV-2/vaccine, etc.)</p>
<p class="noindent2">Bacterial, fungal, rickettsial, TB, Lyme (mild myocarditis, often with AVB)</p>
<p class="noindent2">Chagas: apical aneurysm ± thrombus, RBBB, megaesophagus/colon <span class="r1">(</span><span class="r2">Lancet</span> <span class="r1">2018;391:82)</span></p>
<p class="noindent1">• <b class="calibre7">Autoimmune</b></p>
<p class="noindent2">Idiopathic giant cell myocarditis (GCM): avg age 42, fulminant, AVB/VT <span class="r1">(</span><span class="r2">Circ HF</span> <span class="r1">2013;6:15)</span></p>
<p class="noindent2">Eosinophilic (variable peripheral eos): hypersensitivity (mild HF but at risk for SCD) or acute necrotizing eosinophilic myocarditis (ANEM; STE, effusion, severe HF)</p>
<p class="noindent2">Collagen vasc. dis. (pericarditis &gt;myocarditis): PM, SLE, scleroderma, PAN, RA, EGPA</p>
<p class="h">Clinical manifestations</p>
<p class="noindent1">• Highly variable, ranging from incidental dx based on labs/imaging to fulminant HF w/ shock</p>
<p class="noindent1">• Can present as ACS-like syndrome (chest pain, ECG Δs, ↑ Tn), acute HF, arrhythmias</p>
<p class="h">Diagnostic studies and workup</p>
<p class="noindent1">• Echo: systolic dysfxn (typically global but can be regional); ± ↑ LV wall thickness due to edema; LV size may be small in fulminant and dilated in chronic; ± pericardial effusion</p>
<p class="noindent1">• Cardiac MRI: can show hyperemia, edema, and scar <span class="r1">(</span><span class="r2">JACC</span> <span class="r1">2009;53:1475)</span></p>
<p class="noindent1">• Endomyocardial biopsy: useful in GCM &amp; eosinophilic; ∴ consider if rapidly progressive HF, high-grade AVB or sustained VT, suspected allergic rxn or eosinophilia</p>
<p class="h"><a id="page_1-19" class="calibre4"></a>Treatment</p>
<p class="noindent1">• Standard HF Rx if LV dysfxn (but do not start if e/o shock); temporary MCS as needed</p>
<p class="noindent1">• Immunosuppression: for GCM (high-dose steroids + CsA or tacrolimus ± AZA), collagen vascular disease, peripartum (? IVIg), &amp; eosinophilic; no proven benefit if viral</p>
<p class="h1cr">H<small class="calibre31">YPERTROPHIC</small> C<small class="calibre31">ARDIOMYOPATHY</small> (HCM)</p>
<p class="h">Definition, epidemiology, pathology <span class="r1">(</span><span class="r2">Circ Res</span> <span class="r1">2017;121:749)</span></p>
<p class="noindent1">• LV (usually ≥15 mm) and/or RV hypertrophy disproportionate to hemodynamic load</p>
<p class="noindent1">• Due to gene mutations affecting proteins of or related to sarcomere; prev.: ~1/200-500</p>
<p class="noindent1">• Myocardial fiber disarray with hypertrophy, which creates arrhythmogenic substrate</p>
<p class="noindent1">• Many morphologic hypertrophy variants: asymmetric septal; concentric; midcavity; apical</p>
<p class="noindent1">• Ddx: LVH 2° to HTN, AS, elite athletes (wall usually &lt;13 mm &amp; symmetric and nl/↑ rates of tissue Doppler diastolic relaxation; <span class="r2">Circ</span><span class="r1"> 2011;123:2723</span>), Fabry dis. (↑ Cr, skin findings)</p>
<p class="h">Pathophysiology</p>
<p class="noindent1">• LV outflow tract obstruction (LVOTO) in ≥70%: narrowed tract 2° hypertrophied septum + systolic anterior motion (SAM) of ant. MV leaflet (may be fixed, variable, or nonexistent) and papillary muscle displacement. Gradient (∇) worse w/ ↑ contractility (digoxin, β- agonists, exercise, PVCs), ↓ preload (eg, Valsalva maneuver) or ↓ afterload.</p>
<p class="noindent1">• Mitral regurgitation: due to SAM (mid-to-late, post.-directed regurg. jet) and/or abnl</p>
<p class="noindent2">mitral leaflets and papillary muscles (pansystolic, ant.-directed regurg. jet)</p>
<p class="noindent1">• Diastolic dysfunction: ↑ chamber stiffness + impaired relaxation</p>
<p class="noindent1">• Ischemia: small vessel dis., perforating artery compression (bridging), ↓ coronary perfusion</p>
<p class="h">Clinical manifestations <span class="r">(70% are asymptomatic at dx)</span></p>
<p class="noindent1">• <b class="calibre7">Dyspnea</b> (90%): due to ↑ LVEDP, MR, and diastolic dysfunction</p>
<p class="noindent1">• <b class="calibre7">Angina</b> (25%) even w/o epicardial CAD; microvasc. dysfxn <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2003;349:1027)</span></p>
<p class="noindent1">• <b class="calibre7">Arrhythmias</b> (AF in 20–25%; VT/VF): palpitations, syncope, sudden cardiac death</p>
<p class="h">Physical exam</p>
<p class="noindent1">• Sustained PMI, S<sub class="calibre10">2</sub> paradoxically split if severe outflow obstruction, ⊕ S<sub class="calibre10">4</sub> (occ. palpable)</p>
<p class="noindent1">• <b class="calibre7">Systolic murmur:</b> crescendo-decrescendo; LLSB; ↑ <b class="calibre7">w/ Valsalva</b> &amp; standing (↓ preload)</p>
<p class="noindent1">• ± mid-to-late or holosystolic murmur of MR at apex</p>
<p class="noindent1">• Bifid (biphasic) carotid pulse (brisk rise, decline, then 2<sup class="calibre19">nd</sup> rise); JVP w/ prominent <i class="calibre6">a</i> wave</p>
<p class="noindent1">• Contrast to AS, which has murmur that ↓ w/ Valsalva and ↓ carotid pulses</p>
<p class="h">Diagnostic studies <span class="r1">(</span><span class="r2">EHJ</span> <span class="r1">2014;35:2733)</span></p>
<p class="noindent1">• ECG: LVH, anterolateral TWI and inferior pseudo-Qw, ± apical giant TWI (apical variant)</p>
<p class="noindent1">• <b class="calibre7">Echo:</b> any LV wall segment ≥15 mm (or ? even ≥13 if ⊕ HFx), often but not necessarily involving septum; other findings include dynamic outflow obstruction, SAM, MR</p>
<p class="noindent1">• MRI: hypertrophy + patchy delayed enhancement (useful for dx &amp; prog) <span class="r1">(</span><span class="r2">Circ</span> <span class="r1">2015;132:292)</span></p>
<p class="noindent1">• Cardiac cath: subaortic pressure ∇; <i class="calibre6">Brockenbrough sign</i> = ↓ pulse pressure post-PVC (in contrast to AS, in which pulse pressure ↑ post-PVC); spike &amp; dome Ao pressure pattern</p>
<p class="noindent1">• Consider genotyping for family screening; pathogenic variant ID’d in &lt;½ <span class="r1">(</span><span class="r2">Circ</span> <span class="r1">2020;142:e558)</span></p>
<p class="h">Treatment <span class="r1">(</span><span class="r2">Circ</span> <span class="r1">2020;142:e558;</span> <span class="r2">Lancet</span> <span class="r1">2021;398:2102;</span> <span class="r2">JACC</span><span class="r1"> 2022;79:390)</span></p>
<p class="noindent1">• Heart failure</p>
<p class="noindent2">⊖ <b class="calibre7">inotropes/chronotropes:</b> β-blockers <span class="r1">(</span><span class="r2">JACC</span> <span class="r1">2021;78:2505)</span>, CCB (verapamil), disopyramide</p>
<p class="noindent2">Careful use of diuretics, because may further ↓ preload. If LVOTO, <i class="calibre6">avoid vasodilators</i>. Avoid digoxin b/c ↑ contractility and ∴ outflow obstruction.</p>
<p class="noindent2">If sx refractory to drug Rx + <i class="calibre6">obstructive</i> physio. (∇ ≥30 mmHg at rest or w/ provocation):</p>
<p class="noindent2">(a) Surgical myectomy: long-term ↓ symptoms in 90% <span class="r1">(</span><span class="r2">Circ</span> <span class="r1">2014;130:1617)</span></p>
<p class="noindent2">(b) Alcohol septal ablation <span class="r1">(</span><span class="r2">JACC</span> <span class="r1">2018;72:3095)</span>: ∇ ↓ by ~80%, only 5–20% remain w/ NYHA III–IV sx; 14% require repeat ablation or myectomy. Good alternative for older Pts, multiple comorbidities. Complic: transient (&amp; occ. delayed) 3° AVB w/ 10–20% req. PPM; VT due to scar formation.</p>
<p class="noindent2">Mavacamten (cardiac myosin inhibitor) ↓ HF sxs &amp; LVOT ∇ <span class="r1">(</span><span class="r2">Lancet</span> <span class="r1">2020;396,750)</span></p>
<p class="noindent2">If refractory to drug therapy and there is <i class="calibre6">nonobstructive</i> pathophysiology: transplant</p>
<p class="noindent1">• Acute HF: can be precip. by dehydration or tachycardia; Rx w/ fluids, βB, phenylephrine</p>
<p class="noindent1">• AF: rate control w/ βB, maintain SR w/ disopyramide or amio; low threshold to anticoag</p>
<p class="noindent1">• ICD if VT/VF. Reasonable for 1° prevention if ≥1 risk factor: ⊕ FHx SCD, unexplained syncope, LV wall ≥30 mm, LV aneurysm or EF &lt;50%; consider if NSVT, failure of SBP to ↑ or fall from peak ≥20 mmHg w/ exercise, ? extensive MRI delayed enhancement. EPS <i class="calibre6">not</i> useful. HCM Risk-SCD Score (<a href="https://doc2do.com/hcm/webHCM.html" class="calibre4">https://doc2do.com/hcm/webHCM.html</a>).</p>
<p class="noindent1">• Counsel to avoid dehydration, extreme exertion</p>
<p class="noindent1">• 1<sup class="calibre19">st</sup>-degree relatives: screen w/ TTE q12–18m as teen or athlete then q5y as adult, ECG (because timing of HCMP onset variable). Genetic testing if known mutation.</p>
<p class="h1cr"><a id="page_1-20" class="calibre8"></a>R<small class="calibre31">ESTRICTIVE</small> &amp; I<small class="calibre31">NFILTRATIVE</small> CMP</p>
<p class="h">Definition <span class="r1">(</span><span class="r2">JACC</span> <span class="r1">2018;71:1130 &amp; 1149)</span></p>
<p class="noindent1">• Restrictive CMP: ↓ ventricular filling with ↓ compliance in nonhypertrophied, nondilated ventricles; nl/↓ diastolic volumes, nl or near-nl EF; must r/o pericardial disease</p>
<p class="noindent1">• Infiltrative CMP: myocardial deposition; ± ↑ wall thickness; may present as RCM or DCM</p>
<p class="h">Etiologies <span class="r1">(</span><span class="r2">JACC</span> <span class="r1">2018;71:1130 &amp; 1149)</span></p>
<p class="noindent1">• <b class="calibre7">Amyloidosis</b>: age at presentation ~60 y; ♂:♀ = 3:2</p>
<p class="noindent2">AL (eg, MM, etc.); familial (transthyretin, ATTR-m); senile (ATTR-wt)</p>
<p class="noindent2">ECG: ↓ QRS amplitude (50%), pseudoinfarction pattern (Qw), AVB (10–20%), hemiblock (20%), BBB (5–20%)</p>
<p class="noindent2">Echo: biventricular wall thickening (<i class="calibre6">yet w/ low voltage on ECG</i>), granular sparkling (30%), biatrial enlargement (40%), valve thickening, small effusions</p>
<p class="noindent2">Normal ECG voltage &amp; septal thickness has NPV ~90%</p>
<p class="noindent2">Cardiac MRI: distinct late gadolinium enhancement pattern <span class="r1">(</span><span class="r2">JACC</span> <span class="r1">2008;51:1022)</span></p>
<p class="noindent1">• <b class="calibre7">Sarcoidosis</b> (can also be DCM): presents at age ~30 y; ↑ in blacks, N. Europe, ♀</p>
<p class="noindent2">Cardiac involvement in 25–58% of sarcoid, many not overt; cardiac w/o systemic in 10%</p>
<p class="noindent2">ECG: AVB (75%), RBBB (20–60%), VT; PET: ↑ FDG uptake in affected area</p>
<p class="noindent2">Echo: regional WMA (particularly basal septum) w/ thinning or mild hypertrophy</p>
<p class="noindent2">Cardiac MRI: T2 early gad (edema); fibrosis/scar in basal septum; LGE prognostic</p>
<p class="noindent1">• <b class="calibre7">Other myocardial processes</b></p>
<p class="noindent2">Hemochromatosis: often middle-aged men (espec N. European); 15% w/ cardiac sx</p>
<p class="noindent2">Diabetes; radiation (also accelerated athero, valvular disease, constrictive pericarditis)</p>
<p class="noindent2">Autoimmune (scleroderma, polymyositis-dermatomyositis)</p>
<p class="noindent1">• <b class="calibre7">Endomyocardial diseases</b>: carcinoid heart disease (R-sided HF w/ TR/TS, PR/PS); Löffler’s endocarditis (↑ eos; mural thrombi that can embolize; fibrosis); endomyocardial fibrosis (tropical climates; resembles Löffler’s but w/o eos)</p>
<p class="noindent1">• <b class="calibre7">Storage diseases</b>: Fabry (glycosphingolipids); Gaucher (glucocerebrosidase)</p>
<p class="h">Pathophysiology</p>
<p class="noindent1">• ↓ myocardial compliance → nl EDV but ↑ EDP → ↑ systemic &amp; pulm. venous pressures</p>
<p class="noindent1">• ↓ ventricular cavity size → ↓ SV and ↓ CO</p>
<p class="h">Clinical manifestations <span class="r1">(</span><span class="r2">JACC</span> <span class="r1">2018;71:1130 &amp; 1149)</span></p>
<p class="noindent1">• <b class="calibre7">Right-sided</b> &gt;<b class="calibre7">left-sided heart failure</b> with peripheral edema &gt;pulmonary edema</p>
<p class="noindent1">• <b class="calibre7">Diuretic “refractoriness”; thromboembolic events</b></p>
<p class="noindent1">• Poorly tolerated tachyarrhythmias; VT → syncope/sudden cardiac death</p>
<p class="h">Physical exam</p>
<p class="noindent1">• ↑ JVP, ± Kussmaul’s sign (JVP not ↓ w/ inspir., classically seen in <i class="calibre6">constrict. pericarditis</i>)</p>
<p class="noindent1">• Cardiac: ± S<sub class="calibre10">3</sub> and S<sub class="calibre10">4</sub>, ± murmurs of MR and TR</p>
<p class="noindent1">• Congestive hepatomegaly, ± ascites and jaundice, peripheral edema</p>
<p class="h">Diagnostic studies</p>
<p class="noindent1">• CXR: normal ventricular chamber size, enlarged atria, ± pulmonary congestion</p>
<p class="noindent1">• ECG: low voltage, pseudoinfarction pattern (Qw), ± arrhythmias</p>
<p class="noindent1">• Echo: ± symmetric wall thickening, biatrial enlarge., ± mural thrombi, ± cavity oblit. w/ diast dysfxn: ↑ early diast (E) and ↓ late atrial (A) filling, ↑ E/A ratio; ↓ mitral annular velocity (e′) on tissue Doppler, ↑ E/e′ ratio</p>
<p class="noindent1">• Cardiac MRI/PET: may reveal inflammation or evidence of infiltration (but nonspecific)</p>
<p class="noindent1">• Amyloid (qv) workup: ✓ for plasma cell dyscrasia (immunofix. &amp; serum free light chains). If ⊕ → fat pad bx. If ⊖ → PYP SPECT for TTR evaluation (not AL).</p>
<p class="noindent1">• Endomyocardial biopsy if suspect amyloid (Se ~100%) &amp; noninvasive tests non-dx. Se low for sarcoidosis b/c patchy disease infiltrative process.</p>
<p class="noindent1">• Cardiac catheterization</p>
<p class="noindent2">Atria: <b class="calibre7">M’s</b> or <b class="calibre7">W’s</b> (prominent <i class="calibre6">x</i> and <i class="calibre6">y</i> descents)</p>
<p class="noindent2">Ventricles: <b class="calibre7">dip &amp; plateau</b> (rapid ↓ pressure at onset of diastole, rapid ↑ to early plateau)</p>
<p class="noindent2"><b class="calibre7">Concordance</b> of LV–RV pressure peaks w/ respiration (vs. discordance in constriction)</p>
<p class="noindent1">• Restrictive cardiomyopathy vs. constrictive pericarditis: see “Pericardial Disease”</p>
<p class="h">Treatment <span class="r">(in addition to Rx’ing underlying disease)</span></p>
<p class="noindent1">• Gentle diuresis. May not tolerate CCB or other vasodilators.</p>
<p class="noindent1">• Control HR (but can ↓ CO); maintain SR (helps filling). Digoxin ↑ arrhythmias in amyloid.</p>
<p class="noindent1">• Anticoagulation (particularly with AF or low CO)</p>
<p class="noindent1">• Transplantation for refractory cases</p>
<p class="noindent1">• AL amyloid: Rx targeted at plasma cell dyscrasia</p>
<p class="noindent1">• ATTR amyloid: tafamidis (TTR binder) ↓ death and CV hosp, ↑QoL <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2018;379:1007)</span></p>
<p class="noindent1">• Sarcoid: consider steroids/immunomodulators if FDG PET ⊕ for inflammation + AVB, VT or LV dysfxn; ↑ risk for VT; unique indications for ICD placement <span class="r1">(</span><span class="r2">Circ</span> <span class="r1">2018;138:e272)</span></p>
<h2 class="ct"><a id="h10" class="calibre8"></a><a id="page_1-21" class="calibre8"></a><a href="part0003.html#rh14" class="calibre8">VALVULAR HEART DISEASE</a></h2>
<p class="h1cr">A<small class="calibre31">ORTIC</small> S<small class="calibre31">TENOSIS</small> (AS)</p>
<p class="h">Etiology</p>
<p class="noindent1">• <b class="calibre7">Calcific:</b> predominant cause in Pts &gt;70 y; risk factors: HTN, ↑ LDL-C, ↑ Lp(a), ESRD</p>
<p class="noindent1">• <b class="calibre7">Congenital</b> (ie, bicuspid AoV w/ premature calcification): cause in 50% of Pts &lt;70 y</p>
<p class="noindent1">• <b class="calibre7">Rheumatic heart disease</b> (AS usually accompanied by AR and MV disease)</p>
<p class="noindent1">• AS mimickers: subvalvular (HCMP, subaortic membrane) or supravalvular stenosis</p>
<p class="h">Clinical manifestations <span class="r">(usually indicates AVA &lt;</span>1<span class="r"> cm<sup class="calibre19">2</sup> or concomitant CAD)</span></p>
<p class="noindent1">• <b class="calibre7">Angina:</b> ↑ O<sub class="calibre10">2</sub> demand (hypertrophy) + ↓ O<sub class="calibre10">2</sub> supply (↓ cor perfusion pressure) ± CAD</p>
<p class="noindent1">• <b class="calibre7">Syncope</b> (<i class="calibre6">exertional</i>): peripheral vasodil. w/ fixed CO → ↓ MAP → ↓ cerebral perfusion</p>
<p class="noindent1">• <b class="calibre7">Heart failure:</b> outflow obstruct + diastolic dysfxn → pulm. edema, esp. if ↑ HR/AF (↓ LV fill.)</p>
<p class="noindent1">• Acquired vWF disease (~20% of sev. AS): destruction of vWF; GI angiodysplasia</p>
<p class="noindent1">• Natural hx: usually slowly progressive (AVA ↓ ~0.1 cm<sup class="calibre19">2</sup>/y, but varies; <span class="r2">Circ</span> <span class="r1">1997;95:2262</span>), until sx develop; mean survival based on sx: angina = 5 y; syncope = 3 y; CHF = 2 y</p>
<p class="h">Physical exam</p>
<p class="noindent1">• <b class="calibre7">Midsystolic crescendo-decrescendo</b> murmur at <b class="calibre7">RUSB</b>, harsh, high-pitched, radiates to carotids, apex (holosystolic = Gallavardin effect), ↑ w/ passive leg raise, ↓ w/ standing &amp; Valsalva. Dynamic outflow obstruction (HCM) is the reverse.</p>
<p class="noindent1">• Ejection click after S<sub class="calibre10">1</sub> sometimes heard with <i class="calibre6">bicuspid</i> AoV</p>
<p class="noindent1">• Signs of severity: <i class="calibre6">late-peaking</i> murmur, paradoxically split S<sub class="calibre10">2</sub> or inaudible A<sub class="calibre10">2</sub>, small and delayed carotid pulse (“<i class="calibre6">pulsus parvus et tardus</i>”), LV heave, ⊕ S<sub class="calibre10">4</sub> (occasionally palpable)</p>
<p class="image"><img src="../images/00021.jpeg" alt="" class="calibre5"/></p>
<p class="capf"><i class="calibre6">Pathophys Heart Dis</i>., 7th ed., 2021, for this et al.</p>
<p class="h">Diagnostic studies</p>
<p class="noindent1">• ECG: may see LVH, LAE, LBBB, AF (in late disease)</p>
<p class="noindent1">• CXR: cardiomegaly, AoV calcification, poststenotic dilation of ascending Ao, pulmonary congestion</p>
<p class="noindent1">• <b class="calibre7">Echo:</b> valve morph., jet velocity → estimate pressure gradient (∇) &amp; calculate AVA, dimensionless index (DI); LVEF</p>
<p class="noindent1">• <b class="calibre7">Cardiac cath:</b> usually to <i class="calibre6">r/o CAD</i> (in ~½ of calcific AS); for hemodyn. if disparity between exam &amp; echo: ✓ pressure gradient (∇) across AoV, calc AVA (underestim. if mod/sev AR)</p>
<p class="noindent1">• <b class="calibre7">Dobutamine challenge</b> (echo or cath): if low EF and mean ∇ &lt;40, use to differentiate:</p>
<p class="noindent2"><i class="calibre6">Afterload mismatch:</i> 20% ↑ SV &amp; ∇, no ∆ AVA (implies contractile reserve, ↑ EF post-AVR)</p>
<p class="noindent2"><i class="calibre6">Pseudostenosis:</i> 20% ↑ SV, no ∆ in ∇, ↑ AVA (implies low AVA <i class="calibre6">artifact</i> of LV dysfxn)</p>
<p class="noindent2"><i class="calibre6">Limited contractile reserve:</i> no ∆ SV, ∇ or AVA (implies EF prob. will not improve w/ AVR)</p>
<p class="imaget"><img src="../images/00022.jpeg" alt="" class="calibre5"/></p>
<p class="tfn"><sup class="calibre22"><a id="rfn17-a" class="calibre8"></a>a</sup>AVA indexed to BSA &lt;0.6 cm<sup class="calibre22">2</sup>/m<sup class="calibre22">2</sup> also severe (use for smaller Pts); <sup class="calibre22"><a id="rfn17-b" class="calibre8"></a>b</sup>DSE → max jet vel ≥4 &amp; AVA ≤1.0; <sup class="calibre22"><a id="rfn17-c" class="calibre8"></a>c</sup>Small LV w/ ↓ stroke vol (LVSVi &lt;35 mL/m<sup class="calibre22">2</sup>), severe LVH with marked diastolic dysfunction, consider cardiac amyloid</p>
<p class="h">Valve replacement <span class="r1">(</span><span class="r2">Circ</span> <span class="r1">2021;143:e72)</span></p>
<p class="noindent1">• Based on <i class="calibre6">symptoms:</i> once they develop → AVR needed</p>
<p class="noindent1">• <i class="calibre6">Indicated in:</i> <b class="calibre7">sx severe</b> (stage D1; D2; D3 if AS felt to be cause of sx); <b class="calibre7">asx severe</b> +<b class="calibre7"> EF</b> &lt;<b class="calibre7">50%</b> (stage C2); or severe (stage C1) <i class="calibre6">and</i> undergoing other cardiac surgery</p>
<p class="noindent1">• <i class="calibre6">Reasonable if:</i> <b class="calibre7">asx severe</b> (C1) <i class="calibre6">but</i> either <b class="calibre7">sx or</b> ↓<b class="calibre7"> BP w/ exercise</b> (can <i class="calibre6">carefully</i> exercise asx AS to uncover sx; do <i class="calibre6">not</i> exercise sx AS), <b class="calibre7">very severe,</b> ↑ BNP, rapid progression</p>
<p class="noindent1">• Growing data to support AVR in <b class="calibre7">asx severe</b> AS <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2020;382:111;</span> <span class="r2">Circ</span> <span class="r1">2021;143:e72)</span></p>
<p class="noindent1">• Type of valve: mechanical reasonable if Pt &lt;50 yrs, bioprosthetic if &gt;65 yrs or cannot tolerate long-term anticoagulation; individualize if 50–65 yrs</p>
<p class="noindent1">• Transcatheter AoV implantation (TAVI, see below) attractive alternative to surgery</p>
<p class="noindent1"><a id="page_1-22" class="calibre4"></a>• Medical (if not AVR candidate or to temporize): careful diuresis prn, control HTN, maintain</p>
<p class="noindent2">SR; digoxin if ↓ EF &amp; HF or if AF; <i class="calibre6">avoid</i> venodilators (nitrates) &amp; ⊖ inotropes (βB/CCB) if</p>
<p class="noindent2">severe AS; avoid vigorous physical exertion once AS mod–severe</p>
<p class="noindent2">? nitroprusside (w/ PAC) in HF w/ sev. AS, ↓ EF/CO, &amp; HTN <span class="r1">(</span><span class="r2">Circ</span> <span class="r1">2013;128:1349)</span></p>
<p class="noindent1">• IABP: stabilization, bridge to surgery</p>
<p class="noindent1">• Balloon valvotomy (now rare): ↑ AVA, <i class="calibre6">but</i> risk CVA/AR &amp; restenosis; ∴ bridge or palliation</p>
<p class="h">TAVI <span class="r">(transcatheter AoV implantation)</span> <span class="r1">(</span><span class="r2">JAMA</span> <span class="r1">2021;325:2480;</span> <span class="r2">Circ</span> <span class="r1">2021;143:e72)</span></p>
<p class="noindent1">• Valves: balloon-expandable or self-expanding.</p>
<p class="noindent1">• Most commonly deployed retrograde via perc. transfemoral access (best outcomes)</p>
<p class="noindent1">• Peri- &amp; postprocedural complic.: CHB ~15% at 30d, more common if preexisting RBBB <span class="r1">(</span><span class="r2">JACC</span> <span class="r1">2020;76:2391)</span>; annular rupture or coronary occlusion (both rare); stroke; local vascular; paravalvular leaks</p>
<p class="noindent1">• Postprocedural antithrombotic Rx: ASA 75–100 mg/d superior to DAPT <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2020;383:1447)</span>. In Pts <i class="calibre6">with indication for OAC</i>: OAC alone superior to OAC + P2Y<sub class="calibre10">12</sub> <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2020;382:1696;</span> <span class="r2">Circ</span><span class="r1"> 2021;143:e72)</span>; apixaban &amp; edoxaban appear comparable to warfarin <span class="r1">(ATLANTIS, ACC 2021;</span> <span class="r2">NEJM</span> <span class="r1">2021;385:2150)</span></p>
<p class="noindent1">• Outcomes w/ TAVI: In <i class="calibre6">nonoperative Pts</i> (ie, vs. med Rx): ↓ mortality but still ~72% 5 y mortality in TAVI reflective of comorbidities <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2012;366:1696;</span> <span class="r2">Lancet</span><span class="r1"> 2015;385:2485)</span>.</p>
<p class="noindent2">TAVI noninferior to SAVR in terms of risk of death or disabling stroke for high,</p>
<p class="noindent2">intermediate, and low surgical risk Pts <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2014;370:1790; 2020;382:799; 2019;380:1695 &amp;</span></p>
<p class="noindent2"><span class="r1">2019;380:1706;</span> <span class="r2">JACC</span><span class="r1"> 2021;77:1149)</span>.</p>
<p class="h1cr">A<small class="calibre31">ORTIC</small> R<small class="calibre31">EGURGITATION</small> (AR)</p>
<p class="h">Etiology <span class="r1">(</span><span class="r2">Circ</span> <span class="r1">2006;114:422)</span></p>
<p class="noindent1">• <b class="calibre7">Valve disease</b> (43%): <b class="calibre7">rheumatic</b> (usually mixed AS/AR + MV disease); <b class="calibre7">bicuspid AoV</b> (natural hx: ⅓→ normal, ⅓→ AS, ⅙→ AR, ⅙→ endocarditis → AR); <b class="calibre7">infective endocarditis;</b> valvulitis (RA, SLE, certain anorectics &amp; serotonergics, XRT)</p>
<p class="noindent1">• <b class="calibre7">Root disease</b> (57%): <b class="calibre7">HTN</b>, aortic aneurysm/dissection, annuloaortic ectasia (ie, Marfan), <b class="calibre7">aortic inflammation</b> (GCA, Takayasu’s, ankylosing spond., reactive arthritis, syphilis)</p>
<p class="h">Clinical manifestations</p>
<p class="noindent1">• Acute: sudden ↓ forward SV and ↑ LVEDP (noncompliant ventricle) → pulmonary edema ± hypotension and cardiogenic shock</p>
<p class="noindent1">• Chronic: clinically silent while LV dilates (to ↑ compliance to keep LVEDP low) more than it hypertrophies → chronic volume overload → LV decompensation → CHF</p>
<p class="noindent1">• Natural hx: <i class="calibre6">variable</i> progression (unlike AS, can be fast or slow); once decompensation begins, prognosis poor w/o AVR (mortality ~10%/y)</p>
<p class="h">Physical exam</p>
<p class="noindent1">• <b class="calibre7">Early diastolic decrescendo murmur at LSB</b> (RSB if dilated Ao root); ↑ w/ sitting forward, expir, handgrip; severity of AR ∝ duration of murmur (except in acute and severe late); <i class="calibre6">Austin Flint murmur:</i> mid-to-late diastolic rumble at apex (AR jet interfering w/ mitral inflow)</p>
<p class="noindent1">• <b class="calibre7">Wide pulse pressure</b> due to ↑ stroke volume, hyper-dynamic pulse; pulse pressure narrows in late AR with ↓ LV fxn; bisferiens (twice-beating) arterial pulse</p>
<p class="noindent1">• PMI diffuse and laterally displaced; soft S<sub class="calibre10">1</sub> (early closure of MV); ± S<sub class="calibre10">3</sub> (≠ ↓ EF but rather just volume overload in AR)</p>
<p class="image1"><img src="../images/00023.jpeg" alt="" class="calibre5"/></p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre20"/>
<col class="calibre21"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="2"><p class="tbodyc"><b class="calibre7">Classic Eponymous Signs in Chronic AR</b> <span class="sm">(<i class="calibre6">South Med J</i> 1981;74:459)</span></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Sign</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Description</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Corrigan’s pulse</p></td>
<td class="th1"><p class="tbody">“water hammer” pulse (ie, rapid rise/fall or distention/collapse)</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Hill’s sign</p></td>
<td class="th1"><p class="tbody">(popliteal SBP – brachial SBP) &gt;60 mmHg</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Duroziez’s sign</p></td>
<td class="th1"><p class="tbody">to-and-fro murmur heard over femoral artery w/ light compression</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Pistol shot sounds</p></td>
<td class="th1"><p class="tbody">pistol shot sound heard over femoral artery</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Traube’s sound</p></td>
<td class="th1"><p class="tbody">double sound heard over femoral artery when compressed distally</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">de Musset’s sign</p></td>
<td class="th1"><p class="tbody">head-bobbing with each heartbeat (low Se)</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Müller’s sign</p></td>
<td class="th1"><p class="tbody">systolic pulsations of the uvula</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Quincke’s pulses</p></td>
<td class="th1"><p class="tbody">subungual capillary pulsations (low Sp)</p></td>
</tr>
</tbody>
</table>
<p class="h">Diagnostic studies</p>
<p class="noindent1">• ECG: can see LVH, LAD, abnl repol; CXR: cardiomegaly ± ascending Ao dilatation</p>
<p class="noindent1">• <b class="calibre7">Echo:</b> severity of AR (severe = regurg jet width ≥65% LVOT, regurg fraction ≥50%, effective regurg orifice ≥0.3 cm<sup class="calibre19">2</sup>, holodiastolic flow reversal in descend. Ao; moderate = jet width 25–64%, regurg fraction 30–49%, regurg orifice 0.1–0.29 cm<sup class="calibre19">2</sup>); LV size &amp; fxn</p>
<p class="h"><a id="page_1-23" class="calibre4"></a>Treatment <span class="r1">(</span><span class="r2">Lancet</span> <span class="r1">2016;387:1312;</span> <span class="r2">Circ</span> <span class="r1">2021;143:e72)</span></p>
<p class="noindent1">• Acute decompensation (consider endocarditis as possible acute precipitant): <i class="calibre6">surgery</i> usually urgently needed for acute severe AR, which is poorly tolerated by LV IV afterload reduction (nitroprusside) and inotropic support (dobutamine) ± chronotropic support (↑ HR → ↓ diastole → ↓ time for regurgitation) pure vasoconstrictors and IABP contraindicated</p>
<p class="noindent1">• In chronic AR, management decisions based on <i class="calibre6">LV size and fxn</i> (and before sx occur); low diastolic BP and high resting HR associated with mortality <span class="r1">(</span><span class="r2">JACC</span> <span class="r1">2020;75:29)</span></p>
<p class="noindent1">• <b class="calibre7">Surgery</b> (AVR, replacement or repair if possible):</p>
<p class="noindent2"><b class="calibre7">Severe</b> and <b class="calibre7">sx</b> (if equivocal, consider stress test)</p>
<p class="noindent2"><b class="calibre7">Asx</b> <i class="calibre6">and</i> either <b class="calibre7">EF</b> ≤<b class="calibre7">55%</b>, <b class="calibre7">LV dilation</b> [LVESD &gt;50 mm or LVESDi (indexed to BSA) ≥ 25 mm/m<sup class="calibre19">2</sup> <span class="r1">(</span><span class="r2">JACC</span> <span class="r1">2019;73:1741)</span>], or <b class="calibre7">undergoing cardiac surg</b></p>
<p class="noindent1">• Transcatheter AoV implantation (TAVI) being explored <span class="r1">(</span><span class="r2">JACC</span> <span class="r1">2013;61:1577 &amp; 2017;70:2752)</span></p>
<p class="noindent1">• Medical therapy: <b class="calibre7">vasodilators</b> (nifedipine, ACEI/ARB, hydralazine) if severe AR w/ sx or LV dysfxn &amp; not operative candidate or to improve hemodynamics before AVR.</p>
<p class="h1cr">M<small class="calibre31">ITRAL</small> R<small class="calibre31">EGURGITATION</small> (MR)</p>
<p class="h">Etiology <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2010;363:156 &amp; 2020;383:1458)</span></p>
<p class="noindent1">• <b class="calibre7">Primary</b> (degeneration of valve apparatus)</p>
<p class="noindent2"><i class="calibre6">Leaflet abnl:</i> myxomatous (MVP), endocarditis, calcific, RHD, valvulitis (collagen-vascular disease), congenital, anorectic drugs (phen-fen), XRT</p>
<p class="noindent2"><i class="calibre6">Chordae tendineae</i> rupture: myxomatous, endocarditis, spontaneous, trauma</p>
<p class="noindent2"><i class="calibre6">Papillary muscle dysfxn</i> b/c of ischemia or <i class="calibre6">rupture</i> during MI [usu. posteromedial papillary m. (supplied predominantly by PDA) vs. anterolateral (suppl. by diags &amp; OMs)]</p>
<p class="noindent1">• <b class="calibre7">Secondary (functional):</b> inferoapical papillary muscle displacement due to ischemic LV remodeling or DCM; HCM <span class="r1">(</span><span class="r2">JACC</span> <span class="r1">2015;65:1231)</span></p>
<p class="h">Clinical manifestations</p>
<p class="noindent1">• Acute: <b class="calibre7">pulmonary edema</b>, hypotension, cardiogenic shock <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2004;351:1627)</span></p>
<p class="noindent1">• Chronic: typically asx for yrs, then as LV fails → progressive DOE, fatigue, AF, PHT</p>
<p class="noindent1">• Prognosis: 5-y survival w/ medical therapy is 80% if asx, but only 45% if sx</p>
<p class="h">Physical exam</p>
<p class="noindent1">• <b class="calibre7">High-pitched, blowing, holosystolic murmur at apex;</b> radiates to axilla; ± thrill; ↑ w/ handgrip (Se 68%, Sp 92%),</p>
<p class="noindent2">↓ w/ Valsalva (Se 93%)</p>
<p class="noindent2">ant. leaflet abnl → post. jet heard at spine</p>
<p class="noindent2">post. leaflet abnl → ant. jet heard at sternum</p>
<p class="noindent1">• ± diastolic rumble b/c ↑ flow across valve</p>
<p class="noindent1">• Lat. displ. hyperdynamic PMI, obscured S<sub class="calibre10">1</sub>, widely split S<sub class="calibre10">2</sub> (A<sub class="calibre10">2</sub> early b/c ↓ LV afterload, P<sub class="calibre10">2</sub> late if PHT); ± S<sub class="calibre10">3</sub></p>
<p class="noindent1">• Carotid upstroke brisk (vs. diminished and delayed in AS)</p>
<p class="image1"><img src="../images/00024.jpeg" alt="" class="calibre5"/></p>
<p class="h">Diagnostic studies <span class="r1">(</span><span class="r2">Circ</span><span class="r1"> 2021;143:e72)</span></p>
<p class="noindent1">• ECG: may see LAE, LVH, ± atrial fibrillation</p>
<p class="noindent1">• CXR: dilated LA, dilated LV, ± pulmonary congestion</p>
<p class="noindent1">• <b class="calibre7">Echo:</b> MV anatomy (ie, etiol); MR severity: jet area, jet width at origin (vena contracta) or effective regurgitant orifice (ERO; predicts survival); LV fxn (EF should be <i class="calibre6">supranormal</i> if compensated, ∴ EF &lt;60% w/ sev. MR = LV dysfxn)</p>
<p class="noindent1">• TEE or cardiac MR if TTE not sufficiently informative</p>
<p class="noindent1">• Cardiac cath: prominent PCWP <i class="calibre6">c-v</i> waves (not spec. for MR), LVgram for MR severity &amp; EF</p>
<p class="imaget"><img src="../images/00025.jpeg" alt="" class="calibre5"/></p>
<p class="tfn"><sup class="calibre22"><a id="rfn18-a" class="calibre8"></a>a</sup>Influenced by LV function, etc. <sup class="calibre22"><a id="rfn18-b" class="calibre8"></a>b</sup>1+ = LA clears w/ each beat; 2+ = LA does not clear, faintly opac. after several beats; 3+ = LA &amp; LV opac. equal. <sup class="calibre22"><a id="rfn18-c" class="calibre8"></a>c</sup>For 2° MR, ERO ≥0.20 severe as underestimated &amp; likely LV dysfxn.</p>
<p class="h">Treatment <span class="r1">(</span><span class="r2">Circ</span> <span class="r1">2021;143:e72)</span></p>
<p class="noindent1">• <b class="calibre7">Acute severe MR:</b> consider ischemia &amp; endocarditis as precipitants; IV afterload reduction (nitroprusside), relieve congestion (diuresis &amp; NTG), ± inotropes (dobuta), IABP, avoid vasoconstrictors; <i class="calibre6">surgery</i> usually needed b/c prognosis poor w/o <span class="r1">(</span><span class="r2">JAMA</span> <span class="r1">2013;310:609)</span></p>
<p class="noindent1">• <b class="calibre7">Chronic severe <i class="calibre6">primary</i> MR: surgery</b> (repair [preferred if feasible] vs. replacement) if <b class="calibre7">sx; asx &amp; either EF</b> <b class="calibre7">60% or LVESD</b> <b class="calibre7">40 mm</b>; reasonable if low surgical risk + high prob successful repair; consider transcatheter repair if not surg candidate</p>
<p class="noindent1"><a id="page_1-24" class="calibre4"></a>• For primary MR, surgery superior to percutaneous repair <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2011;364:1395)</span></p>
<p class="noindent1">• If undergoing surgery &amp; AF, MAZE ↓ AF recurrence, Ø ∆ stroke <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2015;372:1399)</span>; surgical LAA occlusion ↓ risk of stroke; nb, Pts remained on anticoag <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2021;384:2081)</span></p>
<p class="noindent1">• <b class="calibre7">Chronic sx severe <i class="calibre6">secondary</i> MR:</b> if on optimal GDMT, EF 20–50%, LVESD ≤70 mm, &amp; PASP ≤70 mmHg<b class="calibre7">, transcatheter edge-to-edge repair</b> (TEER) may ↑ survival &amp; ↓ HF hosp., but conflicting trial data <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2018:379;2297 &amp; 2307;</span> <span class="r2">JACC</span> <span class="r1">2021;77:1029 &amp; 78:2326)</span>; consider MV surgery if EF≥50% or EF≤50% but not meeting criteria for repair</p>
<p class="noindent1">• Transcathether replacement (TMVR) remains under study <span class="r1">(</span><span class="r2">JACC Intv</span> <span class="r1">2021;14:489)</span></p>
<p class="noindent1">• If sx &amp; EF&lt;60% but not operative candidate: Rx (βB, ACE/ARB ± MRA); ↓ preload w/ diuretics, NTG (espec. if ischemic MR) for sx relief ± ↓ ERO; maintain SR</p>
<p class="noindent1">• Asymptomatic: Ø proven benefit of medical therapy; βB ↑ LV fxn <span class="r1">(</span><span class="r2">JACC</span> <span class="r1">2012;60:833)</span></p>
<p class="h1cr">M<small class="calibre31">ITRAL</small> V<small class="calibre31">ALVE</small> P<small class="calibre31">ROLAPSE</small> (MVP)</p>
<p class="h">Definition and Etiology</p>
<p class="noindent1">• Billowing of MV leaflet ≥2 mm above mitral annulus in parasternal long axis echo view</p>
<p class="noindent1">• Primary: sporadic or familial myxomatous proliferation of spongiosa of MV apparatus</p>
<p class="noindent1">• Secondary: trauma, endocarditis, congenital, CTD (eg, Marfan’s, OI, Ehlers-Danlos)</p>
<p class="h">Clinical manifestations (usually asymptomatic)</p>
<p class="noindent1">• MR, endocarditis, emboli, arrhythmias (rarely SCD from VT from papillary muscle)</p>
<p class="noindent1">• High-pitched, midsystolic click (earlier w/ ↓ preload) ± mid-to-late systolic murmur</p>
<p class="noindent1">• No Rx <i class="calibre6">per se</i> [endocarditis Ppx not rec. <span class="r1">(</span><span class="r2">Circ</span> <span class="r1">2007;116:1736)</span>]; Rx MR as above</p>
<p class="h1cr">M<small class="calibre31">ITRAL</small> S<small class="calibre31">TENOSIS</small> (MS)</p>
<p class="h">Etiology <span class="r1">(</span><span class="r2">Lancet</span> <span class="r1">2012;379:953)</span></p>
<p class="noindent1">• <b class="calibre7">Rheumatic heart disease</b> (RHD): <i class="calibre6">fusion of commissures</i> → “fish-mouth” valve from autoimmune rxn to β strep infxn; seen largely in developing world <span class="r1">(</span><span class="r2">Circ</span> <span class="r1">2020;142:e337)</span></p>
<p class="noindent1">• <b class="calibre7">Mitral annular calcification:</b> encroachment upon leaflets → fxnal MS; espec in ESRD</p>
<p class="noindent1">• Postsurgical repair or post-TEER w/ reduced mitral valve area (MVA)</p>
<p class="noindent1">• Congenital, infectious endocarditis w/ large lesion, myxoma near MV, thrombus</p>
<p class="noindent1">• Valvulitis (eg, SLE, amyloid, carcinoid) or infiltration (eg, mucopolysaccharidoses)</p>
<p class="h">Clinical manifestations <span class="r1">(</span><span class="r2">Lancet</span> <span class="r1">2009;374:1271)</span></p>
<p class="noindent1">• <b class="calibre7">Dyspnea and pulmonary edema</b> (if due to RHD, sx usually begin in 30s) precipitants: exercise, fever, anemia, volume overload (incl. pregnancy), tachycardia, AF</p>
<p class="noindent1">• <b class="calibre7">Atrial fibrillation:</b> onset often precipitates heart failure in Pts w/ MS</p>
<p class="noindent1">• <b class="calibre7">Embolic events:</b> commonly cerebral, espec in AF or endocarditis</p>
<p class="noindent1">• Pulmonary: hemoptysis, frequent bronchitis (due to congestion), PHT, RV failure</p>
<p class="noindent1">• Ortner’s syndrome: hoarseness from LA compression of recurrent laryngeal nerve</p>
<p class="image1"><img src="../images/00026.jpeg" alt="" class="calibre5"/></p>
<p class="h">Physical exam</p>
<p class="noindent1">• <b class="calibre7">Low-pitched mid-diastolic rumble at apex</b> w/ presystolic accentuation (if not in AF); best heard in L lat decubitus position during expiration, ↑ w/ exercise; severity proportional to <i class="calibre6">duration</i> (not intensity) of murmur; loud S<sub class="calibre10">1</sub></p>
<p class="noindent1">• <b class="calibre7">Opening snap</b> (high-pitched early diastolic sound at apex) from fused leaflet tips; MVA proportional to S<sub class="calibre10">2</sub>–OS interval (tighter valve → ↑ LA pressure → shorter interval)</p>
<p class="noindent1">• Loud S<sub class="calibre10">1</sub> (unless MV calcified and immobile)</p>
<p class="h">Diagnostic studies</p>
<p class="noindent1">• ECG: <b class="calibre7">LAE</b> (“P mitrale”), ± AF, ± RVH</p>
<p class="noindent1">• CXR: <b class="calibre7">dilated LA</b> (flat L heart border, R double density, displaced L mainstem bronchus)</p>
<p class="noindent1">• <b class="calibre7">Echo:</b> estimate pressure gradient (∇), RVSP, valve area, valve echo score (0–16, based on leaflet mobility &amp; thick, subvalvular thick., Ca<sup class="calibre19">++</sup>); exer. TTE (to assess ∆ RVSP and ∇) if sx &amp; severity of MS at rest discrepant; TEE to assess for LA thrombus before PMBC</p>
<p class="noindent1">• <b class="calibre7">Cardiac cath:</b> ∇, calculated MVA; LA tall <i class="calibre6">a</i> wave &amp; blunted <i class="calibre6">y</i> descent; ↑ PA pressures</p>
<p class="imaget"><img src="../images/00027.jpeg" alt="" class="calibre5"/></p>
<p class="h"><a id="page_1-25" class="calibre4"></a>Treatment <span class="r1">(</span><span class="r2">Lancet</span> <span class="r1">2016;387:1324;</span> <span class="r2">Circ</span> <span class="r1">2021;143:e72)</span></p>
<p class="noindent1">• Medical: Na restriction, cautious diuresis, βB, AF control, sx-limited physical stress</p>
<p class="noindent1">• Antibiotic Ppx recommended if h/o RHD w/ valvular disease for 10 y or until age 40</p>
<p class="noindent1">• Anticoag w/ warfarin (not DOAC) if: AF; prior embolism; LA clot</p>
<p class="noindent1">• Mechanical intervention indicated if <b class="calibre7">sx severe MS</b>; reasonable if asx severe MS but PASP &gt;50 mmHg and morphology favorable for PMBC; consider PMBC if non-severe MS but exertional sx and hemodyn signif w/ exercise, or if asx severe MS and new-onset AF</p>
<p class="noindent1">• <b class="calibre7">Percutaneous mitral balloon commissurotomy</b> (PMBC): preferred Rx if RHD; ≈ MVR <i class="calibre6">if</i> valvuloplasty score &lt;8, Ø if mod-severe MR or LA clot</p>
<p class="noindent1">• Surgical (MV repair if possible, o/w replacement) if PMBC contraindicated</p>
<p class="noindent1">• Calcific MS: surgical MVR if severe &amp; highly sx; use of transcatheter aortic prosthesis experimental and w/ high rate of complications <span class="r1">(</span><span class="r2">Circ CVI</span> <span class="r1">2020;13:e008425)</span></p>
<p class="noindent1">• Pregnancy: if NYHA class III/IV → PMBC, o/w medical Rx w/ low-dose diuretic &amp; βB</p>
<p class="h1cr">T<small class="calibre31">RICUSPID</small> R<small class="calibre31">EGURGITATION</small> <span class="r3">(<i class="calibre6">Circ</i> 2014;129:2440; <i class="calibre6">Lancet</i> 2016;388:2431)</span></p>
<p class="noindent1">• Fxnl etiol (90%): RV dilation, PHT (may be 2° to L-sided dis.), large L → R shunts</p>
<p class="noindent1">• 1° etiol: myxomatous, IE, pacemaker leads, RHD, CTD, XRT, Ebstein’s, carcinoid, tumors</p>
<p class="noindent1">• Holosystolic murmur, 3<sup class="calibre19">rd</sup>/4<sup class="calibre19">th</sup> ICS, ↑ w/ insp (Carvallo’s sign); S<sub class="calibre10">3</sub>; prominent <i class="calibre6">cv</i> wave in JVP</p>
<p class="noindent1">• Consider repair/replacement in severe TR (eg, ERO ≥0.40 cm<sup class="calibre19">2</sup>) undergoing L-sided surgery, R heart failure or ? progressive RV dysfxn; emerging transcatheter Rx <span class="r1">(</span><span class="r2">JACC</span> <span class="r1">2018;71:2935)</span></p>
<p class="h1cr">P<small class="calibre31">ROSTHETIC</small> H<small class="calibre31">EART</small> V<small class="calibre31">ALVES</small></p>
<p class="h">Mechanical</p>
<p class="noindent1">• Bileaflet (eg, St. Jude Medical); tilting disk; caged-ball</p>
<p class="noindent1">• Very durable (20–30 y), but thrombogenic and ∴ require anticoagulation consider if age &lt;50 y or if anticoagulation already indicated <span class="r1">(</span><span class="r2">JACC</span> <span class="r1">2010;55:2413)</span></p>
<p class="h">Bioprosthetic</p>
<p class="noindent1">• Bovine pericardial or porcine heterograft (eg, Carpentier-Edwards), homograft</p>
<p class="noindent1">• Less durable, but min. thrombogenic; consider if &gt;~65 y, lifespan &lt;20 y, or Ø anticoag</p>
<p class="noindent1">• If 50–69 y, 2× reop but ½ bleeding or stroke vs. mech <span class="r1">(</span><span class="r2">JAMA</span> <span class="r1">2014;312:1323 &amp; 2015;313:1435)</span></p>
<p class="h">Physical exam</p>
<p class="noindent1">• <b class="calibre7">Crisp sounds</b> ± soft murmur during forward flow (normal to have small ∇)</p>
<p class="h">Anticoagulation &amp; antiplatelet therapy <span class="r1">(</span><span class="r2">Circ</span> <span class="r1">2021;143:e72)</span></p>
<p class="noindent1">• <b class="calibre7">Mechanical:</b> warfarin (not DOAC), INR 3 or 2.5 if low-risk mech AVR (none of following: prior thromboembolism, AF, EF &lt;30–35%, hypercoagulable).</p>
<p class="noindent2">If thrombosis, ↑ intensity (eg, INR 2–3 → 2.5–3.5; 2.5–3.5 → 3.5–4.5; or + ASA if not on)</p>
<p class="noindent1">• <b class="calibre7">Bioprosthetic:</b></p>
<p class="noindent2"><i class="calibre6">Surgical:</i> ASA (75–100 mg/d) or warfarin INR 2.5 ×3–6 mo, then ASA (75–100 mg/d). DOAC reasonable alternative to warfarin if indication for anticoag <span class="r1">(</span><span class="r2">NEJM</span><span class="r1"> 2020;383:2117)</span>.</p>
<p class="noindent2"><i class="calibre6">TAVI:</i> ASA 75–100 mg/d. If need OAC, then no antiplt (vide supra).</p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre20"/>
<col class="calibre21"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="2"><p class="tbodyc"><b class="calibre7">Periprocedural “Bridging” of Anticoagulation in Pts with Mechanical Valve(s)</b></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbody">AVR w/o risk factors</p></td>
<td class="th1"><p class="tbody">d/c warfarin 2–4 d before surg; restart 12–24 h after surg</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">MVR or AVR w/ risk factors</p></td>
<td class="th1"><p class="tbody">Preop: d/c warfarin, start UFH (preferred to LMWH) when INR &lt;2 4–6 h preop: d/c UFH; postop: restart UFH &amp; warfarin ASAP</p></td>
</tr>
</tbody>
</table>
<p class="tfn"><i class="calibre6">JACC</i> 2017;70:253. Procedures include noncardiac surgery, invasive procedures, and major dental work.</p>
<p class="h">Correction of overanticoagulation <span class="r1">(</span><span class="r2">Circ</span> <span class="r1">2021;143:e72)</span></p>
<p class="noindent1">• Risk from major bleeding must be weighed against risk of valve thrombosis</p>
<p class="noindent1">• Not bleeding: if INR 5–10, withhold warfarin</p>
<p class="noindent1">• Bleeding: PCC (or FFP); reversal agent for DOACs; ± low-dose (1 mg) vit K IV if on VKA</p>
<p class="h">Endocarditis prophylaxis: <span class="r">for all prosthetic valves (see “Endocarditis”)</span></p>
<p class="h">Complications</p>
<p class="noindent1">• Structural failure (r/o endocarditis); mechanical valves: rare except for Bjork-Shiley; bioprosth: up to 30% rate w/in 10–15 y, mitral &gt;aortic; consider TAVR <span class="r1">(</span><span class="r2">JACC</span> <span class="r1">2017; 69:2253)</span></p>
<p class="noindent1">• Paravalvular leak (r/o endocarditis); small <i class="calibre6">central</i> jet of regurg is normal in mech. valves</p>
<p class="noindent1">• Obstruction from thrombosis <span class="r1">(</span><span class="r2">JACC</span> <span class="r1">2013;62:1731)</span> or pannus: ✓ TTE, TEE, CTA, or fluoro significantly symptomatic <i class="calibre6">pannus</i> ingrowth: remove w/ surgery</p>
<p class="noindent2"><b class="calibre7">thrombosis</b>: surgery if sx or large L-sided mech valve obstruction; UFH ± low-dose lytic if small, not surgical candidate, or R-sided; OAC for sx bioprosthetic thrombosis</p>
<p class="noindent1">• Infective endocarditis ± valvular abscess and conduction system dis. (see “Endocarditis”)</p>
<p class="noindent1">• Embolization (r/o endocarditis); risk highest 1<sup class="calibre19">st</sup> 90 d, ~1%/y w/ warfarin (vs. 2% w/ ASA, or 4% w/o meds); mech MVR 2× risk of embolic events vs. mech AVR <span class="r1">(</span><span class="r2">Circ</span> <span class="r1">1994;89:635)</span></p>
<p class="noindent1">• Bleeding (from anticoag), hemolysis (espec w/ caged-ball valves or paravalvular leak)</p>
<h2 class="ct"><a id="h11" class="calibre8"></a><a id="page_1-26" class="calibre8"></a><a href="part0003.html#rh15" class="calibre8">PERICARDIAL DISEASE</a></h2>
<p class="h">Anatomy</p>
<p class="noindent1">• 2-layered (parietal &amp; visceral) tissue sac surrounding heart &amp; proximal great vessels</p>
<p class="h">Disease states</p>
<p class="noindent1">• Inflammation (w/ or w/o fluid accumulation) → pericarditis</p>
<p class="noindent1">• Fluid accumulation → effusion ± tamponade</p>
<p class="noindent1">• Decrease in compliance (sequela of inflammation) → constrictive pericarditis</p>
<p class="noindent1">• Tamponade and constriction characterized by increased ventricular interdependence</p>
<p class="h1cr">P<small class="calibre31">ERICARDITIS</small> <small class="calibre31">AND</small> P<small class="calibre31">ERICARDIAL</small> E<small class="calibre31">FFUSION</small></p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre20"/>
<col class="calibre26"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="2"><p class="tbodyc"><b class="calibre7">Etiologies of Acute Pericarditis</b> <span class="sm">(<i class="calibre6">JACC</i> 2020;75:76)</span></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Idiopathic</b> (~90%)</p></td>
<td class="th1"><p class="tbodyh">Most presumed to be undiagnosed viral etiologies</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Infectious</b> (&lt;5% can be confirmed infectious)</p></td>
<td class="th1"><p class="tbodyh">Viral: Coxsackie, Parvovirus B19, echo, adeno, EBV, VZV, HIV, influenza, SARS CoV-2</p>
<p class="tbodyh">Bacterial (from endocarditis, pneumonia, or s/p cardiac surgery): <i class="calibre6">S. pneumo, N. meningitidis, S. aureus, Borrelia</i> (Lyme); TB</p>
<p class="tbodyh">Fungi: <i class="calibre6">Histo, Coccidio, Candida</i>; Parasite: <i class="calibre6">Entamoeba, Echino</i></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Neoplastic</b> (&lt;10%)</p></td>
<td class="th1"><p class="tbodyh"><i class="calibre6">Common:</i> metastatic (lung, breast, lymphoma, leukemia, RCC)</p>
<p class="tbodyh"><i class="calibre6">Rare:</i> primary cardiac &amp; serosal tumors (mesothelioma)</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Autoimmune</b></p></td>
<td class="th1"><p class="tbodyh">Connective tissue diseases: SLE, RA, scleroderma, Sjögren’s</p>
<p class="tbodyh">Vasculitides: PAN, ANCA ⊕ (EGPA, GPA)</p>
<p class="tbodyh">Drug-induced: procainamide, hydralazine, inh, CsA</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Uremia</b></p></td>
<td class="th1"><p class="tbodyh">~5–13% of Pts prior to HD; ~20% occurrence in chronic HD Pts</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Cardiovascular</b></p></td>
<td class="th1"><p class="tbodyh">STEMI, late post-MI (Dressler’s syndrome), but rare in modern era; prox AoD; chest trauma/postpericardiotomy; PCI or EP complication</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Radiation</b></p></td>
<td class="th1"><p class="tbodyh">&gt;40 Gy to mediastinum; acute or delayed; may be transudative</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Effusion w/o pericarditis</b></p></td>
<td class="th1"><p class="tbodyh">HF (particularly R-sided as pericardial fluid drains into RA), cirrhosis, nephrotic syndrome, hypothyroidism, amyloidosis. Transudative.</p></td>
</tr>
</tbody>
</table>
<p class="h">Clinical manifestations <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2014;371:2410;</span> <span class="r2">JACC</span> <span class="r1">2020;75:76)</span></p>
<p class="noindent1">• <b class="calibre7">Pericarditis:</b> retrosternal CP, pleuritic, positional (often ↓ by sitting forward), → trapezius; may be <i class="calibre6">absent</i> in TB, neoplastic, XRT, or uremic; ± fever; ± s/s of systemic etiologies</p>
<p class="noindent1">• <b class="calibre7">Effusion:</b> present in 50–65% of Pts w/ pericarditis; ranges from asx to tamponade</p>
<p class="noindent1">• <b class="calibre7">Definitions:</b> acute (&lt;4–6 wks), incessant (persistent sx &gt;4–6 wks), recurrent (after a symptom-free interval of 4–6 wks), chronic (lasting &gt;3 mos)</p>
<p class="h">Physical exam</p>
<p class="noindent1">• <b class="calibre7">Pericarditis:</b> multiphasic <b class="calibre7">friction rub</b> best heard at LLSB w/ diaphragm of stethoscope. Notoriously variable and evanescent leathery sound w/ up to 3 components: atrial contraction, ventricular contraction, ventricular relaxation <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2012;367:e20)</span>.</p>
<p class="noindent1">• <b class="calibre7">Effusion:</b> distant heart sounds, dullness over left posterior lung field due to compressive atelectasis from pericardial effusion (Ewart’s sign)</p>
<p class="h">Diagnostic studies <span class="r1">(</span><span class="r2">JAMA</span> <span class="r1">2015;314:1498;</span> <span class="r2">EHJ</span> <span class="r1">2015;36:2921;</span> <span class="r2">JACC</span> <span class="r1">2020;75:76)</span></p>
<p class="noindent1">• Need ≥2 of the following: chest pain (as noted above), friction rub, ECG findings, effusion</p>
<p class="noindent1">• <b class="calibre7">ECG:</b> may show diffuse STE (<i class="calibre6">concave up</i>) &amp; PR depression (except in aVR: ST ↓ &amp; PR ↑), TWI; classically and in contrast to STEMI, TWI do not occur until STs normalize</p>
<p class="noindent2">Stages: (I) STE &amp; PR ↓; (II) ST &amp; PR normalize; (III) diffuse TWI; (IV) Tw normalize</p>
<p class="noindent2">ECG may show evidence of large effusion w/ low-voltage &amp; electrical alternans (beat-to-beat ∆ in QRS amplitude and/or axis due to swinging heart)</p>
<p class="noindent1">• CXR: if lg effusion (&gt;250 mL) → ↑ cardiac silhouette w/ “water-bottle” heart &amp; epicardial halo</p>
<p class="noindent1">• <b class="calibre7">Echocardiogram:</b> presence, size, &amp; location of <i class="calibre6">effusion;</i> presence of <i class="calibre6">tamponade physiology;</i> pericarditis itself w/o spec. abnl (∴ echo can be nl), although can see pericardial stranding (fibrin or tumor); can also detect LV/RV dysfxn (myocarditis?)</p>
<p class="noindent1">• CT: effusion (often larger by CT than by echo) ± calcif.; pericard. enhancement w/ contrast</p>
<p class="noindent1">• <b class="calibre7">MRI:</b> may reveal pericardial thickening/inflammation, as well as myocardial involvement</p>
<p class="noindent1">• ⊕ cTn in ~30%, indicative of concomitant myocarditis <span class="r1">(</span><span class="r2">JACC</span> <span class="r1">2003;42:2144)</span>. Inflammatory biomarkers (ESR, CRP) elevated in 80% of presentations; CRP predicts recurrence.</p>
<p class="h">Workup for effusion</p>
<p class="noindent1">• r/o infxn: usually apparent from Hx &amp; CXR; ? value of ✓ acute and convalescent serologies</p>
<p class="noindent1">• r/o noninfectious etiologies: BUN, Cr, ANA, RF, HIV, screen for common malignancies</p>
<p class="noindent1">• Pericardiocentesis if suspect infxn or malignancy or large effusion (&gt;2 cm) or recurrent</p>
<p class="noindent2">✓ cell counts, TP, LDH, glc, Gram stain &amp; Cx, AFB, cytology</p>
<p class="noindent2">ADA, PCR for MTb, and specific tumor markers as indicated by clinical suspicion</p>
<p class="noindent2">“exudate”: TP &gt;3 g/dL, TP<sub class="calibre10">eff</sub>/TP<sub class="calibre10">serum</sub> &gt;0.5, LDH<sub class="calibre10">eff</sub>/LDH<sub class="calibre10">serum</sub> &gt;0.6 or glc &lt;60 mg/dL; high Se (~90%) but <i class="calibre6">very low</i> Sp (~20%); overall low utility <span class="r1">(</span><span class="r2">Chest</span> <span class="r1">1997;111:1213)</span></p>
<p class="noindent1">• Pericardial bx if suspicion for malignancy or TB; perform during every surgical drainage</p>
<p class="h"><a id="page_1-27" class="calibre4"></a>Treatment of pericarditis <span class="r1">(</span><span class="r2">JACC</span> <span class="r1">2020;75:76)</span></p>
<p class="noindent1">• High-dose <b class="calibre7">NSAID</b> (eg, ibuprofen 600–800 mg tid) or ASA (eg, 650–1000 mg tid) × 7–14 d then taper over wks; ASA preferred over NSAID in acute MI; consider PPI to ↓ risk of GIB</p>
<p class="noindent1">• <b class="calibre7">Add colchicine</b> 0.6 mg bid (qd if ≤70 kg) × 3 mo; 50% ↓ risk of refractory or recurrent pericarditis <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2013;369:1522)</span>. Amio, dilt, verap &amp; atorva ↓ P-gp &amp; ↑ risk of colchicine tox.</p>
<p class="noindent1">• Avoid steroids except for systemic autoimmune disorder, uremia, preg., NSAIDs contra- indicated. Appear to ↑ rate of pericarditis recurrence; risk lower w/ low-dose wt-based (ie, prednisone 0.2–0.5 mg/kg) with slow taper <span class="r1">(</span><span class="r2">Circ</span> <span class="r1">2008;118:667 &amp; 2011;123:1092)</span>.</p>
<p class="noindent1">• Avoid anticoagulants (although no convincing data that ↑ risk of hemorrhage/tamponade)</p>
<p class="noindent1">• Infectious effusion → pericardial drainage (preferably surgically) + systemic antibiotics</p>
<p class="noindent1">• Restrict activity until sx resolve/hsCRP ↓; athletes must also wait ~1–3 mos w/ nl TTE/ECG</p>
<p class="noindent1">• Acute idiopathic pericarditis self-limited in 70–90% of cases</p>
<p class="noindent1">• <b class="calibre7">Recurrent pericarditis</b> <span class="r1">(</span><span class="r2">Circ</span> <span class="r1">2007;115:2739)</span> risk factors: subacute, lg effusion/tamponade, T &gt;38°C, no NSAID response after 7 d. Rx: colchicine 0.6 mg bid × 6 mo <span class="r1">(</span><span class="r2">Lancet</span> <span class="r1">2014;383: 2232)</span>. IL-1 antagonists: anakinra <span class="r1">(</span><span class="r2">JAMA</span> <span class="r1">2016;316:1906)</span> or rilonacept <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2021;384:31)</span>.</p>
<p class="noindent1">• Recurrent effusions: consider pericardial window (percutaneous vs. surgical)</p>
<p class="h1cr">P<small class="calibre31">ERICARDIAL</small> T<small class="calibre31">AMPONADE</small></p>
<p class="h">Etiology</p>
<p class="noindent1">• Any cause of pericarditis but espec <b class="calibre7">malignancy</b>, <b class="calibre7">infectious</b>, uremia, ascending AoD, myocardial rupture, periprocedural complication, trauma, post-cardiotomy</p>
<p class="noindent1">• Rapidly accumulating effusions most likely to cause tamponade b/c no time for pericardium to stretch (eg, to ↑ compliance) and accommodate ↑ intrapericardial fluid volume</p>
<p class="h">Pathophysiology <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2003;349:684)</span></p>
<p class="noindent1">• ↑ intrapericardial pressure, compression of heart chambers, ↓ venous return → ↓ CO</p>
<p class="noindent1">• Diastolic pressures ↑ &amp; equalize in all cardiac chambers → minimal flow of blood from RA to RV when TV opens → blunted <i class="calibre6">y</i> descent</p>
<p class="noindent1">• ↑ ventricular interdependence → pulsus paradoxus (pathologic exaggeration of nl physio) Inspiration → ↓ intrapericardial &amp; RA pressures → ↑ venous return → ↑ RV size → septal shift to left. Also, ↑ pulmonary vascular compliance → ↓ pulm venous return. Result is ↓ LV filling → ↓ <b class="calibre7">LV stroke volume</b> &amp; blood pressure &amp; pulse pressure.</p>
<p class="h">Clinical manifestations</p>
<p class="noindent1">• <b class="calibre7">Cardiogenic shock</b> (hypotension, fatigue) <b class="calibre7">without pulmonary edema</b></p>
<p class="noindent1">• Dyspnea (seen in ~85%) may be due to ↑ respiratory drive to augment venous return</p>
<p class="h">Physical exam <span class="r1">(</span><span class="r2">EHJ</span> <span class="r1">2014;35:2279)</span></p>
<p class="noindent1">• <b class="calibre7">Beck’s triad</b> (present in minority of cases): <b class="calibre7">distant heart sounds</b> (28%)<b class="calibre7">,</b> ↑<b class="calibre7"> JVP</b> (76%) w/ blunted <i class="calibre6">y</i> descent<b class="calibre7">, hypotension</b> (26%); ± pericardial friction rub (30%)</p>
<p class="noindent1">• Reflex tachycardia (77%), cool extremities</p>
<p class="noindent1">• <b class="calibre7">Pulsus paradoxus</b> (Se 82%, Sp 70%) = ↓ SBP ≥10 mmHg during inspiration</p>
<p class="noindent2">⊕ LR 3.3 (5.9 if pulsus &gt;12), ⊖ LR 0.03</p>
<p class="noindent2">Ddx = PE, hypovolemia, severe COPD, auto-PEEP, periconstriction (~⅓), RV infarct</p>
<p class="noindent2">Can be absent if preexisting ↑ LVEDP, arrhythmia, severe AR, ASD, regional tamponade</p>
<p class="noindent1">• Tachypnea and orthopnea but <i class="calibre6">clear lungs</i></p>
<p class="h">Diagnostic studies</p>
<p class="noindent1">• ECG: ↑ HR, ↓ voltage (seen in 42%), electrical alternans (20%), ± signs of pericarditis</p>
<p class="noindent1">• CXR: ↑ cardiac silhouette (89%)</p>
<p class="noindent1">• <b class="calibre7">Echocardiogram</b>: ⊕ <b class="calibre7">effusion</b>, IVC plethora, <b class="calibre7">septal shift</b> with inspiration</p>
<p class="noindent2"><b class="calibre7">diastolic collapse</b> of RA (Se 85%, Sp 80%) and/or RV (Se &lt;80%, Sp 90%)</p>
<p class="noindent2"><b class="calibre7">respirophasic</b> ∆’<b class="calibre7">s in transvalvular velocities</b> (↑ across TV &amp; ↓ across MV w/ inspir.)</p>
<p class="noindent2">postsurgical tamponade may be localized and not easily visible</p>
<p class="noindent1">• Cardiac cath (right heart and pericardial): elevation (15–30 mmHg) and equalization of</p>
<p class="noindent2">intrapericardial and diastolic pressures (RA, RV, PCWP), blunted <i class="calibre6">y</i> descent in RA</p>
<p class="noindent2">↑ in stroke volume postpericardiocentesis = ultimate proof of tamponade</p>
<p class="noindent2">if RA pressure remains high after drainage, Ddx: effusive-constrictive dis. (visceral pericardium constriction), myocardial. dysfxn (eg, concomitant myocarditis)</p>
<p class="h">Treatment <span class="r1">(</span><span class="r2">EHJ</span> <span class="r1">2014;35:2279)</span></p>
<p class="noindent1">• Volume (but be careful b/c overfilling can worsen tamponade) and ⊕ inotropes (avoid βB)</p>
<p class="noindent1">• Avoid vasoconstrictors b/c will ↓ stroke volume &amp; potentially ↓ HR</p>
<p class="noindent1">• Avoid positive pressure ventilation b/c it can further impair cardiac filling <span class="r1">(</span><span class="r2">Circ</span> <span class="r1">2006;113:1622)</span></p>
<p class="noindent1">• <b class="calibre7">Pericardiocentesis</b> (except if due to aortic/myocardial rupture, for which emergent surgery is treatment of choice; if too unstable, consider small pericardiocentesis to prevent PEA)</p>
<p class="noindent1">• Surgical drainage considered if fluid rapidly reaccumulates, loculated, or hemorrhagic</p>
<p class="h1cr"><a id="page_1-28" class="calibre8"></a>C<small class="calibre31">ONSTRICTIVE</small> P<small class="calibre31">ERICARDITIS</small></p>
<p class="h">Etiology <span class="r1">(</span><span class="r2">Circ</span> <span class="r1">2011;124:1270)</span></p>
<p class="noindent1">• Any cause of pericarditis (~1–2% incidence overall after acute pericarditis)</p>
<p class="noindent1">• Highest risk w/ <b class="calibre7">TB</b>, <b class="calibre7">bacterial</b>, <b class="calibre7">neoplastic</b>, <b class="calibre7">XRT</b>, connective tissue, postcardiac surgery</p>
<p class="noindent1">• <b class="calibre7">Viral/idiopathic</b>, b/c most common cause of pericarditis, also account for signif proportion</p>
<p class="h">Pathophysiology</p>
<p class="noindent1">• Adhesion of visceral and parietal pericardial layers → rigid pericardium that limits diastolic filling of ventricles → ↑ systemic venous pressures</p>
<p class="noindent1">• Venous return is limited only after early rapid filling phase; ∴ rapid ↓ in RA pressure with atrial relaxation and opening of tricuspid valve and <i class="calibre6">prominent x and y descents</i></p>
<p class="noindent1">• Kussmaul sign: JVP does not decrease with inspiration (↑ venous return with inspiration, but negative intrathoracic pressure not transmitted to heart because of rigid pericardium)</p>
<p class="h">Clinical manifestations <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2011;364:1350)</span></p>
<p class="noindent1">• Right-sided &gt;left-sided heart failure (systemic congestion &gt;pulmonary congestion)</p>
<p class="h">Physical exam</p>
<p class="noindent1">• ↑ <b class="calibre7">JVP</b> with <b class="calibre7">prominent <i class="calibre6">y</i> descent</b>, ⊕ <b class="calibre7">Kussmaul sign</b> [Ddx: tricuspid stenosis, acute cor pulmonale, RV dysfxn (CMP, RV MI), SVC syndrome]</p>
<p class="noindent1">• Hepatosplenomegaly, ascites, peripheral edema. Consider in Ddx of idiopathic cirrhosis.</p>
<p class="noindent1">• PMI usually not palpable, <b class="calibre7">pericardial knock</b>, usually no pulsus paradoxus</p>
<p class="h">Diagnostic studies</p>
<p class="noindent1">• ECG: nonspecific, AF common (up to 33%) in advanced cases</p>
<p class="noindent1">• CXR: calcification (MTb most common), espec in lateral view (although not specific)</p>
<p class="noindent1">• Echocardiogram: ± thickened pericardium, “<b class="calibre7">septal bounce</b>” = abrupt displacement of septum during rapid filling in early diastole</p>
<p class="noindent1">• Cardiac catheterization: atria w/ <b class="calibre7">Ms</b> or <b class="calibre7">Ws</b> (prominent <i class="calibre6">x</i> and <i class="calibre6">y</i> descents)</p>
<p class="noindent2">ventricles: <b class="calibre7">dip-and-plateau</b> or <b class="calibre7">square-root sign</b> (rapid ↓ pressure at onset of diastole, rapid ↑ to early plateau)</p>
<p class="noindent2"><i class="calibre6">discordance</i> between LV &amp; RV pressure peaks during respiratory cycle <span class="r1">(</span><span class="r2">Circ</span> <span class="r1">1996;93:2007)</span></p>
<p class="noindent1">• CT or <b class="calibre7">MRI:</b> thickened pericardium (&gt;4 mm; Se ~80%) w/ tethering <span class="r1">(</span><span class="r2">Circ</span> <span class="r1">2011;123:e418)</span></p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre12"/>
<col class="calibre33"/>
<col class="calibre34"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="3"><p class="tbodyc"><b class="calibre7">Constrictive Pericarditis vs. Restrictive Cardiomyopathy</b> <span class="sm">(<i class="calibre6">JACC</i> 2016;68;2329)</span></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Evaluation</b></p></td>
<td class="th1"><p class="tbodyh"><b class="calibre7">Constrictive Pericarditis</b></p></td>
<td class="th1"><p class="tbodyh"><b class="calibre7">Restrictive Cardiomyopathy</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Physical exam</p></td>
<td class="th1"><p class="tbodyh">⊕ Kussmaul sign</p>
<p class="tbodyh">Absent PMI</p>
<p class="tbodyh">⊕ Pericardial knock</p></td>
<td class="th1"><p class="tbodyh">± Kussmaul sign</p>
<p class="tbodyh">Powerful PMI, ± S<sub class="calibre17">3</sub> and S<sub class="calibre17">4</sub></p>
<p class="tbodyh">± <b class="calibre7">Murmurs of MR, TR</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">ECG</p></td>
<td class="th1"><p class="tbodyh">± Low voltage</p></td>
<td class="th1"><p class="tbodyh">Low voltage if infiltrative myopathy</p>
<p class="tbodyh">± <b class="calibre7">Conduction abnormalities</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Echocardiogram</p></td>
<td class="th1"><p class="tbodyh"><b class="calibre7">Respirophasic variation</b> (25–40%): inspir. → ↑ flow across TV and ↓ flow across MV</p>
<p class="tbodyh">e′ (tissue velocity) nl/↑ (&gt;12 cm/sec)</p>
<p class="tbodyh"><b class="calibre7">Expir.</b> hepatic vein flow reversal</p>
<p class="tbodyh"><b class="calibre7">Septal bounce in early diastole</b></p>
<p class="tbodyh">Normal wall thickness</p></td>
<td class="th1"><p class="tbodyh">&lt;10% respirophasic variation</p>
<p class="tbodyh">Slower peak filling rate</p>
<p class="tbodyh">Longer time to peak filling rate</p>
<p class="tbodyh"><b class="calibre7">e</b>′ ↓ (&lt;8 cm/sec; Se &amp; Sp ~95%)</p>
<p class="tbodyh"><b class="calibre7">Inspir.</b> hepatic vein flow reversal</p>
<p class="tbodyh"><b class="calibre7">Biatrial enlargement</b></p>
<p class="tbodyh">± ↑ wall thickness</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">CT/MRI</p></td>
<td class="th1"><p class="tbodyh"><b class="calibre7">Usually w/ thickened pericardium</b></p></td>
<td class="th1"><p class="tbodyh">Normal pericardium</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">NT-proBNP</p></td>
<td class="th1"><p class="tbodyh">Variable</p></td>
<td class="th1"><p class="tbodyh">Typically ↑/↑↑ <span class="sm">(<i class="calibre6">JACC</i> 2005;45:1900)</span></p></td>
</tr>
<tr class="calibre15">
<td rowspan="2" class="th1"><p class="tbody">Cardiac catheterization</p></td>
<td colspan="2" class="tbn"><p class="tbodyc">Prominent <i class="calibre6">x</i> and <i class="calibre6">y</i> descents (more so in constriction)</p>
<p class="tbodyc">Dip-and-plateau sign (more so in constriction)</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyh">LVEDP = RVEDP</p>
<p class="tbodyh">RVSP &lt;55 mmHg (Se 90%, Sp 29%)</p>
<p class="tbodyh">RVEDP &gt;⅓ RVSP (Se 93%, Sp 46%)</p>
<p class="tbodyh"><b class="calibre7">Discordance</b> of LV &amp; RV pressure peaks during respiratory cycle</p>
<p class="tbodyh"><b class="calibre7">Systolic area index</b> (ratio of RV to LV pressure–time area in inspir vs. expir) &gt;1.1 (Se 97%, Sp 100%)</p></td>
<td class="th1"><p class="tbodyh"><b class="calibre7">LVEDP</b> &gt; <b class="calibre7">RVEDP</b> (esp. w/ vol.)</p>
<p class="tbodyh">RVSP &gt;55 mmHg</p>
<p class="tbodyh">RVEDP &lt;⅓ RVSP</p>
<p class="tbodyh">Concordance of LV &amp; RV pressure peaks during respiratory cycle</p>
<p class="tbodyh">Systolic area index ≤1.1 <span class="sm">(<i class="calibre6">JACC</i> 2008;51:315)</span></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Endomyocardial biopsy</p></td>
<td class="th1"><p class="tbodyh">Usually normal</p></td>
<td class="th1"><p class="tbodyh">± <b class="calibre7">Specific etiology of RCMP</b> (fibrosis, infiltration, hypertrophy)</p></td>
</tr>
</tbody>
</table>
<p class="h">Treatment</p>
<p class="noindent1">• Diuresis if intravascular volume overload; surgical pericardiectomy if infectious or advanced</p>
<h2 class="ct"><a id="h12" class="calibre8"></a><a id="page_1-29" class="calibre8"></a><a href="part0003.html#rh16" class="calibre8">HYPERTENSION</a></h2>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre12"/>
<col class="calibre33"/>
<col class="calibre34"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="3"><p class="tbodyc"><b class="calibre7">ACC/AHA Classification for Office-Based BP</b> <span class="sm">(<i class="calibre6">HTN</i> 2018;71:e13)</span></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Category</b></p></td>
<td class="th1"><p class="tbodyc"><b class="calibre7">Systolic (mmHg)</b></p></td>
<td class="th1"><p class="tbodyc"><b class="calibre7">Diastolic (mmHg)</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Normal</p></td>
<td class="th1"><p class="tbodyc">&lt;120</p></td>
<td class="th1"><p class="tbodyc">&lt;80</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Elevated</p></td>
<td class="th1"><p class="tbodyc">120–129</p></td>
<td class="th1"><p class="tbodyc">&lt;80</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Stage 1 hypertension</p></td>
<td class="th1"><p class="tbodyc">130–139</p></td>
<td class="th1"><p class="tbodyc">80–89</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Stage 2 hypertension</p></td>
<td class="th1"><p class="tbodyc">≥140</p></td>
<td class="th1"><p class="tbodyc">≥90</p></td>
</tr>
</tbody>
</table>
<p class="tfn">Average ≥2 measurements &gt;1–2 minutes apart. If disparity in a category between systolic and diastolic, higher value determines stage. Elevated office BP should be confirmed with out-of-office (ABPM or home cuff) to confirm; can treat stage 2 immediately. White coat (≥Stage 1 in office but &lt;at home) at heightened risk of developing HTN. Masked (&lt;Stage 1 in office but ≥at home), if persistent, treat as HTN.</p>
<p class="h">Epidemiology <span class="r1">(</span><span class="r2">Circ</span> <span class="r1">2021;143:e254;</span> <span class="r2">Lancet</span> <span class="r1">2021;398:957)</span></p>
<p class="noindent1">• Prevalence 47% in U.S. adults, higher in African-Americans; M = F</p>
<p class="noindent1">• Of those with HTN, ~40% unaware of dx; of those dx w/ HTN, only ½ achieve target BP</p>
<p class="h">Etiologies <span class="r1">(</span><span class="r2">JACC</span> <span class="r1">2017;71:127)</span></p>
<p class="noindent1">• <b class="calibre7">Essential</b> (95%): onset 25–55 y; ⊕ FHx. Unclear mechanism but ? additive microvasc renal injury over time w/ contribution of hyperactive sympathetics <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2002;346:913)</span>.</p>
<p class="noindent2">↑ Age → ↓ art compliance → HTN. Genetics + environment involved <span class="r1">(</span><span class="r2">Nature</span> <span class="r1">2011;478:103)</span>.</p>
<p class="noindent1">• <b class="calibre7">Secondary:</b> Consider if Pt &lt;20 or &gt;50 y or if sudden onset, severe, refractory HTN</p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre25"/>
<col class="calibre33"/>
<col class="calibre23"/>
<col class="calibre23"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="4"><p class="tbodyc"><b class="calibre7">Secondary Causes of Hypertension</b></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td colspan="2" class="th1"><p class="tbody"><b class="calibre7">Diseases</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Suggestive Findings</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Initial Workup</b></p></td>
</tr>
<tr class="calibre15">
<td class="tb" rowspan="2"><p class="tbodyc"><b class="calibre7">RENAL</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Renal parenchymal</b></p>
<p class="tbody">(2–3%)</p></td>
<td class="th1"><p class="tbody">h/o DM, polycystic kidney disease, glomerulonephritis</p></td>
<td class="th1"><p class="tbody">CrCl, albuminuria</p>
<p class="tbody">See “Kidney Disease”</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Renovascular</b> (1–2%)</p>
<p class="tbody">Athero (90%)</p>
<p class="tbody">FMD (10%, young women)</p>
<p class="tbody">PAN, scleroderma</p></td>
<td class="th1"><p class="tbody">ARF induced by ACEI/ARB</p>
<p class="tbody">Recurrent flash pulm edema</p>
<p class="tbody">Renal bruit; hypokalemia</p>
<p class="tbody"><span class="sm">(<i class="calibre6">NEJM</i> 2009;361:1972)</span></p></td>
<td class="th1"><p class="tbody">MRA (&gt;90% Se &amp; Sp, less for FMD), CTA, duplex U/S, angio,</p>
<p class="tbody">plasma renin (low Sp)</p></td>
</tr>
<tr class="calibre15">
<td class="tb" rowspan="4"><p class="tbodyc"><b class="calibre7">ENDO</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Hyperaldo or</b></p>
<p class="tbody"><b class="calibre7">Cushing’s</b> (1–5%)</p></td>
<td class="th1"><p class="tbody">Hypokalemia</p>
<p class="tbody">Metabolic alkalosis</p></td>
<td class="th1"><p class="tbody">See “Adrenal Disorders”</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Pheochromocytoma (&lt;1%)</p></td>
<td class="th1"><p class="tbody">Paroxysmal HTN, H/A, palp.</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Myxedema (&lt;1%)</p></td>
<td class="th1"><p class="tbody">See “Thyroid Disorders”</p></td>
<td class="th1"><p class="tbody">TFTs</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Hypercalcemia (&lt;1%)</p></td>
<td class="th1"><p class="tbody">Polyuria, dehydration, ∆ MS</p></td>
<td class="th1"><p class="tbody">iCa</p></td>
</tr>
<tr class="calibre15">
<td class="tb" rowspan="4"><p class="tbodyc"><b class="calibre7">OTHER</b></p></td>
<td class="th1" colspan="3"><p class="tbody"><b class="calibre7">Obstructive sleep apnea</b> (qv); alcohol</p></td>
</tr>
<tr class="calibre15">
<td class="th1" colspan="3"><p class="tbody"><b class="calibre7">Medications:</b> OCP, steroids, licorice; NSAIDs (espec COX-2); Epo; CsA; TKI</p></td>
</tr>
<tr class="calibre15">
<td class="th1" colspan="3"><p class="tbody">Aortic coarctation: ↓ LE pulses, systolic murmur, radial-femoral delay; abnl TTE, CXR</p></td>
</tr>
<tr class="calibre15">
<td class="th1" colspan="3"><p class="tbody">Polycythemia vera: ↑ Hct</p></td>
</tr>
</tbody>
</table>
<p class="h">Standard workup <span class="r1">(</span><span class="r2">JAMA</span> <span class="r1">2021;325:1650 &amp; 326:339)</span></p>
<p class="noindent1">• Goals: (1) identify CV risk factors; (2) consider 2° causes; (3) assess for target-organ damage</p>
<p class="noindent1">• History: CAD, HF, TIA/CVA, PAD, DM, renal insufficiency, sleep apnea, preeclampsia; ⊕ FHx for HTN; diet, Na intake, smoking, alcohol, prescription and OTC meds, OCP</p>
<p class="noindent1">• Physical exam: ✓ <b class="calibre7">BP in both arms;</b> funduscopic exam, BMI, cardiac (LVH, murmurs), vascular (bruits, radial-femoral delay), abdominal (masses or bruits), neuro exam</p>
<p class="noindent1">• Testing: K, BUN, Cr, Ca, glc, Hct, U/A, lipids, TSH, urinary albumin:creatinine (if ↑ Cr, DM, peripheral edema), ? renin, ECG (for LVH), CXR, TTE (eval for valve abnl, LVH)</p>
<p class="noindent1">• Ambulatory BP monitoring (ABPM): consider for episodic, masked, resistant, or white coat HTN; stronger predictor of mortality than clinic BP <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2018;378:1509)</span>; 24 h target &lt;130/80</p>
<p class="h">Complications of HTN</p>
<p class="noindent1">• Neurologic: <b class="calibre7">TIA/CVA</b>, ruptured aneurysms, vascular dementia</p>
<p class="noindent1">• Retinopathy: stage I = arteriolar narrowing; II = copper-wiring, AV nicking; III = hemorrhages and exudates; IV = papilledema</p>
<p class="noindent1">• Cardiac: <b class="calibre7">CAD</b>, <b class="calibre7">LVH</b>, <b class="calibre7">HF, AF</b></p>
<p class="noindent1">• Vascular: aortic dissection, aortic aneurysm (HTN = key risk factor for aneurysms)</p>
<p class="noindent1">• Renal: proteinuria, <b class="calibre7">renal failure</b></p>
<p class="h">Treatment <span class="r1">(</span><span class="r2">J Clin HTN</span> <span class="r1">2014;16:14;</span> <span class="r2">Circ</span><span class="r1"> 2018;138:e426;</span> <span class="r2">NEJM</span><span class="r1"> 2018;378:636)</span></p>
<p class="noindent1">• Every ↓ 5 mmHg → ~10% ↓ ischemic heart disease, stroke, and HF <span class="r1">(</span><span class="r2">Lancet</span> <span class="r1">2021;397:1625)</span></p>
<p class="noindent1">• <b class="calibre7">Lifestyle modifications</b> (each may ↓ SBP ~5 mmHg)</p>
<p class="noindent2">weight loss: goal BMI 18.5–24.9; aerobic exercise: 90–150 min exercise/wk</p>
<p class="noindent2">diet: rich in fruits &amp; vegetables, low in saturated &amp; total fat (DASH, <span class="r2">NEJM</span><span class="r1"> 2001;344:3</span>)</p>
<p class="noindent2">limit Na: ideally ≤1.5 g/d or ↓ 1 g/d; ↑ K intake / use salt substitute <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2021;385:1067)</span></p>
<p class="noindent2">limit alcohol: ≤2 drinks/d in men; ≤1 drink/d in women &amp; lighter-wt Pts; avoid NSAIDs</p>
<p class="noindent1"><a id="page_1-30" class="calibre4"></a>• ACC/AHA: initiate BP med if BP ≥130/80 &amp; <i class="calibre6">either</i> clinical ASCVD, HF, CKD, T2DM, ≥65 yrs old <i class="calibre6">or</i> 10-y ASCVD risk ≥10%; otherwise if BP ≥140/90</p>
<p class="noindent1">• In high CV risk w/o DM, SBP target &lt;120 (via unattended automated cuff) ↓ MACE &amp; mortality vs. &lt;140 mmHg, but w/ ↑ HoTN, AKI, syncope, electrolyte abnl <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2021;384:1921 &amp; 385:1268)</span></p>
<p class="noindent1">• <b class="calibre7">Pharmacologic options</b></p>
<p class="noindent2"><b class="calibre7"><span class="underline">Pre-HTN</span>:</b> ARB prevents onset of HTN, no ↓ in clinical events <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2006;354:1685)</span></p>
<p class="noindent2"><b class="calibre7"><span class="underline">HTN</span>:</b> choice of therapy controversial, concomitant disease and stage may help guide Rx; ? improved control with nighttime administration <span class="r1">(</span><span class="r2">EHJ</span> <span class="r1">2020;41:4564)</span></p>
<p class="noindent2"><b class="calibre7">Uncomplicated:</b> CCB, ARB/ACEI, or thiazide (chlorthalidone preferred) are 1<sup class="calibre19">st</sup> line; βB not.</p>
<p class="noindent3">For black Pts, reasonable to start with CCB or thiazide.</p>
<p class="noindent2">+<b class="calibre7"> CAD</b> <span class="r1">(</span><span class="r2">Circ</span> <span class="r1">2015;131:e435)</span>: ACEI or ARB; ACEI+CCB superior to ACEI+thiazide <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2008;359:2417)</span> or βB+diuretic <span class="r1">(</span><span class="r2">Lancet</span> <span class="r1">2005;366:895)</span>; may require βB and/or nitrates for anginal relief; if h/o MI, βB ± ACEI/ARB ± aldo antag (see “ACS”)</p>
<p class="noindent2">+<b class="calibre7"> HF:</b> ARNI/ACEI/ARB, βB, diuretics, aldosterone antagonist (see “Heart Failure”)</p>
<p class="noindent2">+<b class="calibre7"> prior stroke:</b> ACEI ± thiazide <span class="r1">(</span><span class="r2">Lancet</span> <span class="r1">2001;358:1033)</span></p>
<p class="noindent2">+<b class="calibre7"> diabetes mellitus:</b> ACEI or ARB; can also consider thiazide or CCB</p>
<p class="noindent2">+<b class="calibre7"> chronic kidney disease:</b> ACEI or ARB <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2001;345:851 &amp; 861)</span></p>
<p class="noindent1">• Tailoring therapy: if stage 1, start w/ monoRx; if stage 2, consider starting w/ combo (eg, ACEI + CCB; <span class="r2">NEJM</span><span class="r1"> 2008;359:2417</span>); start at ½ max dose; after ~1 mo, uptitrate or add drug</p>
<p class="noindent1">• <b class="calibre7">Pregnancy:</b> methyldopa, labetalol, &amp; nifed pref. Hydral OK; avoid diuretics; Ø ACEI/ARB. Targeting DBP 85 vs. 105 safe and ↓ severe HTN <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2015;372:407)</span>.</p>
<p class="h">Resistant HTN <span class="r">(BP &gt;goal on ≥3 drugs incl diuretic;</span> <span class="r2">HTN</span><span class="r1"> 2018;72:e53</span><span class="r">)</span></p>
<p class="noindent1">• Exclude: 2° causes (see table) and <i class="calibre6">pseudoresistance:</i> inaccurate measure (cuff size), diet noncomp (↑ Na), poor Rx compliance/dosing, white coat HTN (✓ ABPM)</p>
<p class="noindent1">• Ensure effective diuresis (chlorthalidone or indapamide &gt;HCTZ; loop &gt;thiazide if eGFR &lt;30)</p>
<p class="noindent1">• Can add aldosterone antagonist <span class="r1">(</span><span class="r2">Lancet</span> <span class="r1">2015;386:2059)</span>, β-blocker (particularly vasodilators such as carvedilol, labetalol, or nebivolol), α-blocker, or direct vasodilator</p>
<p class="noindent1">• Consider renal denervation therapy <span class="r1">(</span><span class="r2">Lancet</span> <span class="r1">2018;391:2346; 2021;397:2476)</span></p>
<p class="h1cr">H<small class="calibre31">YPERTENSIVE</small> C<small class="calibre31">RISES</small></p>
<p class="noindent1">• <b class="calibre7">Hypertensive emergency:</b> ↑ BP (usually SBP &gt;180 or DBP &gt;120) → target-organ damage</p>
<p class="noindent2">Neurologic damage: encephalopathy, hemorrhagic or ischemic stroke, papilledema</p>
<p class="noindent2">Cardiac damage: ACS, HF/pulmonary edema, aortic dissection</p>
<p class="noindent2">Renal damage: proteinuria, hematuria, acute renal failure; scleroderma renal crisis</p>
<p class="noindent2">Microangiopathic hemolytic anemia; preeclampsia-eclampsia</p>
<p class="noindent1">• <b class="calibre7">Hypertensive urgency:</b> SBP &gt;180 or DBP &gt;120 (? 110) w/o target-organ damage</p>
<p class="h">Precipitants</p>
<p class="noindent1">• Progression of essential HTN ± medical noncompliance (espec clonidine) or ∆ in diet</p>
<p class="noindent1">• Progression of renovascular disease; acute glomerulonephritis; scleroderma; preeclampsia</p>
<p class="noindent1">• Endocrine: pheochromocytoma, Cushing’s</p>
<p class="noindent1">• Sympathomimetics: cocaine, amphetamines, MAO inhibitors + foods rich in tyramine</p>
<p class="h">Treatment – tailor to clinical condition <span class="r1">(</span><span class="r2">Circ</span> <span class="r1">2018;138:e426)</span></p>
<p class="noindent1">• AoD, eclampsia/severe preeclampsia, pheo: target SBP &lt;140 (&lt;120 for AoD) in <b class="calibre7"><sub class="calibre10">1</sub> hour</b></p>
<p class="noindent1">• Emerg w/o above: ↓ BP by ~25% in 1 h; to 160/100–110 over next 2–6 h, then nl over 1–2 d</p>
<p class="noindent1">• Acute ischemic stroke (w/in 72 hr from sx onset): &lt;185/110 before lysis initiated, o/w target &lt;220/120 (same SBP goal for ICH)</p>
<p class="noindent1">• Watch UOP, Cr, mental status: may indicate a lower BP is not tolerated</p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre12"/>
<col class="calibre33"/>
<col class="calibre34"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="3"><p class="tbodyc"><b class="calibre7">IV Drugs for Hypertensive Crises</b> <span class="sm">(<i class="calibre6">Circ</i> 2018;138:e426; <i class="calibre6">Stroke</i> 2018;49:46)</span></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Drug</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Dose</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Preferred for</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Labetalol</p></td>
<td class="th1"><p class="tbody">20–80 mg IVB q10min or 0.4–2 mg/min</p></td>
<td class="th1"><p class="tbody">AoD, ACS, Stroke, Eclampsia</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Esmolol</p></td>
<td class="th1"><p class="tbody">0.5–1 mg/kg load → 50–200 µg/kg/min</p></td>
<td class="th1"><p class="tbody">AoD, ACS</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Nitroprusside<sup class="calibre27"><a id="fn24-s1" class="calibre8"></a><a href="part0007.html#rfn24-s1" class="calibre8">*</a></sup></p></td>
<td class="th1"><p class="tbody">0.25–10 µg/kg/min</p></td>
<td class="th1"><p class="tbody">Pulm edema</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Nitroglycerin</p></td>
<td class="th1"><p class="tbody">5–500 µg/min</p></td>
<td class="th1"><p class="tbody">Pulm edema, ACS</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Nicardipine</p></td>
<td class="th1"><p class="tbody">5–15 mg/h (can ↑ 2.5 mg/h q 5 min)</p></td>
<td class="th1"><p class="tbody">Stroke, AKI, Eclampsia, Pheo</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Clevidipine</p></td>
<td class="th1"><p class="tbody">1–32 mg/h (can titrate q 5–10 min)</p></td>
<td class="th1"><p class="tbody">Stroke, Pulm edema, AKI, Pheo</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Fenoldopam</p></td>
<td class="th1"><p class="tbody">0.1–1.6 µg/kg/min</p></td>
<td class="th1"><p class="tbody">AKI</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Hydralazine</p></td>
<td class="th1"><p class="tbody">10–20 mg q20–30min prn</p></td>
<td class="th1"><p class="tbody">Eclampsia</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Phentolamine</p></td>
<td class="th1"><p class="tbody">5–15 mg bolus q5–15min</p></td>
<td class="th1"><p class="tbody">Pheo</p></td>
</tr>
</tbody>
</table>
<p class="tfn"><sup class="calibre22"><a id="rfn24-s1" class="calibre8"></a><a href="part0007.html#fn24-s1" class="calibre8">*</a></sup>Metabolized to cyanide → ∆ MS, lactic acidosis, death. Limit use of very high doses (8–10 µg/kg/min) to &lt;10 min.</p>
<p class="noindent1">• HTN urgency: goal to return to normal BP over hrs to days. Reinstitute/intensify anti-HTN Rx. Additional PO options: labetalol 200–800 mg q8h, captopril 12.5–100 mg q8h, hydralazine 10–75 mg q6h, clonidine 0.2 mg load → 0.1 mg q1h.</p>
<h2 class="ct"><a id="h13" class="calibre8"></a><a id="page_1-31" class="calibre8"></a><a href="part0003.html#rh17" class="calibre8">AORTIC ANEURYSMS</a></h2>
<p class="h">Definitions</p>
<p class="noindent1">• <b class="calibre7">True</b> (≥50% dilation of all 3 layers; &lt;50% = ectasia) vs. <b class="calibre7">false</b> (rupture w/in adventitia)</p>
<p class="noindent1">• <b class="calibre7">Location:</b> root (annuloaortic ectasia), thoracic aortic aneurysm (TAA), thoracoabdominal aortic aneurysm (TAAA), abdominal aortic aneurysm (AAA)</p>
<p class="noindent1">• <b class="calibre7">Type:</b> fusiform (circumferential dilation) vs. saccular (localized dilation of aortic wall)</p>
<p class="h">Epidemiology <span class="r1">(</span><span class="r2">Circ</span> <span class="r1">2010;121:e266, 2011;124:2020;</span> <span class="r2">Nat Rev Cardiol</span> <span class="r1">2011;8:92)</span></p>
<p class="noindent1">• <b class="calibre7">TAA:</b> ~10/100,000 Pt-yrs; ♂:♀ 2:1; ~60% root/ascending; 40% descending</p>
<p class="noindent1">• <b class="calibre7">AAA:</b> ~4–8% prev in those &gt;60 y; 5× more common in ♂; mostly infrarenal</p>
<p class="h">Pathophysiology &amp; risk factors <span class="r1">(</span><span class="r2">JACC</span><span class="r1"> 2020:76:201 &amp; 2021;78:201)</span></p>
<p class="noindent1">• Medial degen and/or ↑ wall stress; wall stress ∝ [(∆P × r) / (wall thickness)] (Laplace’s law)</p>
<p class="noindent1">• <b class="calibre7">TAA:</b> medial degeneration (muscle apoptosis, elastin fiber weakening); a/w CTD, aortitis</p>
<p class="noindent1">• <b class="calibre7">AAA:</b> long-standing HTN + athero/inflammation → medial weakening</p>
<p class="noindent1">• <b class="calibre7">Clinical risk factors:</b> HTN, athero, smoking, age, ♂, presence of other aortic dilation</p>
<p class="noindent1">• <b class="calibre7">CTD</b> (Marfan, Ehlers-Danlos type IV, Loeys-Dietz); <b class="calibre7">congenital</b> (bicuspid AoV, Turner’s) <b class="calibre7">aortitis</b> (Takayasu’s GCA, spondyloarthritis, IgG4); infection (eg, syphilis); FQ; trauma</p>
<p class="h">Screening <span class="r1">(</span><span class="r2">JAMA</span> <span class="r1">2015;313:1156)</span></p>
<p class="noindent1">• <b class="calibre7">TAA:</b> if bicuspid AoV or 1° relative w/: (a) TAA or bicuspid AoV, (b) CTD as above</p>
<p class="noindent1">• <b class="calibre7">AAA:</b> ✓ for pulsatile abd mass; U/S ♂ &gt;60 y w/ FHx of AAA &amp; ♂ 65–75 y w/ prior tobacco</p>
<p class="h">Diagnostic studies <span class="r1">(</span><span class="r2">JACC</span> <span class="r1">2020;76:201)</span></p>
<p class="noindent1">• <b class="calibre7">Contrast CT:</b> quick, noninvasive, high Se &amp; Sp for all aortic aneurysms</p>
<p class="noindent1">• <b class="calibre7">TTE/TEE:</b> TTE most useful for root and proximal Ao; TEE can visualize other sites of TAA</p>
<p class="noindent1">• <b class="calibre7">MRI:</b> favored over CT for AoRoot imaging; useful in AAA but time consuming; noncontrast “black blood” MR to assess aortic wall</p>
<p class="noindent1">• <b class="calibre7">Abdominal U/S:</b> screening/surveillance test of choice for infrarenal AAA</p>
<p class="h">Treatment <span class="r1">(</span><span class="r2">Circ</span> <span class="r1">2010;121:e266 &amp; 2016;133:680;</span> <span class="r2">JACC</span><span class="r1"> 2020;76:201</span><span class="r2">; NEJM</span><span class="r1"> 2021;385:1690)</span></p>
<p class="noindent1">• Goal is to prevent rupture (50% mortality prior to hospital) by modifying risk factors</p>
<p class="noindent1">• <b class="calibre7">Risk factor modification:</b> smoking cessation; statins to achieve LDL-C &lt;70 mg/dL</p>
<p class="noindent1">• <b class="calibre7">BP control</b> (goal SBP 100–120): <b class="calibre7">βB</b> (↓ dP/dt) ↓ aneurysm growth; <b class="calibre7">ACEI</b> a/w ↓ rupture risk <span class="r1">(</span><span class="r2">Lancet</span> <span class="r1">2006;368:659)</span>; <b class="calibre7">ARB</b> may ↓ rate of aortic root growth in Marfan <span class="r1">(</span><span class="r2">NEJM</span><span class="r1"> 2008;358:2787)</span></p>
<p class="noindent1">• Mod CV exercise OK, no burst activity requiring Valsalva maneuvers (eg, heavy lifting)</p>
<p class="noindent1">• <b class="calibre7">Indications for intervention</b> (individualized based on FHx, body size, sex, anatomy)</p>
<p class="noindent2"><b class="calibre7">TAA:</b> sxs; ascending Ao ≥5.5 cm (4–5 cm if Marfan, L-D, EDS, bicuspid AoV); descending Ao &gt;6 cm; ≥4.5 cm and planned AoV surgery; ↑ &gt;0.5 cm/y</p>
<p class="noindent2"><b class="calibre7">AAA:</b> sx; infrarenal ≥5.5 cm; consider ≥5.0 cm in ♀; ↑ &gt;0.5 cm/y; inflam/infxn</p>
<p class="h">Surgery <span class="r1">(</span><span class="r2">EHJ</span> <span class="r1">2014;25:2873)</span></p>
<p class="noindent1">• Resection &amp; replacement w/ graft. If involves root, need to address AoV &amp; coronaries.</p>
<p class="h">Endovascular repair (EVAR) <span class="r1">(</span><span class="r2">Circ</span> <span class="r1">2015;131:1291;</span> <span class="r2">NEJM</span><span class="r1"> 2019;380:2126)</span></p>
<p class="noindent1">• Requires favorable aortic anatomy</p>
<p class="noindent1">• <b class="calibre7">TEVAR</b> (thoracic EVAR) for descending TAA ≥5.5 cm may ↓ periop morbidity and possibly mortality <span class="r1">(</span><span class="r2">Circ</span> <span class="r1">2010;121:2780;</span> <span class="r2">JACC</span><span class="r1"> 2010;55:986;</span> <span class="r2">J Thorac CV Surg</span> <span class="r1">2010;140:1001 &amp; 2012;144:604)</span></p>
<p class="noindent1">• <b class="calibre7">AAA:</b> guidelines support open repair or EVAR for infrarenal AAA in good surg candidates</p>
<p class="noindent2">↓ short-term mort., bleeding, LOS; but long-term graft complic. (3–4%/y; endoleak, need for reintervention, rupture) necessitate periodic surveillance, with no difference in mortality long term, except ? in those &lt;70 y <span class="r1">(</span><span class="r2">Lancet</span> <span class="r1">2016;388:2366;</span> <span class="r2">NEJM</span><span class="r1"> 2019;380:2126)</span></p>
<p class="noindent2">In Pts unfit for surgery or high periop risks: ↓ aneurysm-related mortality but no ∆ in overall mortality over med Rx <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2010;362:1872)</span>. EVAR noninferior (? superior) to open repair in ruptured AAA w/ favorable anatomy <span class="r1">(</span><span class="r2">Ann Surg</span> <span class="r1">2009;250:818)</span>.</p>
<p class="h">Complications <span class="r1">(</span><span class="r2">Circ</span> <span class="r1">2010;121:e266;</span> <span class="r2">Nat Rev Cardiol</span> <span class="r1">2011;8:92)</span></p>
<p class="noindent1">• <b class="calibre7">Pain:</b> gnawing chest, back, or abdominal pain; new or worse pain may signal rupture</p>
<p class="noindent1">• <b class="calibre7">Rupture:</b> risk ↑ w/ diameter, ♀, current smoking, HTN</p>
<p class="noindent2"><b class="calibre7">TAA:</b> ~2.5%/y if &lt;6 cm vs. 7%/y if &gt;6 cm</p>
<p class="noindent2"><b class="calibre7">AAA:</b> ~1%/y if &lt;5 cm vs. 6.5%/y if 5–5.9 cm; ~80% mortality at 24 h</p>
<p class="noindent1">• Aortic insufficiency (TAA), CHF, acute aortic syndromes (qv)</p>
<p class="noindent1">• <b class="calibre7">Thromboembolic ischemic events</b> (eg, to CNS, viscera, extremities)</p>
<p class="noindent1">• <b class="calibre7">Compression of adjacent structures</b> (eg, SVC, trachea, esophagus, laryngeal nerve)</p>
<p class="h">Follow-up <span class="r1">(</span><span class="r2">Circ</span> <span class="r1">2010;121:e266;</span> <span class="r2">Nat Rev Cardiol</span> <span class="r1">2011;8:92;</span> <span class="r2">JAMA</span><span class="r1"> 2013;309:806)</span></p>
<p class="noindent1">• Expansion rate ~0.1 cm/y for TAA, ~0.3–0.4 cm/y for AAA</p>
<p class="noindent1">• TAA: 6 mo after dx to ensure stable, and if stable, then annually <span class="r1">(</span><span class="r2">Circ</span><span class="r1"> 2005;111:816)</span></p>
<p class="noindent1">• AAA: &lt;4 cm q2–3y; 4–5.4 cm q6–12mo; more often if rate of expansion &gt;0.5 cm in 6 mo</p>
<p class="noindent1">• Screen for CAD, PAD, &amp; aneurysms elsewhere, espec popliteal. ~25% of Pts w/ TAA will also have AAA, and 25% of AAA Pts will have a TAA: consider pan-Ao imaging.</p>
<h2 class="ct"><a id="h14" class="calibre8"></a><a id="page_1-32" class="calibre8"></a><a href="part0003.html#rh18" class="calibre8">ACUTE AORTIC SYNDROMES</a></h2>
<p class="h">Definitions <span class="r1">(</span><span class="r2">Circ</span><span class="r1"> 2010;121:e266;</span> <span class="r2">Eur Heart J</span> <span class="r1">2012;33:26)</span></p>
<p class="noindent1">• <b class="calibre7">Aortic dissection:</b> intimal tear → blood extravasates into Ao media (creates false lumen)</p>
<p class="noindent1">• <b class="calibre7">Intramural hematoma</b> (IMH): vasa vasorum rupture → medial hemorrhage that does not communicate with aortic lumen; 6% of aortic syndromes; clinically managed as AoD</p>
<p class="noindent1">• <b class="calibre7">Penetrating ulcer:</b> atherosclerotic plaque penetrates elastic lamina → medial hemorrhage</p>
<p class="h">Classification <span class="r">(proximal more common than distal;</span> <span class="r2">JACC</span><span class="r1"> 2019;74:1494 &amp; 2020;76:1703</span><span class="r">)</span></p>
<p class="noindent1">• <b class="calibre7">Proximal:</b> involves ascending Ao, regardless of origin (= Stanford A, DeBakey I &amp; II)</p>
<p class="noindent1">• <b class="calibre7">Distal:</b> involves descending Ao only, distal to L subclavian art. (= Stanford B, DeBakey III)</p>
<p class="h">Risk factors <span class="r1">(</span><span class="r2">Lancet</span> <span class="r1">2015;385:800)</span></p>
<p class="noindent1">• <b class="calibre7">Classic</b> (in older Pts): <b class="calibre7">HTN</b> (h/o HTN in &gt;70% of dissections); <b class="calibre7">age</b> (60s–70s), <b class="calibre7">sex</b> (~65% ♂); <b class="calibre7">smoking;</b> ↑ lipids. <b class="calibre7">Acute</b> ↑<b class="calibre7"> BP:</b> cocaine, Valsalva (eg, weightlifting).</p>
<p class="noindent1">• <b class="calibre7">Genetic:</b> <i class="calibre6">CTD</i> (Marfan, Loeys-Dietz, Ehlers-Danlos type IV); <i class="calibre6">congenital anomaly</i> (bicuspid AoV, coarct [eg, Tuner’s syndrome], PCKD); FHx (AoD or aneurysm in 1<sup class="calibre19">st</sup> degree relative)</p>
<p class="noindent1">• <b class="calibre7">Acquired:</b> <i class="calibre6">aortitis</i> (Takayasu’s, GCA, Behçet’s, syphilis); <i class="calibre6">preg.</i> (typically 3<sup class="calibre19">rd</sup> trim.); FQ use</p>
<p class="noindent1">• <b class="calibre7">Trauma:</b> blunt, decel. injury (eg, MVA); IABP, cardiac/aortic surgery, Impella, cardiac cath</p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre26"/>
<col class="calibre23"/>
<col class="calibre23"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="3"><p class="tbodyc"><b class="calibre7">Clinical Manifestations and Physical Exam<sup class="calibre27"><a id="fn25-s1" class="calibre8"></a><a href="part0007.html#rfn25-s1" class="calibre8">*</a></sup></b> <span class="sm">(<i class="calibre6">JAMA</i> 2000;283:897)</span></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Feature</b></p></td>
<td class="th1"><p class="tbodyc"><b class="calibre7">Proximal</b></p></td>
<td class="th1"><p class="tbodyc"><b class="calibre7">Distal</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">“Aortic” pain</b> (abrupt, severe, tearing or ripping quality, <i class="calibre6">maximal at onset</i> [vs. crescendo for ACS])</p></td>
<td class="th1"><p class="tbodyc"><b class="calibre7">94%</b></p>
<p class="tbodyc">(chest, back)</p></td>
<td class="th1"><p class="tbodyc"><b class="calibre7">98%</b></p>
<p class="tbodyc">(back, chest, abd)</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Syncope</b> (often due to tamponade)</p></td>
<td class="th1"><p class="tbodyc">1<b class="calibre7">3%</b></p></td>
<td class="th1"><p class="tbodyc">4%</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">HF</b> (usually due to acute AI)</p></td>
<td class="th1"><p class="tbodyc"><b class="calibre7">9%</b></p></td>
<td class="th1"><p class="tbodyc">3%</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">CVA</b></p></td>
<td class="th1"><p class="tbodyc"><b class="calibre7">6%</b></p></td>
<td class="th1"><p class="tbodyc">2%</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">HTN</b></p></td>
<td class="th1"><p class="tbodyc">36%</p></td>
<td class="th1"><p class="tbodyc"><b class="calibre7">70%</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">HoTN or shock</b> (tamponade, AI, MI, rupture)</p></td>
<td class="th1"><p class="tbodyc"><b class="calibre7">25%</b></p></td>
<td class="th1"><p class="tbodyc">4%</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Pulse deficit</b> (if involves carotid, subclavian, fem)</p></td>
<td class="th1"><p class="tbodyc">1<b class="calibre7">9%</b></p></td>
<td class="th1"><p class="tbodyc"><b class="calibre7">9%</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">AR murmur</b></p></td>
<td class="th1"><p class="tbodyc"><b class="calibre7">44%</b></p></td>
<td class="th1"><p class="tbodyc">12%</p></td>
</tr>
</tbody>
</table>
<p class="tfn"><sup class="calibre22"><a id="rfn25-s1" class="calibre8"></a><a href="part0007.html#fn25-s1" class="calibre8">*</a></sup>S/S correlate w/ affected branch vessels &amp; distal organs; may ∆ as dissection progresses</p>
<p class="h">Initial evaluation &amp; diagnostic studies <span class="r1">(</span><span class="r2">Circ</span> <span class="r1">2010;121:e266;</span> <span class="r2">EHJ</span><span class="r1"> 2018;39:739)</span></p>
<p class="noindent1">• H&amp;P, incl. bilat BP &amp; radial pulses for symmetry; ECG w/ STE if propagates to cor</p>
<p class="noindent1">• <b class="calibre7">CXR</b>: abnl in 60–90% [↑ mediast. (absence ⊖ LR 0.3), L pl effusion] but <i class="calibre6">cannot</i> r/o AoD</p>
<p class="noindent1">• <b class="calibre7">CT:</b> quick and available, Se ≥93%, Sp 98%; facilitates “triple rule-out” ACS vs. PE vs. AoD</p>
<p class="noindent1">• <b class="calibre7">MRI:</b> Se &amp; Sp &gt;98%, but time-consuming test &amp; not readily available</p>
<p class="noindent1">• <b class="calibre7">TEE:</b> Se &gt;95% prox, 80% for distal; can assess cors/peric/AI; “blind spot” behind trachea</p>
<p class="noindent1">• ⊖ Initial imaging but high clinical suspicion → further studies (⅔ w/ AoD have ≥2 studies)</p>
<p class="noindent1">• <b class="calibre7">D-dimer</b> &lt;500 ng/mL has Se/NPV ~97%, Sp ~50%, <i class="calibre6">but not if high risk</i> and not for IMH</p>
<p class="noindent1">• Risk score (0–3 points): high-risk (eg, genetics, recent Ao manip); aortic pain; e/o perfusion deficit, AI or shock. Score &gt;1 → imaging; ≤1 &amp; DD &lt;500 has NPV &gt;99% <span class="r1">(</span><span class="r2">Circ</span> <span class="r1">2018;137:250)</span></p>
<p class="h">Treatment <span class="r1">(</span><span class="r2">Circ</span> <span class="r1">2010;121:1544;</span> <span class="r2">EHJ</span><span class="r1"> 2018;39:739;</span> <span class="r2">JACC</span><span class="r1"> 2019;74:1494 &amp; 2020;76:1703)</span></p>
<p class="noindent1">• ↓ <b class="calibre7">dP/dt</b> targeting HR &lt;60 &amp; central BP &lt;120 (or lowest that preserves perfusion; r/o pseudohypotension, eg, arm BP ↓ due to subclavian dissection; use highest BP reading)</p>
<p class="noindent1">• <b class="calibre7"><i class="calibre6">First</i> IV βB</b> (eg, esmolol, labetalol) to blunt reflex ↑ HR &amp; inotropy in response to vasodilators; verapamil/diltiazem if βB contraindic; <b class="calibre7"><i class="calibre6">then</i></b> ↓<b class="calibre7"><i class="calibre6"> SBP w/</i> IV vasodilators</b> (eg, nitroprusside)</p>
<p class="noindent1">• <b class="calibre7">If HoTN:</b> urgent surgical consult, IVF to achieve euvolemia, pressors to keep MAP 60-65 mmHg; r/o complication (eg, tamponade, contained rupture, severe AI)</p>
<p class="noindent1">• <b class="calibre7">Proximal:</b> surgery considered in <b class="calibre7">all acute</b> and in chronic if c/b progression, AI or aneurysm</p>
<p class="noindent1">• <b class="calibre7">Distal:</b> med Rx unless complication (see below) or favorable TEVAR anatomy w/ high-risk imaging features <span class="r1">(</span><span class="r2">JACC</span> <span class="r1">2019;74:1494)</span>; pre-emptive TEVAR may ↓ late complic. &amp; mortality</p>
<p class="h">Complications <span class="r">(<i class="calibre6">occur in</i> ~20%;</span> <span class="r2">Circ</span><span class="r1"> 2010;121:e266;</span> <span class="r2">Lancet</span><span class="r1"> 2015;385:800</span><span class="r">)</span></p>
<p class="noindent1">• <i class="calibre6">Freq assess (sx, BP, UOP), pulses, labs (Cr, Hb, lactic acid), imaging (~7 d or sooner if ∆s)</i></p>
<p class="noindent1">• <i class="calibre6">Uncontrolled BP or persistent pain may indicate complication/extension</i></p>
<p class="noindent1">• <b class="calibre7">Progression:</b> propagation of dissection, ↑ aneurysm size, ↑ false lumen size</p>
<p class="noindent1">• <b class="calibre7">Rupture:</b> pericardial sac → tamponade (avoid pericardiocentesis unless PEA); blood in pleural space, mediast., retroperitoneum; ↑ in hematoma on imaging portends rupture</p>
<p class="noindent1">• <b class="calibre7">Malperfusion</b> (partial or complete obstruction of branch artery; can be <i class="calibre6">static</i> or <i class="calibre6">dynamic</i>) <i class="calibre6">coronary</i> → MI (usually RCA → IMI b/c dissection follows outer Ao curvature); <i class="calibre6">innominate/carotid</i> → CVA, Horner; <i class="calibre6">intercostal/lumbar</i> → spinal cord ischemia/paraplegia; <i class="calibre6">innominate/subclavian</i> → upper ext ischemia; <i class="calibre6">iliac</i> → lower ext ischemia; <i class="calibre6">celiac/mesenteric</i> → bowel ischemia; <i class="calibre6">renal</i> → AKI or slow ↑ Cr, refractory HTN</p>
<p class="noindent1">• <b class="calibre7">AI:</b> due to annular dilatation or disruption or displacement of leaflet by false lumen</p>
<p class="noindent1">• Mortality: 20–40% for proximal; 6% for uncomplicated and ~20% for complicated distal</p>
<p class="noindent1">• <b class="calibre7">Long-term serial imaging</b> (CT or MRI; ↓ rad w/ MRI) at 1, 3, and 6 mo, and then annually</p>
<h2 class="ct"><a id="h15" class="calibre8"></a><a id="page_1-33" class="calibre8"></a><a href="part0003.html#rh19" class="calibre8">ARRHYTHMIAS</a></h2>
<p class="h1cr">B<small class="calibre31">RADYCARDIAS</small>, AV B<small class="calibre31">LOCK</small>, <small class="calibre31">AND</small> AV D<small class="calibre31">ISSOCIATION</small></p>
<p class="h">Sinus bradycardia <span class="r">(SB, &lt;50–60 bpm)</span> <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2000;342:703,</span> <span class="r2">Circ</span><span class="r1"> 2019;140:e382)</span></p>
<p class="noindent1">• Etiologies: <b class="calibre7">meds</b> (incl βB, CCB, amio, Li, dig), ↑ <b class="calibre7">vagal tone</b> (incl. athletes, sleep, IMI), <b class="calibre7">metabolic</b> (hypoxia, sepsis, myxedema, hypothermia, ↓ glc), OSA, ↑ ICP</p>
<p class="noindent1">• Treatment: if no sx, none; atropine, β<sub class="calibre10">1</sub> agonists (short-term) or pacing if symptomatic</p>
<p class="noindent1">• Most common cause of sinus pause is <i class="calibre6">blocked premature atrial beat</i></p>
<p class="h">Tachycardia-bradycardia (“tachy-brady”) syndrome</p>
<p class="noindent1">• Features may include: periods of unprovoked SB, SA arrest, paroxysms of SB and atrial</p>
<p class="noindent2">tachyarrhythmias, chronotropic incompetence w/ ETT</p>
<p class="noindent1">• Treatment: meds alone usually fail (adeq. control tachy → unacceptable brady); usually need <b class="calibre7">combination of meds</b> (βB, CCB, dig) for tachycardia &amp; <b class="calibre7">PPM</b> for bradycardia</p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre12"/>
<col class="calibre32"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="2"><p class="tbodyc"><b class="calibre7">AV Block</b> <span class="sm">(<i class="calibre6">Circ</i> 2019;140:e382)</span></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Type</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Features</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">1°</b></p></td>
<td class="th1"><p class="tbodyh">Prolonged PR (&gt;200 ms), all atrial impulses conducted (1:1).</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">2° Mobitz I (Wenckebach)</b></p></td>
<td class="th1"><p class="tbodyh">Progressive ↑ PR until impulse not conducted (→ ”grouped beating”).</p>
<p class="tbodyh"><b class="calibre7">AV node</b> pathology: ischemia (IMI), inflammation (myocarditis, endocarditis, MV surgery), high vagal tone (athletes), drug induced.</p>
<p class="tbodyh">Classically (~50%), absolute ↑ in PR <i class="calibre6">decreases</i> over time (→ ↓ RR intervals, duration of pause &lt;2× preceding RR interval); nl QRS.</p>
<p class="tbodyh">AVB usually worsens w/ carotid sinus massage, improves w/ atropine.</p>
<p class="tbodyh">Often paroxysmal/nocturnal/asx, no Rx required.</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">2° Mobitz II</b></p></td>
<td class="th1"><p class="tbodyh">Blocked impulses w/ consistent PR interval, often prolonged QRS</p>
<p class="tbodyh"><b class="calibre7">His-Purkinje</b> pathology: ischemia (AMI), degeneration of conduction system, infiltrative disease, inflammation.</p>
<p class="tbodyh">AVB may improve w/ carotid sinus massage, may worsen w/ atropine.</p>
<p class="tbodyh">May progress to 3° AVB. Pacing pads; transven. pacing often required.</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">3° (complete)</b></p></td>
<td class="th1"><p class="tbodyh">No AV conduction. Escape, if present, narrow (jxnal) or wide (vent.)</p></td>
</tr>
</tbody>
</table>
<p class="tfn">Nb, if 2:1 block, cannot distinguish type I vs. II 2° AVB (no chance to observe PR prolongation); usually categorize based on other ECG &amp; clinical data. High-grade AVB usually refers to block of ≥2 successive impulses</p>
<p class="h">AV dissociation</p>
<p class="noindent1">• <i class="calibre6">Default:</i> slowing of SA node allows subsidiary pacemaker (eg, AV junction) to take over</p>
<p class="noindent1">• <i class="calibre6">Usurpation:</i> acceleration of subsidiary pacemaker (eg, AV junctional tach, VT)</p>
<p class="noindent1">• <i class="calibre6">3</i>° <i class="calibre6">AV block:</i> atrial pacemaker unable to capture ventricles, subsidiary pacemaker emerges; distinguish from <i class="calibre6">isorhythmic dissociation</i> (A ≈ V rate, some P waves nonconducting)</p>
<p class="h">Temporary pacing wires</p>
<p class="noindent1">• Consider w/ bradycardia with hemodyn instability or unstable escape rhythm when perm pacer not readily available. Risks: infxn, RV perf, VT, PTX, CHB if existing LBBB.</p>
<p class="noindent1">• Consider instead of PPM for sx brady from reversible cause (βB/CCB O/D, Lyme, SBE, myocarditis, s/p cardiac surgery/trauma/TAVR), TdP, acute MI (sx brady/high-grade AVB)</p>
<p class="h1cr">S<small class="calibre31">UPRAVENTRICULAR</small> T<small class="calibre31">ACHYCARDIAS</small> (SVT<small class="calibre31">S</small>)</p>
<p class="center"><i class="calibre6">Arise above the ventricles, ∴</i> <b class="calibre7"><i class="calibre6">narrow QRS</i></b><i class="calibre6"> unless aberrant conduction or pre-excitation.</i></p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre12"/>
<col class="calibre33"/>
<col class="calibre34"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="3"><p class="tbodyc"><b class="calibre7">Common Etiologies of SVT</b> <span class="sm">(<i class="calibre6">NEJM</i> 2012;367:1438)</span></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbody"> </p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Type</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Features</b></p></td>
</tr>
<tr class="calibre15">
<td class="tb" rowspan="5"><p class="tbodyc"><b class="calibre7">Atrial</b></p></td>
<td class="th1"><p class="tbody">Sinus tachycardia (ST)</p></td>
<td class="th1"><p class="tbody">Caused by pain, fever, hypovolemia, hypoxia, PE, anemia, anxiety, withdrawal, β-agonists, etc.</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Atrial tachycardia (AT)</p></td>
<td class="th1"><p class="tbody">Originate at site in atria other than SA node. Seen w/ CAD, COPD, ↑ catechols, EtOH, dig.</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Multifocal atrial tachycardia (MAT)</p></td>
<td class="th1"><p class="tbody">↑ automaticity at multiple sites in the atria; seen with underlying pulmonary disease</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Atrial flutter (AFL)</p></td>
<td class="th1"><p class="tbody">Clockwise or counterclockwise macroreentry, usually w/in right atrium</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Atrial fibrillation (AF)</p></td>
<td class="th1"><p class="tbody">Chaotic atrial activation with rapid, irregular AVN bombardment; often from pulmonary veins</p></td>
</tr>
<tr class="calibre15">
<td class="tb" rowspan="3"><p class="tbodyc"><b class="calibre7">AV Jxn</b></p></td>
<td class="th1"><p class="tbody">AV nodal reentrant tach (AVNRT)</p></td>
<td class="th1"><p class="tbody">Reentrant circuit using dual pathways w/in AVN</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Atrioventricular reciprocating tachycardia (AVRT)</p></td>
<td class="th1"><p class="tbody">Reentry using AVN &amp; access. path. May show pre-excitation (WPW) or not (concealed access. path.). Can be ortho or antidromic (vide infra).</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Nonparoxysmal junctional tachycardia (NPJT)</p></td>
<td class="th1"><p class="tbody">↑ jxnal automaticity. May see retro. P, AV dissoc. A/w myo/endocarditis, cardiac surg, IMI, dig.</p></td>
</tr>
</tbody>
</table>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre20"/>
<col class="calibre21"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="2"><a id="page_1-34" class="calibre4"></a><p class="tbodyc"><b class="calibre7">Diagnosis of SVT Type</b> <span class="sm">(<i class="calibre6">NEJM</i> 2012;367:1438)</span></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Onset</b></p></td>
<td class="th1"><p class="tbodyh">Abrupt on/off argues against sinus tachycardia</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Rate</b></p></td>
<td class="th1"><p class="tbodyh">Not dx b/c most can range from 140–250 bpm, <i class="calibre6">but:</i> ST usually &lt;150; AFL often conducts 2:1 → vent. rate 150; AVNRT &amp; AVRT usually &gt;150</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Rhythm</b></p></td>
<td class="th1"><p class="tbodyh">Irregular → AF, AFL w/ variable block, or MAT</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">P wave</b></p>
<p class="tbody"><b class="calibre7">morphology</b></p></td>
<td class="th1"><p class="tbodyh">Before QRS (ie, long RP) → ST, AT (P ≠ sinus), MAT (≥3 morphologies)</p>
<p class="tbodyh">None (ie, buried in or deforming terminal QRS, eg, pseudo RSR′ in V<sub class="calibre17">1</sub>) → typical AVNRT, NPJT</p>
<p class="tbodyh">After QRS (ie, short RP) &amp; inverted in inf. leads (ie, <i class="calibre6">retrograde</i> atrial) → AVNRT, AVRT (usually slightly after QRS; RP interval &gt;100 ms favors AVRT vs. AVNRT), or NPJT</p>
<p class="tbodyh"><i class="calibre6">Fibrillation or no P waves</i> → AF</p>
<p class="tbodyh"><i class="calibre6">Saw-toothed “F” waves</i> (best seen in inferior leads &amp; V<sub class="calibre17">1</sub>) → AFL</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Response to vagal stim. or adenosine</b></p></td>
<td class="th1"><p class="tbodyh">Slowing of HR often seen with ST, AF, AFL, AT, whereas reentrant rhythms (AVNRT, AVRT) may abruptly terminate (classically w/ P wave after last QRS) or no response. Occ AT may terminate.</p>
<p class="tbodyh">In AFL &amp; AF, ↑ AV block may unmask “F” waves or fibrillation</p></td>
</tr>
</tbody>
</table>
<div class="cap">
<p class="caption"><a id="fig1-4" class="calibre4"></a><b class="calibre7">Figure 1-4</b> Approach to SVT (adapted from <span class="sm"><i class="calibre6">NEJM</i> 2012;367:1438)</span></p>
<p class="imagef1"><img src="../images/00028.jpeg" alt="" class="calibre5"/></p>
</div>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre12"/>
<col class="calibre33"/>
<col class="calibre34"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="3"><p class="tbodyc"><b class="calibre7">Treatment of SVT</b> <span class="sm">(<i class="calibre6">Circ</i> 2016;133:e506)</span></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Rhythm</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Acute Treatment</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Long-term Treatment</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Unstable</p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Cardioversion</b> per ACLS</p></td>
<td class="th1"><p class="tbody">n/a</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">ST</p></td>
<td class="th1"><p class="tbody">Treat underlying stressor(s)</p></td>
<td class="th1"><p class="tbody">n/a</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">AT</p></td>
<td class="th1"><p class="tbody">βB, CCB or adenosine; ? amiodarone</p></td>
<td class="th1"><p class="tbody">radiofrequency ablation (RFA); βB or CCB, ± class IC/III AAD</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">AVNRT</p>
<p class="tbody">or AVRT</p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Vagal maneuvers</b></p>
<p class="tbody"><b class="calibre7">Adenosine</b> (caution in AVRT<sup class="calibre27"><a id="fn29-s1" class="calibre8"></a><a href="part0007.html#rfn29-s1" class="calibre8">*</a></sup>)</p>
<p class="tbody"><b class="calibre7">CCB</b> or βB, DCCV if other Rx fail</p></td>
<td class="th1"><p class="tbody"><i class="calibre6">For AVNRT (see next section for AVRT):</i></p>
<p class="tbody"><b class="calibre7">RFA.</b> CCB, βB, or dig (chronic or prn)</p>
<p class="tbody">± Class IC/III AAD (if nl heart)</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">NPJT</p></td>
<td class="th1"><p class="tbody">CCB, βB, amiodarone</p></td>
<td class="th1"><p class="tbody">Rx underlying dis. (eg, dig tox, ischemia)</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">AF</p></td>
<td class="th1"><p class="tbody">β<b class="calibre7">B, CCB, digoxin, AAD</b></p></td>
<td class="th1"><p class="tbody">See “Atrial Fibrillation”</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">AFL</p></td>
<td class="th1"><p class="tbody">β<b class="calibre7">B, CCB, AAD</b></p></td>
<td class="th1"><p class="tbody">RFA; βB or CCB ± class III AAD</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">MAT</p></td>
<td class="th1"><p class="tbody">CCB or βB if tolerated</p></td>
<td class="th1"><p class="tbody">Treat underlying disease. CCB or βB.</p>
<p class="tbody">AVN ablation + PPM if refractory to meds</p></td>
</tr>
</tbody>
</table>
<p class="tfn"><sup class="calibre22"><a id="rfn29-s1" class="calibre8"></a><a href="part0007.html#fn29-s1" class="calibre8">*</a></sup>Avoid adenosine &amp; nodal agents if accessory pathway + pre-excited tachycardia, see below (<i class="calibre6">Circ</i> 2014;130:e199)</p>
<p class="noindent1">• <i class="calibre6">Catheter ablation:</i> high overall success rate (AFL/AVNRT ~95%, AVRT ~90%, AF ~70%)</p>
<p class="noindent2">complications: stroke, MI, bleeding, perforation, conduction block</p>
<p class="h1cr">A<small class="calibre31">CCESSORY</small> P<small class="calibre31">ATHWAYS</small> (W<small class="calibre31">OLFF</small>-P<small class="calibre31">ARKINSON</small>-W<small class="calibre31">HITE</small>)</p>
<p class="h">Definitions</p>
<p class="noindent1">• <b class="calibre7">Accessory pathway</b> (bypass tract) of conducting myocardium connecting atria &amp; ventricles, allowing impulses to bypass normal AVN delay</p>
<p class="noindent1">• <b class="calibre7">Pre-excitation (WPW) pattern:</b> ↓ PR interval, ↑ QRS width w/ δ wave (slurred onset, <i class="calibre6">can be subtle</i>). ST &amp; Tw abnl (can mimic old IMI).</p>
<p class="noindent2"><i class="calibre6">Only seen w/ pathways that conduct antegrade</i> (if pathway only conducts retrograde, then ECG will be normal during SR; “concealed” bypass tract).</p>
<p class="noindent1">• PAC can exaggerate pre-excitation if AV node conduction slowed</p>
<p class="noindent1">• <b class="calibre7">WPW syndrome:</b> WPW accessory pathway + paroxysmal tachycardia</p>
<p class="h">Classic tachycardias of WPW accessory pathways</p>
<p class="noindent1">• <b class="calibre7">Orthodromic AVRT:</b> <i class="calibre6">narrow-complex</i> SVT (typically), conducting ↓ AVN &amp; ↑ accessory pathway; requires retrograde conduction and ∴ can occur w/ concealed bypass tracts</p>
<p class="noindent1"><a id="page_1-35" class="calibre4"></a>• <b class="calibre7">Antidromic AVRT</b> (rare): <i class="calibre6">wide-complex</i> SVT, conducting ↓ accessory pathway &amp; ↑ AVN; requires antegrade conduction and ∴ should see pre-excitation pattern during SR</p>
<p class="noindent1">• <b class="calibre7">AF</b> w/ rapid conduction down accessory pathway; ∴ wide-complex irregular SVT; requires antegrade conduction; ∴ should see pre-excitation in SR. Rarely can degenerate into VF.</p>
<p class="h">Treatment <span class="r1">(</span><span class="r2">Heart Rhythm</span> <span class="r1">2012;9:1006,</span> <span class="r2">Circ</span><span class="r1"> 2014;130:e199 &amp; 2016;133:e506)</span></p>
<p class="noindent1">• <b class="calibre7">AVRT</b> (orthodromic): vagal, βB, CCB; care w/ adenosine (can precip AF); <i class="calibre6">have defib ready</i></p>
<p class="noindent1">• <b class="calibre7">AF/AFL</b> w/ conduction down accessory pathway: need to Rx arrhythmia <i class="calibre6">and</i> ↑ pathway refractoriness. Use <b class="calibre7">procainamide</b>, <b class="calibre7">ibutilide</b>, or DCCV; <b class="calibre7"><i class="calibre6">avoid</i></b> CCB, βB, amio, dig, &amp;</p>
<p class="noindent3">adenosine, b/c can ↓ refractoriness of pathway → ↑ vent. rate → VF <span class="r1">(</span><span class="r2">Circ</span> <span class="r1">2016;133:e506)</span>.</p>
<p class="noindent1">• <b class="calibre7">Long term:</b> RFA if sx; if not candidate for RFA, then AAD (IA, III) or CCB/βB.</p>
<p class="noindent2">Consider RFA if asx but AVRT or AF inducible on EPS <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2003;349:1803)</span> or if rapid conduction possible (✓ w/ EPS if pre-excitation persists during exercise testing)</p>
<p class="noindent2">Risk of SCD related to how short RR interval is in AF (eg, &lt;250 ms) and if SVT inducible</p>
<p class="h1cr">W<small class="calibre31">IDE</small>-C<small class="calibre31">OMPLEX</small> T<small class="calibre31">ACHYCARDIAS</small> (WCT<small class="calibre31">S</small>)</p>
<p class="h">Etiologies <span class="r1">(</span><span class="r2">Lancet</span> <span class="r1">2012;380:1520)</span></p>
<p class="noindent1">• <b class="calibre7">Ventricular tachycardia (VT):</b> accounts for 80% of WCT in unselected population</p>
<p class="noindent1">• <b class="calibre7">SVT conducted with aberrancy:</b> either fixed BBB, rate-dependent BBB (usually RBBB), conduction via an accessory pathway or atrially triggered ventricular pacing</p>
<p class="h">Monomorphic ventricular tachycardia (MMVT)</p>
<p class="noindent1">• All beats look similar; predominantly upward in V<sub class="calibre10">1</sub> = RBBB-type vs. downward = LBBB-type</p>
<p class="noindent1">• In obviously <i class="calibre6">structurally abnormal</i> heart: <b class="calibre7">prior MI</b> (scar); <b class="calibre7">CMP</b></p>
<p class="noindent1">• In <i class="calibre6">apparently nl heart that is actually diseased:</i><b class="calibre7"> subtle HCM</b>, <b class="calibre7">infiltrative CMP</b>, <b class="calibre7">myocarditis,</b></p>
<p class="noindent2"><b class="calibre7">arrhythmogenic CMP</b> (ACM): incomplete RBBB,</p>
<p class="noindent2">ε wave (terminal notch in QRS) &amp; TWI in V<sub class="calibre10">1</sub>–V<sub class="calibre10">3</sub> on resting ECG</p>
<p class="noindent2">LBBB-type VT, dx w/ MRI <span class="r1">(</span><span class="r2">Lancet</span> <span class="r1">2009;373:1289)</span></p>
<p class="noindent1">• In structurally <i class="calibre6">normal</i> heart w/ normal resting ECG &amp; cardiac MRI:</p>
<p class="noindent2"><b class="calibre7">RVOT VT:</b> LBBB-type VT or PVCs w/ inferior axis; typically ablate</p>
<p class="noindent2"><b class="calibre7">LVOT VT:</b> RBBB-type VT or PVCs w/ superior axis; responds to verapamil</p>
<p class="image1"><img src="../images/00029.jpeg" alt="" class="calibre5"/></p>
<p class="h">Polymorphic ventricular tachycardia (PMVT)</p>
<p class="noindent1">• QRS morphology changes from beat to beat</p>
<p class="noindent1">• Etiologies: <b class="calibre7">ischemia; CMP;</b> catecholaminergic</p>
<p class="noindent2"><b class="calibre7">torsades de pointes</b> (TdP = “twisting of the points,” PMVT + ↑ QT): ↑ QT <b class="calibre7"><i class="calibre6">acquired</i></b> (meds, lytes, stroke, see “ECG”) w/ risk ↑ w/ ↓ HR, freq PVCs (pause dependent) <b class="calibre7"><i class="calibre6">or congenital</i></b> (K/Na channelopathies) w/ resting Tw abnl &amp; TdP triggered by sympathetic stimulation (eg, exercise, emotion, sudden loud noises) <span class="r1">(</span><span class="r2">Lancet</span> <span class="r1">2008;372:750)</span></p>
<p class="noindent2"><b class="calibre7">Brugada syndrome</b> (Na channelopathy; <span class="r2">JACC</span><span class="r1"> 2018;72:1046</span>): ♂ &gt; ♀; pseudo-RBBB w/ STE in V<sub class="calibre10">1</sub>–V<sub class="calibre10">3</sub> (provoked w/ class IA or IC) on resting ECG</p>
<p class="image1"><img src="../images/00030.jpeg" alt="" class="calibre5"/></p>
<p class="h">Diagnostic clues that favor VT <span class="r">(assume until proven o/w)</span></p>
<p class="noindent1">• <b class="calibre7">Prior MI</b>, <b class="calibre7">CHF</b>, or <b class="calibre7">LV dysfunction</b> <i class="calibre6">best predictors</i> that WCT is VT <span class="r1">(</span><span class="r2">Am J Med</span> <span class="r1">1998;84:53)</span></p>
<p class="noindent1">• Hemodynamics and rate do <i class="calibre6">not</i> reliably distinguish VT from SVT</p>
<p class="noindent1">• MMVT is regular, but initially it may be slightly irregular, mimicking AF w/ aberrancy; <i class="calibre6">grossly</i> irregularly irregular rhythm suggests AF w/ aberrancy or pre-excitation</p>
<p class="noindent1">• ECG features that favor VT <span class="r1">(</span><span class="r2">Circ</span> <span class="r1">2016;133:e506)</span></p>
<p class="noindent2"><i class="calibre6">AV dissociation</i> (independent P waves, capture or fusion beats) proves VT</p>
<p class="noindent2"><i class="calibre6">Very wide QRS</i> (&gt;140 ms in RBBB-type or &gt;160 in LBBB-type); <i class="calibre6">extreme axis deviation</i></p>
<p class="noindent2"><i class="calibre6">QRS morphology atypical for BBB</i> (longest precordial RS &gt;100 ms and R wider than S)</p>
<p class="noindent3">RBBB-type: absence of tall R′ (or presence of monophasic R) in V<sub class="calibre10">1</sub>, r/S ratio &lt;1 in V<sub class="calibre10">6</sub></p>
<p class="noindent3">LBBB-type: onset to nadir &gt;60 ms in V<sub class="calibre10">1</sub>, q wave in V<sub class="calibre10">6</sub></p>
<p class="noindent2"><i class="calibre6">Initial R wave in aVR; concordance</i> (QRS in all precordial leads w/ same pattern/direction)</p>
<p class="h">Long-term management <span class="r1">(</span><span class="r2">EHJ</span> <span class="r1">2015;36:2793;</span> <span class="r2">Circ</span><span class="r1"> 2018;138:e272;</span> <span class="r2">NEJM</span><span class="r1"> 2019;380:1555)</span></p>
<p class="noindent1">• Workup: <b class="calibre7">echo</b> to ✓ LV fxn, <b class="calibre7">cath</b> or <b class="calibre7">stress test</b> to r/o ischemia, ? MRI and/or RV bx to look for infiltrative CMP or ARVC, ? <b class="calibre7">EP study</b> to assess for VT in Pts w/o ICD indication</p>
<p class="noindent1">• <b class="calibre7">ICD:</b> 2° prevention for VT/VF arrest (unless due to reversible cause) or cardiac syncope with inducible VT on EP study. 1° prev. if high risk, eg, EF &lt;30–35% (&gt;40 d after MI, &gt;90 d after revasc), ? ARVC, ? Brugada, certain LQTS, severe HCMP. See “Cardiac Rhythm Mgmt Devices.” Wearable vest if reversible or waiting for ICD? <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2018;379:1205)</span>. Antitachycardia pacing (ATP = burst pacing faster than VT) can terminate VT w/o shock.</p>
<p class="noindent1">• <b class="calibre7">Meds:</b> βB, AAD (amio, sotalol, mexiletine); verapamil if LVOT VT</p>
<p class="noindent1">• If med a/w TdP → QT &gt;500 ± PVCs: d/c med, replete K, give Mg, ± pacing <span class="r1">(</span><span class="r2">JACC</span> <span class="r1">2010;55:934)</span></p>
<p class="noindent1">• <b class="calibre7">Ablate:</b> if isolated VT focus or if recurrent VT triggering ICD firing (↓ VT storm by 34%; <span class="r2">NEJM</span><span class="r1"> 2016;375:111</span>); stereotactic radioablation under investigation <span class="r1">(</span><span class="r2">Circ</span> <span class="r1">2019;139:313)</span>.</p>
<h2 class="ct"><a id="h16" class="calibre8"></a><a id="page_1-36" class="calibre8"></a><a href="part0003.html#rh20" class="calibre8">ATRIAL FIBRILLATION</a></h2>
<p class="h">Classification <span class="r1">(</span><span class="r2">Circ</span> <span class="r1">2014;130:e199)</span></p>
<p class="noindent1">• <b class="calibre7">Paroxysmal</b> (terminates spontaneously or within 7 d) vs. <b class="calibre7">persistent</b> (&gt;7 d) vs. <b class="calibre7">long-standing persistent</b> (&gt;1 y) vs. <b class="calibre7">permanent</b> (no plan for SR)</p>
<p class="noindent1">• <b class="calibre7">Nonvalvular</b> vs. <b class="calibre7">valvular</b> (mechanical heart valve or moderate-severe MS)</p>
<p class="h">Epidemiology and etiologies <span class="r1">(</span><span class="r2">Circ</span> <span class="r1">A&amp;E 2018;11:e006350)</span></p>
<p class="noindent1">• 1–2% of pop. has AF (10% of those age ≥80); M &gt;F; lifetime risk ~25%; mean age 75 y</p>
<p class="noindent1">• Acute (up to 50% w/o identifiable cause)</p>
<p class="noindent2"><b class="calibre7">Cardiac:</b> HF, new CMP, myo/pericarditis, ischemia/MI, HTN crisis, valve dis., cardiac surg</p>
<p class="noindent2"><b class="calibre7">Pulmonary:</b> acute pulmonary disease or hypoxemia (eg, COPD flare, PNA), PE, OSA</p>
<p class="noindent2"><b class="calibre7">Metabolic:</b> high catecholamine states (stress, infection, postop, pheo), thyrotoxicosis</p>
<p class="noindent2"><b class="calibre7">Drugs:</b> alcohol, cocaine, amphetamines, smoking, ibrutinib</p>
<p class="noindent2"><b class="calibre7">Neurogenic:</b> subarachnoid hemorrhage, ischemic stroke</p>
<p class="noindent1">• Chronic: ↑ age, HTN, ischemia, valve dis. (MV, TV, AoV), CMP, hyperthyroidism, obesity</p>
<p class="noindent1">• Aggressive mgmt of HTN, OSA &amp; EtOH <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2020;382:20)</span> to ↓ risk</p>
<p class="h">Evaluation</p>
<p class="noindent1">• H&amp;P, ECG, CXR, TTE (LA size, thrombus, valves, LV fxn, pericardium), K, Mg, Cr, TFTs</p>
<p class="noindent1">• In acute AF &lt;48º, ~70% spont. convert to SR w/in 48 hrs <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2019;380:1499)</span></p>
<div class="cap">
<p class="caption"><a id="fig1-5" class="calibre4"></a><b class="calibre7">Figure 1-5</b> Approach to acute AF (Adapted from <span class="sm"><i class="calibre6">Circ</i> 2014;130:e199)</span></p>
<p class="imagef1"><img src="../images/00031.jpeg" alt="" class="calibre5"/></p>
</div>
<p class="imaget"><img src="../images/00032.jpeg" alt="" class="calibre5"/></p>
<p class="tfn"><i class="calibre6">Lancet</i> 2016;388:818. IV βB, CCB &amp; dig <b class="calibre7"><i class="calibre6">contraindic.</i></b> if evidence (ie, pre-excitation or WCT) of WPW (qv).</p>
<p class="tfn"><sup class="calibre22"><a id="rfn29-s2" class="calibre8"></a>*</sup>Many meds incl. amio, verapamil, quinidine, propafenone, macrolides &amp; azole antifungals ↑ digoxin levels.</p>
<p class="h">Cardioversion</p>
<p class="noindent1">• Consider if: 1<sup class="calibre19">st</sup> AF, sx, tachycardia-mediated CMP, or difficult to rate control</p>
<p class="noindent2">If AF &gt;48 h 2–5% risk stroke w/ cardioversion (<i class="calibre6">pharmacologic or electric</i>) ∴ either TEE to r/o thrombus or ensure therapeutic anticoagulation ≥3 wk prior</p>
<p class="noindent2">If needs to cardiovert urgently, often anticoagulate acutely (eg, IV UFH)</p>
<p class="noindent1">• For AF &lt;36 hrs, no Δ in % in SR at 4 wks w/ early cardioversion vs. wait &amp; see (βb + a/c), with spont cardioversion in 69% and cardioversion required in 28% <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2019;380:1499)</span></p>
<p class="noindent1">• Likelihood of success ∝ AF duration &amp; atrial size; control precipitants (eg, vol status, thyroid)</p>
<p class="noindent1">• Before electrical cardiovert, consider pre-Rx w/ AAD (eg, ibutilide), esp. if 1<sup class="calibre19">st</sup> cardiovert failed</p>
<p class="noindent1">• For pharmacologic cardioversion, class III and IC drugs have best proven efficacy</p>
<p class="noindent1">• If SR returns (spont. or w/ Rx), atria may be <i class="calibre6">mech. stunned;</i> also, high risk of recurrent AF over next 3 mo. ∴ <b class="calibre7">Anticoag postcardioversion</b> ≥<b class="calibre7">4 wk</b> (? unless AF &lt;48 h and low risk).</p>
<p class="h"><a id="page_1-37" class="calibre4"></a>Rhythm control <span class="r1">(</span><span class="r2">Lancet</span> <span class="r1">2016;388:829)</span></p>
<p class="noindent1">• Consider if <i class="calibre6">sx</i> w/ rate control (eg, HF), difficult to control rate, or tachycardia-mediated CMP</p>
<p class="noindent1">• If minimally sx or asx, previously no clear benefit vs. rate control <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2008;358:2667)</span></p>
<p class="noindent1">• For recent AF (~1 mo), rhythm-control w/ AAD (flecainide, amio) &amp; cardioversion (if persist. AF) superior to usual care for achieving SR and ↓ adverse CV events <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2020;383:1305)</span></p>
<p class="imaget"><img src="../images/00033.jpeg" alt="" class="calibre5"/></p>
<p class="h">Ablation <span class="r1">(</span><span class="r2">Heart Rhythm</span> <span class="r1">2017;14:e445;</span> <span class="r2">JACC</span><span class="r1"> 2020;75:1689)</span></p>
<p class="noindent1">• Controlling triggers in pulm veins effective when little atrial fibrosis; as AF persists, substrate more complex</p>
<p class="noindent1">• Pulm vein isolation (radiofreq or cryo; <span class="r2">NEJM</span><span class="r1"> 2016;374:2235</span>): ~70% success; superior to AAD <span class="r1">(</span><span class="r2">JAMA</span> <span class="r1">2014;311:692;</span> <span class="r2">NEJM</span><span class="r1"> 2021;384:305 &amp; 316)</span> &amp; ↑ QoL <span class="r1">(</span><span class="r2">JAMA</span> <span class="r1">2019;321:1059)</span></p>
<p class="noindent1">• If NYHA II–IV + EF &lt;35%, ablation ↓ D/HF hosp vs. rate/rhythm meds <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2018;378:417)</span></p>
<p class="noindent1">• AV node ablation + PPM if other Rx inadequate <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2001;344:1043 &amp; 2002;346:2062)</span></p>
<p class="h">Oral anticoagulation <span class="r1">(</span><span class="r2">Circ</span><span class="r1"> 2014;130:e199 &amp; 2019;140:125;</span> <span class="r2">EHJ</span><span class="r1"> 2021;42:373)</span></p>
<p class="noindent1">• <i class="calibre6">All valvular AF</i> because stroke risk very high</p>
<p class="noindent1">• Nonvalvular AF (NVAF): stroke risk ~4.5%/y but varies; a/c → 68% ↓ stroke but ↑ bleeding</p>
<p class="noindent1">• <b class="calibre7">CHA<sub class="calibre10">2</sub>DS<sub class="calibre10">2</sub></b>-<b class="calibre7">VASc</b> to guide Rx: <b class="calibre7">C</b>HF (1 point); <b class="calibre7">H</b>TN (1); <b class="calibre7">A</b>ge ≥75 y (2); <b class="calibre7">D</b>M (1), <b class="calibre7">S</b>troke/TIA (2); <b class="calibre7">V</b>ascular disease (eg, MI, PAD, Ao plaque) (1); <b class="calibre7">A</b>ge 65–74 (1); ♀ <b class="calibre7">S</b>ex <b class="calibre7">c</b>ategory (1)</p>
<p class="noindent2">Annual risk of stroke <span class="r1">(</span><span class="r2">Lancet</span> <span class="r1">2012;379:648)</span>: at low end, ~1% per point: 0 → ~0%, 1 → 1.3%, 2 → 2.2%, 3 → 3.2%, 4 → 4.0%; at higher scores, risk ↑↑ (5 → 6.7%, ≥6 → ≥10%)</p>
<p class="noindent1">• <b class="calibre7">Score</b> <b class="calibre7">2 in</b> ♂ <b class="calibre7">or</b> <b class="calibre7">3 in</b> ♀→ <b class="calibre7">anticoagulate;</b> scores 1 in ♂ or 2 in ♀ → <b class="calibre7">consider anticoag</b> or ASA or no Rx; <b class="calibre7">score 0</b> → reasonable to not Rx</p>
<p class="noindent1">• <b class="calibre7">Rx options: DOAC</b> (NVAF only) prefered over warfarin (INR 2–3); if Pt refuses anticoag, ASA + clopi or, even less effective, ASA alone <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2009;360:2066)</span></p>
<p class="noindent1">• AF + CAD/ PCI: consider DOAC + clopi (not ticag or prasugrel) + ASA (d/c ~1–4 wks) <span class="r1">(</span><span class="r2">Circ</span> <span class="r1">2021;143:583)</span>; consider DOAC only after 12 mos <span class="r1">(</span><span class="r2">JACC</span> <span class="r1">2021;77:629)</span></p>
<p class="noindent1">• If concern for procedural bleed, interrupt OAC (1–2 d DOAC, 4–5 d VKA). If CHA<sub class="calibre10">2</sub>DS<sub class="calibre10">2</sub>-VASc ≥7 (or ≥5 w/ h/o CVA/TIA), consider bridge w/ UFH/LMWH, otherwise do not <span class="r1">(</span><span class="r2">JACC</span> <span class="r1">2017;69:735)</span>.</p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre12"/>
<col class="calibre33"/>
<col class="calibre34"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="3"><p class="tbodyc"><b class="calibre7">Direct Oral Anticoagulants (DOACs) for NVAF</b> <span class="sm">(<i class="calibre6">Lancet</i> 2014;383:955)</span></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Anticoag</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Dosing</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Efficacy &amp; Safety vs. Warfarin</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Apixaban</b></p>
<p class="tbody">(FXa inhib)</p></td>
<td class="th1"><p class="tbody">5 mg bid (2.5 mg bid if ≥ 2 of: ≥80 y, ≤60 kg, Cr ≥1.5 mg/dL)</p></td>
<td class="th1"><p class="tbody">≈ ischemic stroke &amp; ↓ major bleed incl ICH,</p>
<p class="tbody">11% ↓ death. In Pts felt not cand for warfarin, apixa 55% ↓ stroke w/o ↑ bleed vs ASA alone.</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Rivaroxaban</b></p>
<p class="tbody">(FXa inhib)</p></td>
<td class="th1"><p class="tbody">20 mg qd (15 mg qd if CrCl 15–50) w/ pm meal</p></td>
<td class="th1"><p class="tbody">≈ ischemic stroke &amp; major bleeds, but ↓ fatal bleed incl ICH</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Edoxaban</b></p>
<p class="tbody">(Fxa inhib)</p></td>
<td class="th1"><p class="tbody">60 mg qd if CrCl 51–95 (30 mg if CrCl 15–50)</p></td>
<td class="th1"><p class="tbody">≈ ischemic stroke &amp; ↓ major bleed incl ICH, 14% ↓ CV death. ↑ ischemic CVA if CrCl &gt;95.</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Dabigatran</b></p>
<p class="tbody">(Thromb inhib)</p></td>
<td class="th1"><p class="tbody">150 mg bid (75 mg bid if CrCl 15–30)</p></td>
<td class="th1"><p class="tbody">150 mg: ↓ ischemic stroke &amp; ICH, but ↑ GIB</p>
<p class="tbody">Risks: GI side effects, ↑ MI c/w warfarin</p></td>
</tr>
<tr class="calibre15">
<td colspan="3" class="th1"><p class="tbody">Onset w/in hrs. Reversal: andexanet for FXa inhib; idarucizumab for dabi; 4F-PCC.</p></td>
</tr>
</tbody>
</table>
<p class="h">Nonpharmacologic stroke prevent <span class="r1">(</span><span class="r2">JACC</span> <span class="r1">2015;66:1497)</span></p>
<p class="noindent1">• If contraindic. to long-term OAC, consider perc. left atrial appendage (LAA) occlusion <span class="r1">(</span><span class="r2">JACC</span> <span class="r1">2022;79:1)</span>. Nb, ideally warfarin + ASA × 45 d → DAPT out to 6 mo → ASA.</p>
<p class="noindent1">• Consider surgical LAA occlusion if undergoing cardiac surgery <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2021;384:2081)</span></p>
<p class="h">Atrial flutter</p>
<p class="noindent1">• Macroreentrant atrial loop. Typical involves cavotricuspid isthmus (if counterclockwise, flutter waves ⊖ in inf leads, if clockwise, ⊕). Atypical: other pathways related to prior scar.</p>
<p class="noindent1">• Risk of stroke similar to that of AF, ∴ anticoagulate same as would for AF</p>
<p class="noindent1">• Ablation of typical (cavotricuspid isthmus) AFL has 95% success rate</p>
<h2 class="ct"><a id="h17" class="calibre8"></a><a id="page_1-38" class="calibre8"></a><a href="part0003.html#rh21" class="calibre8">SYNCOPE</a></h2>
<p class="h">Definition</p>
<p class="noindent1">• Symptom of sudden transient loss of consciousness due to global cerebral hypoperfusion</p>
<p class="noindent1">• If CPR or cardioversion required, then SCD and not syncope (different prognosis)</p>
<p class="noindent1">• Presyncope = prodrome of light-headedness without LOC</p>
<p class="h">Etiologies <span class="r1">(</span><span class="r2">JACC</span> <span class="r1">2017;70:e39;</span> <span class="r2">EHJ</span><span class="r1"> 2018;39:1883)</span></p>
<p class="noindent1">• <b class="calibre7">Vasovagal</b> (a.k.a. neurocardiogenic, ~25%): ↑ sympathetic tone → vigorous contraction of LV → LV mechanoreceptors trigger ↑ vagal tone (hyperactive Bezold-Jarisch reflex) → ↓ HR (cardioinhib.) and/or ↓ BP (vasodepressor). Cough, deglutition, defecation, &amp; micturition → ↑ vagal tone and thus can be precipitants. Carotid sinus hypersensitivity (exag vagal resp to carotid massage) is related disorder.</p>
<p class="noindent1">• <b class="calibre7">Orthostatic hypotension</b> (~10%)</p>
<p class="noindent2">hypovolemia/diuretics, deconditioning; vasodilat. (esp. if combined w/ ⊖ chronotropes)</p>
<p class="noindent2">autonomic neuropathy [1° = Parkinson’s, MSA/Shy-Drager, Lewy body dementia, POTS (dysautonomia in the young); 2° = DM, EtOH, amyloidosis, CKD] <span class="r1">(</span><span class="r2">JACC</span> <span class="r1">2018;72:1294)</span></p>
<p class="noindent1">• <b class="calibre7">Cardiovascular</b> (~20%, more likely in men than women)</p>
<p class="noindent2"><i class="calibre6">Arrhythmia</i> (~15%): challenging to dx because often transient</p>
<p class="noindent3">Bradyarrhythmias: SB, SSS, high-grade AV block, ⊖ chronotropes, PPM malfunction</p>
<p class="noindent3">Tachyarrhythmias: VT, SVT (syncope rare unless structural heart disease or WPW)</p>
<p class="noindent2"><i class="calibre6">Mechanical</i> (5%)</p>
<p class="noindent3">Endocardial/Valvular: critical AS, MS, PS, prosthetic valve thrombosis, myxoma</p>
<p class="noindent3">Myocardial: outflow obstruction from HCMP (or VT); pericardial: tamponade</p>
<p class="noindent3">Vascular: PE (in ~25% w/o alt dx; <span class="r2">NEJM</span><span class="r1"> 2016;375:1524</span>), PHT, AoD, ruptured AAA</p>
<p class="noindent1">• <b class="calibre7">Neurologic</b> (~10%): vertebrobasil insuff, cerebrovasc dissection, SAH, TIA/CVA</p>
<p class="noindent1">• Misc. causes of LOC (but not syncope): seizure, ↓ glc, hypoxia, narcolepsy, psychogenic</p>
<p class="h">Workup <span class="r">(etiology cannot be determined in ~40% of cases)</span> <span class="r1">(</span><span class="r2">JAMA</span> <span class="r1">2019;321:2448)</span></p>
<p class="noindent1">• <i class="calibre6">H&amp;P incl. orthostatic VS have highest yield and most cost effective</i></p>
<p class="noindent1">• <i class="calibre6">R/o life-threatening dx including: cardiac syncope, severe blood loss, PE, SAH</i></p>
<p class="noindent1">• <b class="calibre7">History</b> (from Pt and <i class="calibre6">witnesses</i> if available)</p>
<p class="noindent2">activity and posture before the incident</p>
<p class="noindent2">precipitating factors: exertion (AS, HCMP, PHT), positional ∆ (orthostatic HoTN), stressors such as sight of blood, pain, emotional distress, fatigue, prolonged standing, warm environment, N/V, cough/deglutition/micturition/defecation (neurocardiogenic), head turning or shaving (carotid sinus hypersens.); arm exercise (subclavian steal)</p>
<p class="noindent2">sudden onset → cardiac; prodrome (eg, diaphoresis, nausea, blurry vision) → vasovagal</p>
<p class="noindent2">associated sx: chest pain, palp., neurologic, postictal, bowel/bladder incontinence, (convulsive activity for &lt;10 sec may occur w/ transient cerebral HoTN &amp; mimic seizure)</p>
<p class="noindent1">• <b class="calibre7">PMH:</b> prior syncope, previous cardiac or neuro dis.; cardiac more likely if &gt;35 y, known structural heart dis., h/o AF, CV prodrome, syncope while supine or exertional, cyanosis</p>
<p class="noindent1">• <b class="calibre7">Medications that may act as precipitants</b></p>
<p class="noindent2">vasodilators: α-blockers, nitrates, ACEI/ARB, CCB, hydralazine, phenothiazines, antidep.</p>
<p class="noindent2">diuretics; ⊖ chronotropes (eg, βB and CCB)</p>
<p class="noindent2">proarrhythmic or QT prolonging: class IA, IC or III antiarrhythmics (see “ECG”)</p>
<p class="noindent2">psychoactive drugs: antipsychotics, TCA, barbiturates, benzodiazepines, EtOH</p>
<p class="noindent1">• <b class="calibre7">Family history:</b> CMP, SCD, syncope (vasovagal may have genetic component)</p>
<p class="noindent1">• <b class="calibre7">Physical exam</b></p>
<p class="noindent2"><b class="calibre7">VS incl. <i class="calibre6">orthostatics</i></b> (⊕ if supine → standing results in ≥20 mmHg ↓ SBP or ≥10 ↓ DBP or SBP &lt;90 mmHg w/in 3 min; POTS if ≥30 bpm ↑ HR w/in 10 min), BP in both arms</p>
<p class="noindent2">Cardiac: HF (↑ JVP, displ. PMI, S<sub class="calibre10">3</sub>), murmurs, LVH (S<sub class="calibre10">4</sub>, LV heave), PHT (RV heave, ↑ P<sub class="calibre10">2</sub>)</p>
<p class="noindent2">Vascular: ✓ for <i class="calibre6">asymmetric pulses</i>, carotid/vert/subclavian <i class="calibre6">bruits; carotid sinus massage</i> to ✓ for carotid hypersens (if no bruits): ⊕ if asystole &gt;3 sec or ↓ SBP &gt;50 mmHg</p>
<p class="noindent2">Neurologic exam: focal findings, evidence of tongue biting</p>
<p class="noindent1">• <b class="calibre7">ECG</b> (abnormal in ~50%, but only definitively identifies cause of syncope in &lt;10%)</p>
<p class="noindent2">Conduction: SB &lt;40 bpm, sinus pauses &gt;3 sec or sinus arrhythmia, AVB, BBB/IVCD</p>
<p class="noindent2">Arrhythmia: ectopy, ↑ or ↓ QT, preexcitation (WPW), Brugada, ε wave (ACM), SVT/VT</p>
<p class="noindent2">Ischemic changes (new or old): atrial or ventricular hypertrophy</p>
<p class="noindent1">• Lab: glc, Hb, HCG (pre-menop ♀), ? D-dimer, ? troponin/NT-proBNP (↓ yield w/o other s/s)</p>
<p class="h">Other diagnostic studies <span class="r">(consider based on results of H&amp;P and ECG)</span></p>
<p class="noindent1">• Ambulatory ECG monitoring: if suspect arrhythmogenic syncope</p>
<p class="noindent2">Holter monitoring (continuous ECG 24–72 h): useful if <i class="calibre6">frequent</i> events</p>
<p class="noindent2">Event recorder (activated by Pt to record rhythm): limited role if LOC w/o prodrome</p>
<p class="noindent2">External loop recorder (continuously saves rhythm, ∴ can be activated <i class="calibre6">after</i> an event): useful for episodes (including w/o prodrome) likely to occur w/in 2–6 wks; can be coupled w/ mobile cardiac telemetry than can be auto-triggered for specific rhythms</p>
<p class="noindent2"><a id="page_1-39" class="calibre4"></a>External <i class="calibre6">patch</i> recorder (1-lead recording; saves for 1–4 wks): Pt-activated or auto-triggered; more comfortable for Pts</p>
<p class="noindent2"><i class="calibre6">Implantable</i> loop recorders (SC; can record 2–3 y; can be triggered): useful if episodes &lt;1/mo; dx in 55% of cases; recommended for recurrent syncope w/o prodrome</p>
<p class="noindent1">• Echo: consider to r/o structural heart disease (eg, CMP [incl HCMP &amp; ARVC], valvular disease [incl AS, MS, MVP], myxoma, amyloid, PHT, ± anomalous coronaries)</p>
<p class="noindent1">• ETT/CCTA/Cath: esp. w/ exertional syncope; r/o ischemia or catechol-induced arrhythmia</p>
<p class="noindent1">• Electrophysiologic studies (EPS): consider in high-risk Pts in whom tachy or brady etiology is strongly suspected (eg, prior MI), but cannot be confirmed; avoid if ECG/Echo normal.</p>
<p class="noindent2">50% abnl (inducible VT, conduction abnormalities) if heart disease, but ? significance</p>
<p class="noindent2">3–20% abnl if abnl ECG; &lt;1% abnl if normal heart and normal ECG</p>
<p class="noindent1">• Tilt table: debated utility due to poor Se/Sp/reproducibility; consider if suspected neuro- cardiogenic, orthostatic HoTN, POTS, or psychogenic, and initial eval unrevealing</p>
<p class="noindent1">• Cardiac MRI: helpful to dx sarcoid or ARVC if suggestive ECG, echo (RV dysfxn) or ⊕ FHx</p>
<p class="noindent1">• Neurologic studies (cerebrovascular studies, CT, MRI, EEG): if H&amp;P suggestive; low yield</p>
<div class="cap">
<p class="caption"><a id="fig1-6" class="calibre4"></a><b class="calibre7">Figure 1-6</b> Approach to syncope</p>
<p class="imagef1"><img src="../images/00034.jpeg" alt="" class="calibre5"/></p>
</div>
<p class="tfn">(Adapted from <i class="calibre6">JACC</i> 2017;70:e39)</p>
<p class="h">High-risk features <span class="r">(admit w/ tele;</span> <span class="r2">JACC</span><span class="r1"> 2017;70:620;</span> <span class="r2">EHJ</span> <span class="r1">2018;39:1883)</span></p>
<p class="noindent1">• Age &gt;60 y, h/o CAD, HF/CMP, valvular or congenital heart dis., arrhythmias, FHx SCD</p>
<p class="noindent1">• Syncope c/w cardiac cause (⊖ prodrome, exertional, supine, trauma) or recurrent</p>
<p class="noindent1">• Complaint of chest pain or dyspnea; abnl VS, cardiac, pulm, or neuro exam; low Hct</p>
<p class="noindent1">• ECG suggesting conduction abnormality, arrhythmia, or ischemia; Pt w/ PPM/ICD</p>
<p class="noindent1">• Canadian Syncope Risk Score <span class="r1">(</span><span class="r2">CMAJ</span> <span class="r1">2016;188:e289)</span> stratifies from &lt;1% to &gt;20% risk of serious arrhythmias. If low-risk &amp; no arrhythmia in ED × 2 h, 0.2% risk over 30 d.</p>
<p class="h">Treatment <span class="r1">(</span><span class="r2">JACC</span><span class="r1"> 2017;70:620 &amp; 2019;74:2410;</span> <span class="r2">EHJ</span> <span class="r1">2018;39:1883)</span></p>
<p class="noindent1">• Arrhythmia, cardiac mechanical or neurologic syncope: treat underlying disorder, ? ICD if Brugada pattern, sarcoid, ARVC, early repol + syncope</p>
<p class="noindent1">• Vasovagal: avoidance of triggers; physical counterpressure; consider ↑ Na &amp; fluid intake, fludrocortisone or midodrine <span class="r1">(</span><span class="r2">JACC</span> <span class="r1">2016;68:1;</span> <span class="r2">Ann Intern Med</span><span class="r1"> 2021;174:1349)</span>; SSRI; ? βB;</p>
<p class="noindent2">consider PPM if recurrent + pauses on recorder or tilt test <span class="r1">(</span><span class="r2">EHJ</span> <span class="r1">2021;42:508)</span></p>
<p class="noindent1">• Orthostatic: 2–3 L fluid &amp; 10 g Na per day; rise from supine to standing <i class="calibre6">slowly</i>, compression stockings; consider: midodrine, fludrocortisone, droxidopa, ? pyridostigmine, ? octreotide</p>
<p class="h">Prognosis <span class="r1">(</span><span class="r2">Ann Emerg Med</span> <span class="r1">1997;29:459;</span> <span class="r2">NEJM</span> <span class="r1">2002;347:878)</span></p>
<p class="noindent1">• 22% overall recurrence rate if idiopathic, else 3% recurrence</p>
<p class="noindent1">• Cardiac syncope has poor prognosis (20–40% 1-y SCD rate); vasovagal good prognosis</p>
<p class="noindent1">• Unexplained syncope w/ 1.3-fold ↑ in mort., but noncardiac or unexplained syncope w/ nl</p>
<p class="noindent2">ECG, no h/o VT, no HF, age &lt;45 → low recurrence rate and &lt;5% 1-y SCD rate</p>
<p class="noindent1">• ✓ state driving laws and MD reporting requirements. Consider appropriateness of Pt involvement in exercise/sport, operating machinery, high-risk occupation (eg, pilot).</p>
<h2 class="ct"><a id="h18" class="calibre8"></a><a id="page_1-40" class="calibre8"></a><a href="part0003.html#rh22" class="calibre8">CARDIAC RHYTHM MANAGEMENT DEVICES</a></h2>
<p class="imaget"><img src="../images/00035.jpeg" alt="" class="calibre5"/></p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre23"/>
<col class="calibre35"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="2"><p class="tbodyc"><b class="calibre7">Common Pacing Modes</b></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">VVI</b></p></td>
<td class="th1"><p class="tbody">Ventricular pacing on demand w/ single lead in RV. Sensed ventricular beat inhibits V pacing. Used in chronic AF with symptomatic bradycardia.</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">DDD</b></p></td>
<td class="th1"><p class="tbody">A &amp; V sensing/pacing (RA &amp; RV leads). Native A beat inhib A pacing &amp; <i class="calibre6">triggers V pacing</i> → tracking of intrinsic atrial activity. Maintains AV synchrony, ↓ AF.</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Mode Switch</b></p></td>
<td class="th1"><p class="tbody">In atrial tachyarrhythmia (eg, AF), PPM ∆s from DDD to nontracking mode (eg, VVI). Prevents PPM from pacing at max V rate in response to rapid atrial rate.</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Magnet</b> over generator</p></td>
<td class="th1"><p class="tbody">PPM: fixed rate pacing (VOO/DOO). ICD: no shock, pacing preserved.</p>
<p class="tbody">Indic: ✓ capture; surgery; inapprop PPM inhib/ICD shock, PM-mediated tachy</p></td>
</tr>
<tr class="calibre15">
<td class="th1" colspan="2"><p class="tbody"><i class="calibre6">Leadless</i> intracardiac PPM for RV or AV synchronous pacing <span class="sm">(<i class="calibre6">JACC Clin EP</i> 2020;6:94)</span>. His or L bundle pacing: more physiologic than RV pacing or even CRT <span class="sm">(<i class="calibre6">JACC</i> 2018;72:927)</span>.</p></td>
</tr>
</tbody>
</table>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre23"/>
<col class="calibre35"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="2"><p class="tbodyc"><b class="calibre7">Indications for Permanent Pacing</b> <span class="sm">(<i class="calibre6">JACC</i> 2013;61:e6 &amp; 2017;70:e39, <i class="calibre6">Circ</i> 2019;140:e382)</span></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">AV block</b></p></td>
<td class="th1"><p class="tbody">2° type II, high-grade or 3° AVB; symptomatic 1°, 2° type I AVB or asx with Lamin A/C or neuromuscular disease; bifasc or alter. L &amp; RBBB</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Sinus node</b></p></td>
<td class="th1"><p class="tbody">SB, pauses (SSS), chronotrop incompet a/w sx or ? if sx w/o clear assoc</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Tachy-arrhythmia</b></p></td>
<td class="th1"><p class="tbody">AF w/ SSS; sx recurrent SVT term. by pacing after failing drugs/ablation; Sustained pause-dependent VT; ? high-risk congenital long QT</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Syncope</b></p></td>
<td class="th1"><p class="tbody">Carotid sinus hypersensitivity with asystole &gt;3 sec</p>
<p class="tbody">Syncope with bi- or trifascicular block and HV&gt;70 ms on EP study</p>
<p class="tbody">? Recurrent vasovagal syncope w/ abnormal tilt test <span class="sm">(<i class="calibre6">JACC</i> 2017;70:1720)</span></p></td>
</tr>
</tbody>
</table>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre12"/>
<col class="calibre33"/>
<col class="calibre34"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="3"><p class="tbodyc"><b class="calibre7">Pacemaker Complications</b></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Issue</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Manifestation</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Description &amp; etiologies</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Perforation</p></td>
<td class="th1"><p class="tbody">Effusion/tamp/pain</p></td>
<td class="th1"><p class="tbody">Typically acute, consider if HoTN</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Failure to pace</p></td>
<td class="th1"><p class="tbody">Bradycardia</p></td>
<td class="th1"><p class="tbody">↓ Battery, lead fx/dislodgment, ↑ pacing threshold due to tissue rxn/injury; oversense → inapprop. inhib</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Failure to sense</p></td>
<td class="th1"><p class="tbody">Inapprop. pacing</p></td>
<td class="th1"><p class="tbody">Lead dislodgment or sensing threshold too high</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">PM-mediated tachycardia</p></td>
<td class="th1"><p class="tbody">WCT at device upper rate</p></td>
<td class="th1"><p class="tbody">Seen w/ DDD. V → A retrograde conduction; sensed by A lead → triggers V pacing → etc.</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">PM syndrome</p></td>
<td class="th1"><p class="tbody">Palpit, HF</p></td>
<td class="th1"><p class="tbody">Seen w/ VVI, due to loss of AV synchrony</p></td>
</tr>
</tbody>
</table>
<p class="h">Cardiac resynch therapy (CRT)/Biventricular (BiV) pacing <span class="r1">(</span><span class="r2">JACC</span> <span class="r1">2013;61:e6)</span></p>
<p class="noindent1">• 3-lead pacemaker (RA, RV, coronary sinus to LV); R &gt;S in V<sub class="calibre10">1</sub> suggests approp LV capture</p>
<p class="noindent1">• Synch LV fxn (↑ CO/EF, ↓ adv remodeling); ↓ HF sx &amp; hosp, ↑ survival <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2010;363:2385)</span></p>
<p class="noindent1">• <b class="calibre7">Indications:</b> LVEF ≤35% + NYHA II–IV despite med Rx + SR + LBBB ≥150 ms (also reasonable if LBBB ≥120 ms, any non-LBBB ≥150 ms, or &gt;40% V-pacing); mort. benefit w/ CRT-D only if LBBB (&amp; QRS ≥130 ms) <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2014;370:1694)</span></p>
<p class="noindent2">? benefit in NYHA I–III, EF ≤50% w/ PPM indication for AVB <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2013;368:1585)</span></p>
<p class="h">Implantable cardiac defibrillator (ICD) <span class="r1">(</span><span class="r2">Circ</span> <span class="r1">2019;140:e382)</span></p>
<p class="noindent1">• RV lead: defib &amp; pacing (± antitachycardia pacing [ATP] = burst pacing &gt; VT rate to stop VT); ± RA lead for dual-chamber PPM. Subcut-ICD (consider if young), but Ø pace/ATP.</p>
<p class="noindent1">• <b class="calibre7">2° prev</b>: survivors of VT/VF arrest w/o revers cause; asx sustained VT + struct. heart dis.</p>
<p class="noindent1">• <b class="calibre7"><sub class="calibre10">1</sub>° prev</b>: <span class="underline">IHD</span> (wait ≥40 d after MI): LVEF ≤30% <i class="calibre6">or</i> ≤35% &amp; NYHA II–III <i class="calibre6">or</i> ≤40%, spont NSVT &amp; inducible. <span class="underline">NICM (wait</span> ≥90 d after starting GDMT): LVEF ≤35% &amp; NYHA II–III. <span class="underline">High-risk CMP</span> (w/o meeting above criteria): HCM, ACM, sarcoid, laminopathy, Chagas. <span class="underline">Channelopathies</span>: LQTS or Brugada if syncope or high-risk. <span class="underline">ACHD</span>: if SCD risk factors.</p>
<p class="noindent2">More recently, for niCMP ICD ↓ SCD but not overall mortality <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2016;375:1221)</span>.</p>
<p class="noindent2"><i class="calibre6">Life expectancy must be</i> &gt;<i class="calibre6">1 y.</i></p>
<p class="noindent1">• Wearable vest as bridge while waiting for ICD, but no benefit in RCT <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2018;379:1205)</span></p>
<p class="noindent1">• Subcutaneous ICD non-inferior in patients without PPM indication <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2020;383:526)</span></p>
<p class="noindent1">• <b class="calibre7">Risks:</b> inapprop shock in ~15–20% at 3 y (commonly d/t misclassified SVT); infxn; lead fx</p>
<p class="noindent1">• ICD discharge: ✓ device to see if approp; r/o ischemia; 6-mo driving ban (✓ state law)</p>
<p class="noindent1">• MRI: new devices OK; older may be OK <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2017;377:2555)</span>. Consult prescan.</p>
<p class="h">Device infection <span class="r1">(</span><span class="r2">Heart Rhythm</span> <span class="r1">2017;14:e503,</span> <span class="r2">NEJM</span> <span class="r1">2019;380:1895)</span></p>
<p class="noindent1">• Presents as <i class="calibre6">pocket infection</i> (warmth, erythema, tenderness) and/or <i class="calibre6">sepsis w</i>/ <i class="calibre6">bacteremia</i></p>
<p class="noindent1">• ~2% over 5 y; if <i class="calibre6">S. aureus</i> bacteremia, infxn in ≥35%; antibacterial envelope ↓ risk</p>
<p class="noindent1">• TTE/TEE used to help visualize complic. (eg, vegetation), but even ⊖ TEE does not r/o</p>
<p class="noindent1">• Rx: abx; system removal if pocket infxn or GPC bacteremia; Ø routine abx prior to inv. proc.</p>
<h2 class="ct"><a id="h19" class="calibre8"></a><a id="page_1-41" class="calibre8"></a><a href="part0003.html#rh23" class="calibre8">CARDIAC RISK ASSESSMENT FOR NONCARDIAC SURGERY</a></h2>
<p class="center"><i class="calibre6">Goal: characterize risk of Pt &amp; procedure → appropriate testing (ie, results will ∆ management) and interventions (ie, reasonable probability of ↓ risk of MACE)</i></p>
<p class="h">Preoperative evaluation <span class="r1">(</span><span class="r2">Circ</span> <span class="r1">2014;130:e278,</span> <span class="r2">NEJM</span> <span class="r1">2015;373:2258,</span> <span class="r2">JAMA</span><span class="r1"> 2020;324:279)</span></p>
<div class="cap">
<p class="caption"><a id="fig1-7" class="calibre4"></a><b class="calibre7">Figure 1-7</b> Approach to preop CV eval for non-CV surgery</p>
<p class="imagef1"><img src="../images/00036.jpeg" alt="" class="calibre5"/></p>
</div>
<p class="tfn">(Modified with permission <i class="calibre6">Circulation</i>. 2014;130:2215-2245 © 2014 American Heart Association, Inc.)</p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre34"/>
<col class="calibre20"/>
<col class="calibre23"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="3"><p class="tbodyc"><b class="calibre7">Noninvasive Testing Result</b></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">High Risk</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Intermediate Risk</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Low Risk</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7"><i class="calibre6">Ischemia at</i></b> &lt;<b class="calibre7"><i class="calibre6">4 METs</i></b> <i class="calibre6">manifested by</i> ≥1 <i class="calibre6">of:</i></p>
<p class="tnl"><span class="tft">•</span> Horiz/down ST ↓ ≥1 mm or STE</p>
<p class="tnl"><span class="tft">•</span> ≥5 abnl leads or ischemic ECG ∆s</p>
<p class="tnl"><span class="tft">•</span> lasting &gt;3 min after exertion</p>
<p class="tnl"><span class="tft">•</span> SBP ↓ 10 mmHg or typical angina</p></td>
<td class="th1"><p class="tbody"><b class="calibre7"><i class="calibre6">Ischemia at</i></b> &lt;<b class="calibre7">4–6 <i class="calibre6">METs</i></b> <i class="calibre6">manifested by</i> ≥1 <i class="calibre6">of:</i></p>
<p class="tnl"><span class="tft">•</span> Horiz/down ST ↓ ≥1 mm</p>
<p class="tnl"><span class="tft">•</span> 3–4 abnl leads</p>
<p class="tnl"><span class="tft">•</span> 1–3 min after exertion</p></td>
<td class="th1"><p class="tbody"><b class="calibre7"><i class="calibre6">No ischemia or at</i></b> &lt;<b class="calibre7">7 METs w/</b></p>
<p class="tnl"><span class="tft">•</span> ST ↓ ≥1 mm or</p>
<p class="tnl"><span class="tft">•</span> 1–2 abnl leads</p></td>
</tr>
</tbody>
</table>
<p class="h">Additional preoperative testing <span class="r1">(</span><span class="r2">Circ</span> <span class="r1">2014;130:e278)</span></p>
<p class="noindent1">• ECG if known cardiac disease and possibly reasonable in all, except if low-risk surgery</p>
<p class="noindent1">• TTE if any of following &amp; prior TTE &gt;12 mo ago or prior to ∆ in sx: dyspnea of unknown origin; hx of HF w/ ↑ dyspnea; suspect (eg, murmur) or known ≥moderate valvular dis.</p>
<p class="h">Coronary artery disease</p>
<p class="noindent1">• If possible, wait ~60 d after MI in the absence of revascularization before elective surgery</p>
<p class="noindent1">• Coronary revasc guided by standard indications. Has not been shown to ∆ risk of death or postop MI when done prior to elective vasc. surgery <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2004;351:2795)</span>.</p>
<p class="h">Heart failure <span class="r1">(</span><span class="r2">Circ</span> <span class="r1">2014;130:e278)</span></p>
<p class="noindent1">• Decompensated HF should be optimally Rx’d prior to elective surgery</p>
<p class="noindent1">• 30-d CV event rate: symptomatic HF &gt;asx HFrEF &gt;asx HFpEF &gt;no HF</p>
<p class="h">Valvular heart disease</p>
<p class="noindent1">• If meet criteria for valve intervention, do so before elective surgery (postpone if necessary)</p>
<p class="noindent1">• If severe valve disease and surgery urgent, intra- &amp; postoperative hemodynamic monitoring reasonable (espec for AS, because at ↑ risk even if sx not severe; be careful to maintain preload, avoid hypotension, and watch for atrial fibrillation)</p>
<p class="h"><a id="page_1-42" class="calibre4"></a>Cardiac implantable electronic devices</p>
<p class="noindent1">• Discuss w/ surgical team need for device (eg, complete heart block) &amp; consequences if interference w/ fxn, and likelihood of electromagnetic interference</p>
<p class="noindent1">• Consider reprogramming, magnet use, etc. as needed</p>
<p class="h">Pre- &amp; perioperative pharmacologic management</p>
<p class="noindent1">• <b class="calibre7">ASA:</b> continue in Pts w/ existing indication. Initiation prior to surgery does not ↓ 30-d ischemic events and ↑ bleeding <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2014;370:1494)</span>, but Pts w/ recent stents excluded.</p>
<p class="noindent1">• <b class="calibre7">Dual antiplatelet therapy:</b> delay elective surg 14 d after balloon angioplasty, 30 d after BMS and ideally 6 mo (min 3 mo) after DES <span class="r1">(</span><span class="r2">JACC</span> <span class="r1">2016; 68:1082)</span> unless risk of bleeding &gt; risk of stent thrombosis or ACS. If must discontinue P2Y<sub class="calibre10">12</sub> inh, continue ASA and restart P2Y<sub class="calibre10">12</sub> inh ASAP; can consider IV cangrelor if high-risk <span class="r1">(</span><span class="r2">JAMA</span> <span class="r1">2012;307:265)</span>.</p>
<p class="noindent1">• <b class="calibre7">β-blockers</b> <span class="r1">(</span><span class="r2">JAMA</span> <span class="r1">2020;324:279)</span></p>
<p class="noindent2">Continue βB in Pts on them chronically. Do not stop βB abruptly postop (may cause reflex sympathetic activation). Use IV if Pt unable to take PO.</p>
<p class="noindent2">Reasonable to initiate if intermed- or high-risk ⊕ stress test, or RCRI ≥3, espec if vasc surgery. Initiate ≥1 wk prior to surgery (<i class="calibre6">not day of</i>), use low-dose, short-acting βB, and titrate to achieve HR and BP goal (? HR ~55–65). Avoid bradycardia and HoTN.</p>
<p class="noindent1">• <b class="calibre7">Statins:</b> ↓ ischemia &amp; CV events in Pts undergoing vascular surg <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2009;361:980)</span>. Consider if risk factors &amp; non–low-risk surgery and in all Pts undergoing vascular surgery.</p>
<p class="noindent1">• ACEI/ARB: holding 24 h preop to ↓ intraop HoTN <span class="r1">(</span><span class="r2">Anes</span> <span class="r1">2017;126:16)</span>. Restart ASAP.</p>
<p class="noindent1">• Amiodarone: ↓ incidence of postop AF if started prior to surgery <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">1997;337:1785)</span></p>
<p class="h">Postoperative monitoring</p>
<p class="noindent1">• ECG if known CAD or high-risk surgery. Consider if &gt;1 risk factor for CAD.</p>
<p class="noindent1">• Routine troponin prognostic <span class="r1">(</span><span class="r2">JAMA</span> <span class="r1">2017;317:1642)</span> but ✓ only if sx/ECG ∆s suggestive of ACS</p>
<h2 class="ct"><a id="h20" class="calibre8"></a><a href="part0003.html#rh24" class="calibre8">PERIPHERAL ARTERY DISEASE (PAD)</a></h2>
<p class="h">Clinical features <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2016;374:861,</span> <span class="r2">Circ</span> <span class="r1">2021;144:e171)</span></p>
<p class="noindent1">• Prev. ↑ w/ age: &lt;1% if &lt;40 y, ~15% if ≥70 y; risk factors incl. <b class="calibre7">smoking</b>, <b class="calibre7">DM</b>, HTN, chol</p>
<p class="noindent1">• <b class="calibre7">Claudication</b> (ache/cramp, often in calves) precip by walking and relieved by stopping (vs. spinal stenosis, qv); Leriche synd = claudic., ↓ or Ø fem pulses, &amp; erectile dysfxn</p>
<p class="noindent1">• <b class="calibre7">Critical limb ischemia (CLI): rest pain</b> (↑ w/ elevation b/c ↓ perfusion), <b class="calibre7">ulcer</b> (typically at pressure foci, often dry; in contrast, venous ulcers are more often at medial malleolus, wet, and with hemosiderin deposition) or <b class="calibre7">gangrene</b>, due to PAD, and &gt;2-wk duration (implies chronicity vs. acute limb ischemia; see below) <span class="r1">(</span><span class="r2">Circ</span> <span class="r1">2019;140:e657)</span></p>
<p class="h">Diagnosis <span class="r1">(</span><span class="r2">Circ</span> <span class="r1">2016;135:e686,</span> <span class="r2">JAMA</span><span class="r1"> 2021;325:2188)</span></p>
<p class="noindent1">• ↓ peripheral pulses, bruits; signs of chronic PAD: hair loss, skin atrophy, nail hypertrophy</p>
<p class="noindent1">• Ankle: brachial index (ABI): nl 1–1.4; borderline 0.91–0.99; abnl ≤0.90; if &gt;1.4, non-dx possibly due to calcified noncompressible vessel → ✓ PVR, TBI (toe-brachial index). If ABI abnl → segmental ABI w/ PVR to localize disease. If ⊕ sx but nl ABI, ✓ for ↓ lower extrem BP after exercise (≥20% ↓ in ABI w/ exercise or ≥30 mmHg ↓ in ankle pressure).</p>
<p class="noindent1">• Duplex arterial U/S; CTA w/ distal run-off; MRA or angio if dx in ? or possible intervention</p>
<p class="h">Treatment <span class="r1">(</span><span class="r2">JACC</span> <span class="r1">2013;61:1555,</span> <span class="r2">Circ</span> <span class="r1">2021;144:e171,</span> <span class="r2">JAMA</span> <span class="r1">2021;325:2188)</span></p>
<p class="noindent1">• Risk factor modif. Screen for CAD/AAA. Structured high-intensity walking <span class="r1">(</span><span class="r2">JAMA</span> <span class="r1">2021;325:1266)</span>.</p>
<p class="noindent1">• If sx or if asx with ABI ≤0.90, ASA, clopi, or ticag to ↓ D/MI/stroke <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2017; 376:32)</span>. More intensive antiplt Rx ↓ both MACE &amp; limb ischemic events <span class="r1">(</span><span class="r2">JACC</span> <span class="r1">2016;67:2719)</span>. Adding riva 2.5 mg bid to ASA ↓ MACE but ↑ bleeding <span class="r1">(</span><span class="r2">Lancet</span> <span class="r1">2018;391:219;</span> <span class="r2">NEJM</span> <span class="r1">2020;382:1994)</span>.</p>
<p class="noindent1">• Statins &amp; PCSK9i ↓ MACE &amp; limb ischemic events <span class="r1">(</span><span class="r2">Circ</span> <span class="r1">2018;137:338)</span>. Cilostazol (if no HF).</p>
<p class="noindent1">• Endovascular (angioplasty vs. stent) or surgical revasc if limiting/refractory sx or CLI</p>
<p class="h">Acute limb ischemia (ALI) <span class="r1">(</span><span class="r2">Circ</span> <span class="r1">2016;135:e686)</span></p>
<p class="noindent1">• Sudden decrement in limb perfusion (ie, acutely cold &amp; painful) that threatens viability</p>
<p class="noindent1">• Etiologies: embolism &gt; acute thrombosis (eg, athero, APS, HITT), trauma to artery</p>
<p class="noindent1">• Clinical manifestations (<b class="calibre7">6 Ps</b>): pain (distal to proximal, ↑ in severity), poikilothermia, pallor, pulselessness, paresthesias, paralysis</p>
<p class="noindent1">• Testing: pulse &amp; neuro exam; arterial &amp; venous Doppler; angiography, CTA or MRA</p>
<p class="noindent1">• Urgent consultation w/ vascular medicine and/or vascular surgery</p>
<p class="imaget"><img src="../images/00037.jpeg" alt="" class="calibre5"/></p>


  </div>

  
  <div class="calibreToc">
    <h2><a href="../../j09u21sl.html">Table of contents
</a></h2>
    <div>
  <ul>
    <li>
      <a href="part0000.html#0-96ac16803db7461d85d0589a1c192bcf">Cover</a>
    </li>
    <li>
      <a href="part0001.html#UGI0-96ac16803db7461d85d0589a1c192bcf">Title Page</a>
    </li>
    <li>
      <a href="part0002.html#1T140-96ac16803db7461d85d0589a1c192bcf">Copyright Page</a>
    </li>
    <li>
      <a href="part0003.html#2RHM0-96ac16803db7461d85d0589a1c192bcf">Contents</a>
    </li>
    <li>
      <a href="part0004.html#3Q280-96ac16803db7461d85d0589a1c192bcf">Contributing Authors</a>
    </li>
    <li>
      <a href="part0005.html#4OIQ0-96ac16803db7461d85d0589a1c192bcf">Foreword</a>
    </li>
    <li>
      <a href="part0006.html#5N3C0-96ac16803db7461d85d0589a1c192bcf">Preface</a>
    </li>
    <li>
      <a href="part0007.html#6LJU0-96ac16803db7461d85d0589a1c192bcf">CARDIOLOGY</a>
      <ul>
        <li>
          <a href="part0007.html#h1">Electrocardiography</a>
        </li>
        <li>
          <a href="part0007.html#h2">Chest Pain</a>
        </li>
        <li>
          <a href="part0007.html#h3">Noninvasive Evaluation of CAD</a>
        </li>
        <li>
          <a href="part0007.html#h4">Coronary Angiography &amp; PCI</a>
        </li>
        <li>
          <a href="part0007.html#h5">Stable Ischemic Heart Disease</a>
        </li>
        <li>
          <a href="part0007.html#h6">Acute Coronary Syndromes</a>
        </li>
        <li>
          <a href="part0007.html#h7">PA Catheter and Tailored Therapy</a>
        </li>
        <li>
          <a href="part0007.html#h8">Heart Failure</a>
        </li>
        <li>
          <a href="part0007.html#h9">Cardiomyopathies</a>
        </li>
        <li>
          <a href="part0007.html#h10">Valvular Heart Disease</a>
        </li>
        <li>
          <a href="part0007.html#h11">Pericardial Disease</a>
        </li>
        <li>
          <a href="part0007.html#h12">Hypertension</a>
        </li>
        <li>
          <a href="part0007.html#h13">Aortic Aneurysms</a>
        </li>
        <li>
          <a href="part0007.html#h14">Acute Aortic Syndromes</a>
        </li>
        <li>
          <a href="part0007.html#h15">Arrhythmias</a>
        </li>
        <li>
          <a href="part0007.html#h16">Atrial Fibrillation</a>
        </li>
        <li>
          <a href="part0007.html#h17">Syncope</a>
        </li>
        <li>
          <a href="part0007.html#h18">Cardiac Rhythm Management Devices</a>
        </li>
        <li>
          <a href="part0007.html#h19">Cardiac Risk Assessment for Noncardiac Surgery</a>
        </li>
        <li>
          <a href="part0007.html#h20">Peripheral Artery Disease</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0008.html#7K4G0-96ac16803db7461d85d0589a1c192bcf">PULMONARY</a>
      <ul>
        <li>
          <a href="part0008.html#h21">Dyspnea</a>
        </li>
        <li>
          <a href="part0008.html#h22">Pulmonary Function Tests</a>
        </li>
        <li>
          <a href="part0008.html#h23">Asthma</a>
        </li>
        <li>
          <a href="part0008.html#h24">Anaphylaxis</a>
        </li>
        <li>
          <a href="part0008.html#h25">Chronic Obstructive Pulmonary Disease</a>
        </li>
        <li>
          <a href="part0008.html#h26">Solitary Pulmonary Nodule</a>
        </li>
        <li>
          <a href="part0008.html#h27">Hemoptysis</a>
        </li>
        <li>
          <a href="part0008.html#h28">Bronchiectasis</a>
        </li>
        <li>
          <a href="part0008.html#h29">Cystic Fibrosis</a>
        </li>
        <li>
          <a href="part0008.html#h30">Interstitial Lung Disease</a>
        </li>
        <li>
          <a href="part0008.html#h31">Pleural Effusion</a>
        </li>
        <li>
          <a href="part0008.html#h32">Venous Thromboembolism</a>
        </li>
        <li>
          <a href="part0008.html#h33">Pulmonary Hypertension</a>
        </li>
        <li>
          <a href="part0008.html#h34">Respiratory Failure</a>
        </li>
        <li>
          <a href="part0008.html#h35">Mechanical Ventilation</a>
        </li>
        <li>
          <a href="part0008.html#h36">Acute Respiratory Distress Syndrome</a>
        </li>
        <li>
          <a href="part0008.html#h37">Sepsis and Shock</a>
        </li>
        <li>
          <a href="part0008.html#h38">Toxicology</a>
        </li>
        <li>
          <a href="part0008.html#h39">Lung Transplant</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0009.html#8IL20-96ac16803db7461d85d0589a1c192bcf">GASTROENTEROLOGY</a>
      <ul>
        <li>
          <a href="part0009.html#h40">Esophageal and Gastric Disorders</a>
        </li>
        <li>
          <a href="part0009.html#h41">Gastrointestinal Bleeding</a>
        </li>
        <li>
          <a href="part0009.html#h42">Diarrhea</a>
        </li>
        <li>
          <a href="part0009.html#h43">Dysmotility &amp; Nutrition</a>
        </li>
        <li>
          <a href="part0009.html#h44">Disorders of the Colon</a>
        </li>
        <li>
          <a href="part0009.html#h45">Inflammatory Bowel Disease</a>
        </li>
        <li>
          <a href="part0009.html#h46">Intestinal Ischemia</a>
        </li>
        <li>
          <a href="part0009.html#h47">Pancreatitis</a>
        </li>
        <li>
          <a href="part0009.html#h48">Abnormal Liver Tests</a>
        </li>
        <li>
          <a href="part0009.html#h49">Hepatitis</a>
        </li>
        <li>
          <a href="part0009.html#h50">Acute Liver Failure</a>
        </li>
        <li>
          <a href="part0009.html#h51">Cirrhosis</a>
        </li>
        <li>
          <a href="part0009.html#h52">Hepatic Vascular Disease</a>
        </li>
        <li>
          <a href="part0009.html#h53">Ascites</a>
        </li>
        <li>
          <a href="part0009.html#h54">Biliary Tract Disease</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0010.html#9H5K0-96ac16803db7461d85d0589a1c192bcf">NEPHROLOGY</a>
      <ul>
        <li>
          <a href="part0010.html#h55">Acid-Base Disturbances</a>
        </li>
        <li>
          <a href="part0010.html#h56">Sodium and Water Homeostasis</a>
        </li>
        <li>
          <a href="part0010.html#h57">Potassium Homeostasis</a>
        </li>
        <li>
          <a href="part0010.html#h58">Kidney Disease</a>
        </li>
        <li>
          <a href="part0010.html#h59">Glomerular Disease</a>
        </li>
        <li>
          <a href="part0010.html#h60">Urinalysis</a>
        </li>
        <li>
          <a href="part0010.html#h61">Nephrolithiasis</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0011.html#AFM60-96ac16803db7461d85d0589a1c192bcf">HEMATOLOGY-ONCOLOGY</a>
      <ul>
        <li>
          <a href="part0011.html#h62">Anemia</a>
        </li>
        <li>
          <a href="part0011.html#h63">Disorders of Hemostasis</a>
        </li>
        <li>
          <a href="part0011.html#h64">Platelet Disorders</a>
        </li>
        <li>
          <a href="part0011.html#h65">Coagulopathies</a>
        </li>
        <li>
          <a href="part0011.html#h66">Hypercoagulable States</a>
        </li>
        <li>
          <a href="part0011.html#h67">Disorders of Leukocytes</a>
        </li>
        <li>
          <a href="part0011.html#h68">Transfusion Therapy</a>
        </li>
        <li>
          <a href="part0011.html#h69">Myelodysplastic Syndromes</a>
        </li>
        <li>
          <a href="part0011.html#h70">Myeloproliferative Neoplasms</a>
        </li>
        <li>
          <a href="part0011.html#h71">Leukemia</a>
        </li>
        <li>
          <a href="part0011.html#h72">Lymphoma and CLL</a>
        </li>
        <li>
          <a href="part0011.html#h73">Plasma Cell Dyscrasias</a>
        </li>
        <li>
          <a href="part0011.html#h74">Hematopoietic Stem Cell Transplantation</a>
        </li>
        <li>
          <a href="part0011.html#h75">Lung Cancer</a>
        </li>
        <li>
          <a href="part0011.html#h76">Breast Cancer</a>
        </li>
        <li>
          <a href="part0011.html#h77">Prostate Cancer</a>
        </li>
        <li>
          <a href="part0011.html#h78">Colorectal Cancer</a>
        </li>
        <li>
          <a href="part0011.html#h79">Pancreatic Tumors</a>
        </li>
        <li>
          <a href="part0011.html#h80">Other Solid Tumors</a>
        </li>
        <li>
          <a href="part0011.html#h81">Immunotherapy &amp; Cellular Therapy</a>
        </li>
        <li>
          <a href="part0011.html#h82">Oncologic Emergencies</a>
        </li>
        <li>
          <a href="part0011.html#h83">Chemo Side Effects</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0012.html#BE6O0-96ac16803db7461d85d0589a1c192bcf">INFECTIOUS DISEASES</a>
      <ul>
        <li>
          <a href="part0012.html#h84">Pneumonia</a>
        </li>
        <li>
          <a href="part0012.html#h85">Fungal Infections</a>
        </li>
        <li>
          <a href="part0012.html#h86">Infxns in Immunosuppressed Hosts</a>
        </li>
        <li>
          <a href="part0012.html#h87">Urinary Tract Infections</a>
        </li>
        <li>
          <a href="part0012.html#h88">Sexually Transmitted Infections</a>
        </li>
        <li>
          <a href="part0012.html#h89">Skin and Soft Tissue Infections</a>
        </li>
        <li>
          <a href="part0012.html#h90">Infections of the Nervous System</a>
        </li>
        <li>
          <a href="part0012.html#h91">Bacteremia &amp; Endocarditis</a>
        </li>
        <li>
          <a href="part0012.html#h92">Tuberculosis</a>
        </li>
        <li>
          <a href="part0012.html#h93">HIV/AIDS</a>
        </li>
        <li>
          <a href="part0012.html#h94">Tick-Borne Diseases</a>
        </li>
        <li>
          <a href="part0012.html#h95">Fever Syndromes</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0013.html#CCNA0-96ac16803db7461d85d0589a1c192bcf">ENDOCRINOLOGY</a>
      <ul>
        <li>
          <a href="part0013.html#h96">Pituitary Disorders</a>
        </li>
        <li>
          <a href="part0013.html#h97">Thyroid Disorders</a>
        </li>
        <li>
          <a href="part0013.html#h98">Adrenal Disorders</a>
        </li>
        <li>
          <a href="part0013.html#h99">Calcium Disorders</a>
        </li>
        <li>
          <a href="part0013.html#h100">Diabetes Mellitus</a>
        </li>
        <li>
          <a href="part0013.html#h101">Lipid Disorders</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0014.html#DB7S0-96ac16803db7461d85d0589a1c192bcf">RHEUMATOLOGY</a>
      <ul>
        <li>
          <a href="part0014.html#h102">Approach to Rheumatic Disease</a>
        </li>
        <li>
          <a href="part0014.html#h103">Rheumatoid Arthritis</a>
        </li>
        <li>
          <a href="part0014.html#h104">Adult-Onset Still’s Disease &amp; Relapsing Polychondritis</a>
        </li>
        <li>
          <a href="part0014.html#h105">Crystal Deposition Arthritides</a>
        </li>
        <li>
          <a href="part0014.html#h106">Seronegative Spondyloarthritis</a>
        </li>
        <li>
          <a href="part0014.html#h107">Infectious Arthritis &amp; Bursitis</a>
        </li>
        <li>
          <a href="part0014.html#h108">Connective Tissue Diseases</a>
        </li>
        <li>
          <a href="part0014.html#h109">Systemic Lupus Erythematosus</a>
        </li>
        <li>
          <a href="part0014.html#h110">IgG4-Related Disease</a>
        </li>
        <li>
          <a href="part0014.html#h111">Vasculitis</a>
        </li>
        <li>
          <a href="part0014.html#h112">Autoinflammatory Syndromes</a>
        </li>
        <li>
          <a href="part0014.html#h113">Amyloidosis</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0015.html#E9OE0-96ac16803db7461d85d0589a1c192bcf">NEUROLOGY</a>
      <ul>
        <li>
          <a href="part0015.html#h114">Change in Mental Status</a>
        </li>
        <li>
          <a href="part0015.html#h115">Seizures</a>
        </li>
        <li>
          <a href="part0015.html#h116">Alcohol Withdrawal</a>
        </li>
        <li>
          <a href="part0015.html#h117">Dizziness</a>
        </li>
        <li>
          <a href="part0015.html#h118">Stroke</a>
        </li>
        <li>
          <a href="part0015.html#h119">Weakness &amp; Neuromuscular Dysfunction</a>
        </li>
        <li>
          <a href="part0015.html#h120">Headache</a>
        </li>
        <li>
          <a href="part0015.html#h121">Back and Spinal Cord Disease</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0016.html#F8900-96ac16803db7461d85d0589a1c192bcf">CONSULTS</a>
      <ul>
        <li>
          <a href="part0016.html#h122">Surgical Issues</a>
        </li>
        <li>
          <a href="part0016.html#h123">Ob/Gyn Issues</a>
        </li>
        <li>
          <a href="part0016.html#h124">Ophthalmic Issues</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0017.html#G6PI0-96ac16803db7461d85d0589a1c192bcf">APPENDIX</a>
      <ul>
        <li>
          <a href="part0017.html#h125">ICU Medications</a>
        </li>
        <li>
          <a href="part0017.html#h126">Antibiotics</a>
        </li>
        <li>
          <a href="part0017.html#h127">Formulae and Quick Reference</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0018.html#H5A40-96ac16803db7461d85d0589a1c192bcf">ABBREVIATIONS</a>
    </li>
    <li>
      <a href="part0019.html#I3QM0-96ac16803db7461d85d0589a1c192bcf">INDEX</a>
    </li>
    <li>
      <a href="part0020.html#J2B80-96ac16803db7461d85d0589a1c192bcf">PHOTO INSERTS</a>
      <ul>
        <li>
          <a href="part0020.html#h128">Radiology</a>
        </li>
        <li>
          <a href="part0020.html#h129">Echocardiography</a>
        </li>
        <li>
          <a href="part0020.html#h130">Coronary Angiography</a>
        </li>
        <li>
          <a href="part0020.html#h131">Peripheral Blood Smears</a>
        </li>
        <li>
          <a href="part0020.html#h132">Leukemias</a>
        </li>
        <li>
          <a href="part0020.html#h133">Urinalysis</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0021.html#K0RQ0-96ac16803db7461d85d0589a1c192bcf">ACLS</a>
    </li>
  </ul>
</div>


  </div>
  

  <div class="calibreEbNav">
    
      <a href="part0006.html" class="calibreAPrev">previous page
</a>
    

    <a href="../../j09u21sl.html" class="calibreAHome">start
</a>

    
      <a href="part0008.html" class="calibreANext">next page
</a>
    
  </div>

</div>

</body>
</html>
